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Abstract 
Background 
There is currently insufficient evidence for the clinical and cost-effectiveness of 
psychological therapies for post-stroke depression.  
Objective 
To evaluate the feasibility of undertaking a definitive trial to evaluate the clinical and 
cost effectiveness of behavioural activation (BA) compared to usual stroke care for 
treating post-stroke depression.  
Design 
Parallel group, feasibility, multicentre, RCT with nested qualitative research and 
economic evaluation. 
Setting 
Acute and community stroke services in three sites in England. 
Participants 
Community dwelling adults 3 months to 5 years post-stroke, depressed as determined 
by the Patient Health Questionnaire-9 (PHQ-9) or Visual Analog Mood Scales Sad. 
Exclusions: blind, deaf, dementia, unable to communicate in English, without mental 
capacity to consent, receiving treatment for depression at the time of stroke onset, 
currently receiving psychological intervention. 
Randomisation and blinding 
Participants were randomised (1:1 ratio) to BA or usual stroke care. Randomisation 
was conducted using a computer-generated list with random permuted blocks of 
varying sizes, stratified by site. Participants and therapists were aware of the 
allocation, outcome assessors were blind.  
 
Interventions 
The intervention arm received up to 15 sessions of BA over 4 months. BA aims to 
v 
 
improve mood by increasing people’s level of enjoyable or valued activities. The 
control arm received usual care only. 
Outcomes 
Primary: feasibility of recruitment to the main trial, acceptability of research 
procedures and measures, appropriateness of baseline and outcome measures, 
retention of participants, potential value of conducting the definitive trial. Secondary 
feasibility outcomes concerned delivery of the intervention.  
Primary clinical outcome 6 months post-randomisation: PHQ-9.  
Secondary clinical outcomes: Stroke Aphasic Depression Questionnaire-Hospital, 
Nottingham Leisure Questionnaire, Nottingham Extended Activities of Daily Living, 
Carer Strain Index, EuroQol EQ-5D-5L, healthcare resource use questionnaire. 
Results Forty-eight participants were recruited in 27 centre-months of recruitment; a 
recruitment rate of 1.8 participants per centre per month. The 25 participants 
randomised to receive BA attended a mean of 8.5 (SD 4.4) therapy sessions; 23 
participants were allocated to usual care. Outcome assessments were completed by 39 
(81%) participants (18 BA, 21 usual care). Mean PHQ-9 scores at 6-months follow-up 
were 10.1 (SD 6.9) and 14.4 (SD 5.1) in the BA and control groups respectively, a 
difference of -3.8 (95% CI: -6.9 to -0.6) after adjusting for baseline PHQ-9 score and 
centre, representing a reduction in depression in the BA arm. 
Therapy was delivered as intended. BA was acceptable to participants, carers and 
therapists. 
Value of information analysis indicates that the benefits of conducting a definitive 
trial would be likely to outweigh the costs. 
We estimate that a sample size between 580 and 623 would be needed for a definitive 
trial. 
Limitations 
Target recruitment was not achieved although we identified methods to improve 
recruitment. 
vi 
 
Conclusions  
BEADS was feasible with regarding to the majority of outcomes. The outstanding 
issue is whether a sufficient number of participants could be recruited within a 
reasonable timeframe for a definitive trial.  
Future work 
Identify whether there are sufficient sites able to deliver the services required for a 
definitive trial.  
 
Trial registration 
ISRCTN: 12715175 
Funding 
NIHR Health Technology Assessment programme (13/14/01).  
Word count: 500 
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Scientific summary  
 
Background 
About one third of people become depressed after stroke. It is important that 
depression is treated as it can negatively effect recovery, quality of life and carer 
strain. There is currently insufficient evidence for the clinical and cost-effectiveness 
of psychological therapies for post-stroke depression. One-third of stroke survivors 
have aphasia and up to 75% have problems with memory, thinking or understanding 
(cognitive problems). People with communication or cognitive problems are often 
excluded from studies evaluating psychological interventions. We wanted to evaluate 
a psychological intervention that can be delivered to the wide range of stroke 
survivors. 
 
Behavioural activation (BA) therapy may be an appropriate treatment for post–stroke 
depression. BA aims to improve mood by increasing the time people spend doing 
activities they enjoy. Importantly, it can be used with stroke survivors with 
depression, including those with communication or cognitive difficulties. We 
previously completed a randomised controlled trial (RCT) with 105 stroke survivors 
with aphasia and low mood and found that those who received BA had improved 
mood 6 months later. However, this previous study only included people with 
aphasia, did not explore participants’ and carers’ views on the intervention, and did 
not evaluate whether BA was cost effective. We therefore conducted a feasibility 
study of BA with stroke survivors with depression to evaluate whether it would be 
possible to proceed to a definitive multicentre trial and, if so, how we could do this 
BEADS (Behavioural activation therapy for depression after stroke) was funded in 
response to an NIHR commissioned call. 
Objectives  
To evaluate the feasibility of undertaking a definitive trial to evaluate the clinical and 
cost effectiveness of behavioural activation (BA) compared to usual stroke care for 
treating people with post-stroke depression.  
xvii 
 
The primary objective was to determine the feasibility of proceeding to a definitive 
trial. The secondary objective was to determine the feasibility of delivering 
behavioural activation to people with post-stroke depression 
Design 
BEADS was a parallel group, feasibility, multicentre, RCT with nested qualitative 
research and economic evaluation. Randomisation was web based and stratified by 
centre using a computer-generated pseudo-random list with random permuted blocks 
of varying sizes. The researcher completing the outcome assessments was blinded to 
allocation. 
 
Setting 
Recruitment was from acute and community stroke services in three sites in England. 
The intervention was delivered on an individual basis in participants’ homes. 
Participants  
Participants were adults (age 18 years or older) between three months and five years 
post-stroke, living in community settings (including nursing homes), and identified as 
depressed defined as scoring >10 on the Patient Health Questionnaire-9 (PHQ-9) or 
>50/100 on the Visual Analog Mood Scales Sad items. People were excluded if they: 
had a visual or hearing impairment that would impact on their capacity to take part in 
the intervention, had a diagnosis of dementia prior to stroke, were unable to 
communicate in English, had communication difficulties that would impact on their 
ability to take part in the intervention, did not have capacity to consent, were 
receiving medical or psychological treatment for depression at the time of stroke 
onset, or were currently receiving psychological intervention. 
Interventions 
Participants were randomised (1:1 ratio) to BA therapy or usual stroke care. Those 
allocated to intervention could receive a maximum of 15 sessions of BA over 4 
months in addition to their usual care. BA was delivered by an Assistant Psychologist 
or Psychological Wellbeing Practitioner over four months. BA aims to increase 
activity, particularly the frequency of pleasant or enjoyable events, in order to 
improve mood. A BEADS therapy manual was developed and BA therapy techniques 
xviii 
 
included activity monitoring, activity scheduling and graded tasks. The number of 
therapy sessions varied according to the needs of the individual and their progress in 
therapy. The therapists received training in the intervention and additionally in 
communicating with stroke patients with cognitive and/or communication difficulties. 
The control group (usual care) followed their current care pathway and received all 
other services routinely available to them as local practice. 
Main Outcome Measures 
Feasibility outcomes 
The primary endpoints were based on: 
a. Feasibility of recruitment to the main trial 
b. Acceptability of the research procedures and measures 
c. Appropriateness of the baseline and outcome measures for assessing impact 
d. Retention of participants at outcome 
e. Potential value of conducting the definitive trial, based upon value of 
information analysis 
 
The secondary endpoints were related to the feasibility of the behavioural activation 
therapy intervention, based on: 
a. Acceptability of behavioural activation therapy to participants, carers and 
therapists 
b. Feasibility of delivering the intervention by Assistant Psychologists or IAPT 
therapist under supervision of an experienced mental health practitioner 
c. Documentation of ‘usual care’ using healthcare resource use questionnaire 
d. Treatment fidelity of the behavioural activation therapy 
e. Feasibility of delivery of behavioural activation therapy within current 
services and within a definitive trial 
f. Estimation of sample size for a definitive trial 
 
Clinical outcomes 
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The primary clinical outcome measure at 6 months after randomisation was the PHQ-
9.  
 
Secondary clinical outcomes at 6 months after randomisation were: Stroke Aphasic 
Depression Questionnaire-Hospital version (SADQ-H), Nottingham Leisure 
Questionnaire (NLQ), Nottingham Extended Activities of Daily Living (NEADL), 
Carer Strain Index (CSI), EuroQol EQ-5D-5L (standard version and version for 
people with cognitive problems), healthcare resource use questionnaire. Outcome 
measures were sent by post for those without aphasia; phone calls and a home visit 
were offered to those where outcomes were not returned by post. Outcomes were 
completed in person for those with aphasia. 
Views on the acceptability of the trial design, procedures and the BA intervention 
were assessed using semi-structured interviews with a subset of participants and 
carers from each arm, and with all three study therapists. Participants and carers were 
selected for interview using a purposive, maximum-variation sampling strategy. 
Interviews were audio-recorded, transcribed verbatim, and analysed using the 
Framework Approach. 
Fidelity was assessed by describing the content of treatment. Therapists completed a 
time sampling record form at the end of each session to record the time spent on 
different components of the therapy. A sample of therapy sessions were also video 
recorded and coded using a therapy record form.  
For the health economic analysis, value of information analysis was completed. Costs 
and utilities were estimated using the EQ-5D-5L and resource use questionnaires, 
combined with standard costs and valuation sources. 
Results  
Feasibility outcomes 
Forty-eight participants were recruited at three centres in 27 centre-months of 
recruitment; a rate of 1.8 participants recruited per centre per month. Recruitment 
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varied by site. The highest proportions of participants were recruited through hospital 
databases (42.9%) and outpatients (26.5%). 
Participants had a mean age of 65.6 years (SD 13.6) and most participants were men 
(60.4%). Most participants were between  three months to one year post-stroke 
(62.5%). The mean PHQ-9 score at baseline was 16.8 (SD 4.7).  
In total, 25 participants were randomised to receive BA and 23 to the usual care arm. 
Those who received BA attended a mean of 8.5 (SD 4.4) therapy sessions (range 0-
14). Sessions lasted for a mean of 57 minutes (SD = 13, range 10 to 125 minutes). 
Delivery of the intervention was good with high attendance (90%). The main reason 
that sessions were missed was a change in participants’ availability (n=14, 61%), 
illness (n=4, 17%) and change of therapists’ availability (n=3, 13%). Two participants 
(9%) withdrew from treatment. 
Outcome assessments were completed by 39 (81%) participants (18 BA, 21 usual 
care). Most participants (63%) completed the follow up by post and 39% of these had 
at least one reminder contact to complete the assessment. Six-month follow up rate 
was around 80% in most of the outcome questionnaires. 
According to the therapy recording forms, most time during sessions was spent 
covering between-session tasks (18.3%). The second most frequent component was 
activities (18.1%). This included activity monitoring (6.5%), identifying enjoyable 
activities (6.0%) and activity scheduling (4.8%) with relatively little time spent on 
practicing skills or tasks (0.8%). The least amount of time was spent on 
communication and cognitive difficulties (0.8%). The use of graded tasks (2.1%) and 
problem solving (3.8%) were relatively infrequent. Ten therapy sessions were video 
recorded across eight participants. Most components of the manual that were intended 
to be delivered were evident in all sessions and the video recordings highlighted 
aspects not otherwise recorded. 
Sixteen participants and ten carers from both intervention and control arms, and all 
three study therapists were interviewed. BA was found to be acceptable to 
participants, carers and therapists and they were generally positive about their 
experiences. 
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Participants felt that the most helpful aspects of therapy were identifying new and 
meaningful activities, reflection during the sessions, having weekly sessions and 
having the chance to talk with someone. Some participants who received the therapy 
suggested that follow up sessions would help maintain the gains made. Some control 
participants also found participation in the study helpful as it provided opportunities 
to talk about their experiences. However, others were uncertain why they had been 
randomised to usual care. The outcome measures were generally felt to be appropriate 
in content and length. 
 
Therapists found the manual and training helpful but also suggested having a 
summary of each session and an interactive notebook or workbook for participants. 
The biggest challenge reported was the variation in patient presentation although the 
therapy and manual allowed sessions to be tailored for individuals’ needs. The 
therapists reported different experiences of recruiting participants, reflecting local site 
differences. 
 
Clinical outcomes 
The mean PHQ-9 scores at 6 months post-randomisation were 10.1 (SD 6.9) and 14.4 
(SD 5.1) in the BA and control groups respectively, a difference of -3.8 (95%CI -6.9 
to -0.6) after adjusting for baseline and centre, representing a reduction in depression 
in the BA arm. 
On the secondary outcomes the intervention had a positive effect for participants on 
VAMS Sad and the NLQ and for carers on the CSI, although these differences were 
only small. There was no difference between intervention and control groups on 
NEADL. Small negative effects were found for the patient reported EQ-5D-5L and 
SADQH-10.  
Value of information analysis indicated that the benefits of conducting a definitive 
trial would be likely to outweigh the costs, due to high levels of uncertainty around 
key parameters such as resource use, response rates, utility scores and relapse rates 
within the economic model. Our preliminary analysis of the cost-effectiveness of the 
intervention demonstrates the feasibility of conducting a definitive economic 
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evaluation alongside a definite trial. Our preliminary analysis suggests that the 
intervention may represent a dominant treatment strategy (i.e. cost saving and Quality 
Adjusted Life Years gaining) from a societal perspective, but whichmay be of 
borderline cost-effectiveness from an NHS and Personal Social Services (PSS) 
perspective. 
We calculated a sample size for a definitive scale trial comparing BA to usual care in 
participants with post-stroke depression. The primary endpoint used was PHQ-9 at 6 
months post-randomisation. We assumed a target difference in PHQ-9 scores of 
between 3 and 5 points would be clinically and practically important and a 
conservative estimate of SD of between 7 to 11 points giving a range of standardised 
effect sizes of between 0.27-0.71. From this feasibility study, data was used to 
calculate the intra cluster correlation coefficient of 0.06 in the intervention arm based 
on clustering by site. The attrition rate of 18.8% was rounded up to 20% and used to 
adjust the final sample size calculation. A sample size of 580 participants would be 
required to detect a difference of 4 points on the PHQ-9 scale with 90% power and 
5% significance. This would take approximately 24 months of recruitment in 16 sites 
assuming a rate of 1.5 participants per site per month which is similar to the rate 
observed in the feasibility study (recruitment rate= 1.8 participants per site month).A 
sample size of 623 participants would be required to detect a difference of 3 points on 
the PHQ-9 scale with 90% power and 5% significance.  
Conclusions  
Feasibility was demonstrated across the majority of the selected outcomes and 
strategies for improvements were identified. Depression seemed to improve in the 
group who received BA. It was feasible to deliver BA to people with and without 
aphasia or with cognitive impairment and the therapy was acceptable to participants, 
carers and therapists. As the study was not powered for efficacy it is not appropriate 
to draw conclusions on the valueof BA for treating post-stroke depression. Similarly, 
although cost-effectiveness results are preliminary, value of information analysis 
suggests that conducting a definitive trial would represent good value for money.  
Both methods of checking the fidelity of the intervention were feasible. 
Bothhighlighted potential ways that therapy deviated from the treatment described in 
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the manual. However the records kept by therapists were simpler to use and more 
complete. 
The distribution of time on the different components of therapy was as expected. 
However, there was little documentation of graded tasks assignments and training in 
problem solving. This may be because graded tasks were often used as a between 
session task and so were coded as such. 
 
The main issue outstanding is whether there are sufficient sites willing and able to 
deliver the services needed to sustain recruitment for a definitive trial. 
If a definitive trial were to be undertaken, based on the findings from BEADS, our 
recommendations are: 
● Recruit through stroke services rather than using IAPT as a main site for 
recruitment. 
● Provide at site support or central monitoring of recruitment 
● Hold regular teleconferences for the site staff and Principal Investigators to 
improve engagement and recruitment  
● Sending out regular newsletters to participants informing them of the study’s 
progress to improve engagement in the study and increase retention.  
● Amend the therapy record form so that the content of the between session task 
is recorded  
● Ensure that study staff and Clinical Research Network staff resourcing is 
allocated accordingly for the most effective recruitment routes 
● Explore GP databases and social media as other sources to recruit participants 
● Ensure data on NHS, PSS and societal costs are captured. 
● Ensure sufficient data are collected to allow estimation of a relapse rate 
● Improve the collection of usual care data 
● Consider including a booster session(s) to support maintenance of therapy 
gains. 
● Consider providing a Quick Reference Guide for the therapists to use 
alongside the full treatment manual  
● Develop a fidelity checklist to be used to inform the training of therapists and 
the monitoring of  the videos of  therapy sessions during the trial 
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Plain English Summary 
 
Approximately one-third of stroke patients experience depression which   can have 
negative effects on recovery and quality of life. Currently we do not have enough 
evidence to indicate which psychological interventions are effective and affordable to 
the NHS for treating post-stroke depression. 
 
We aimed to determine whether it is feasible to conduct a future large-scale study to 
evaluate a psychological intervention, called behavioural activation (BA) therapy, for 
treating post-stroke depression. BA aims to improve mood by identifying what stroke 
patients enjoy doing and helping them to undertakethese activities. BA can be used 
with all stroke patients with depression including people with cognitive or 
communication difficulties.  
 
We recruited 48 post-stroke patients who had their stroke between three months and 
five years previously People with dementia or significant aphasia were excluded. 
Participants were divided into two groups at random. About half of the participants 
received BA over a four-month period and the other half did not. Participants received 
all other available care. After 6 months, participants completed questionnaires about 
their mood, activity level and quality of life. We also interviewed 16 participants and 
ten carers about their views on the actual  research process and therapy. 
 
Although we were able to recruit participants to the study, this was fewer than the 
original target of 72 due to delays in starting recruitment. However we have identified 
ways to improve participant recruitment in a future study. We found  it was feasible to 
deliver BA and the therapy was found to be acceptable to participants, carers and 
therapists; . The results indicate that conducting the benefits of conducting  a large-
scale future study would outweight the costs.. However, the main consideration will 
be whether we could identify enough stroke services able to run the study for a long 
enough period to recruit the large number of participants required. 
 
Word count: 300 
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1 Introduction 
 
Background 
 
1.1 Post-stroke depression 
 
Stroke 
Stroke is a condition in which interruption of the blood supply to the brain causes 
brain damage. This leads to impairment of motor, sensory and cognitive abilities. 
Cognitive impairments include disorders of communication, such as aphasia, and 
problems with attention, memory, visuospatial abilities and executive function. These 
cognitive impairments have a negative effect on recovery and long term outcomes.
1, 2,3
 
 
Depression after stroke 
Many stroke patients experience emotional consequences, including depression, 
anxiety, post-traumatic stress, anger, apathy and frustration. Depression is the most 
commonly investigated emotional consequence of stroke.
4,5
 
 
Several recent reviews reported
6,7,5,8
 that about a third of stroke patients have 
depression at any time point. Two of these reviews included a meta-analysis. Ayerbe 
et al.
1
 analysed data from 43 studies published between 1983 and 2011. They reported 
an average prevalence of 29% (95% CI 25–32) of stroke survivors with depression, 
with a prevalence of 28% (95% CI 23–34) within a month of stroke, 31% (95% CI 
24–39) at 1 to 6 months, 33% (95% CI 23–43) at 6 months to 1 year and 25% (95% 
CI 19–32) at more than 1 year. Hackett et al.2 conducted a similar review and 
identified 61 studies. They obtained a pooled prevalence of 31% (95% CI 28 to 35%) 
of stroke survivors with depression at any time, up to five-years after stroke. They 
also highlighted that this figure was not significantly different from the proportion in 
their earlier review (33%, 95% CI 29 to 36%, difference of 2%, 95% CI <1 to 
3%),
3
suggesting that the management of the problem had not substantially improved 
over the previousten  years. 
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Factors associated with depression after stroke 
 
Effective treatment of depression is important because depression is associated with 
worse rehabilitation outcomes
4-7
 and increased disability.
1
 Stroke survivors who are 
depressed may engage less in rehabilitation, which in turn can lead to decreased 
functional recovery.
4
 Depression is also associated with increased mortality.
1, 8, 9
 Not 
only does depression affect stroke survivors themselves but it also has an effect on 
their carers.
10
 It has cost implications for the National Health Service because it is 
associated with increased healthcare utilisation.
9
 
 
Most studies have assessed depression and its potential outcomes at the same time 
point, making it unclear whether depression is a cause or consequence of the outcome 
variable. Ayerbe et al.
1
 reviewed only those studies in which depression was assessed 
at an earlier time point than the outcome,  and found that disability, lower quality of 
life and mortality may be outcomes of depression in stroke survivors. In a more recent 
review, Towfighi et al.
11
 concluded that the most consistent predictors of post-stroke 
depression are physical disability, stroke severity, history of depression and cognitive 
impairment. They also reported that post-stroke depression is associated with higher 
rates of healthcare use after stroke. Thus, in addition to improving mood, effective 
treatment of post-stroke depression is important as this has the potential to improve 
functional outcomes and quality of life and reduce health care costs.  
 
Many studies of depression after stroke are based on clinical interview or 
questionnaires to assess depression but these may not be appropriate for those with 
communication problems. About one third of stroke survivors have aphasia
12, 13
 which 
may affect all communication modalities including speaking, understanding, reading 
and writing. Studies that have used measures of depression appropriate forthose with 
communication problems, have reported that stroke survivors with aphasia may be 
particularly susceptible to post-stroke depression.
14, 15
 
 
 
1.2 Current service provision 
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Psychological treatments for depression after stroke 
Previous research
16
 indicates that a high proportion of depressed stroke patients are 
likely to be taking antidepressants and so suggest that antidepressants have not 
resolved the mood problem. Previous research also suggests that few stroke survivors 
receiveon-going psychological treatment.
17
 The Communication and Low Mood 
(CALM) trial of behavioural activation for low mood in people with aphasia
17
 found 
that, at three month follow up, only 14% of participants, who had been identified as 
having low mood after stroke, had received mental health treatment in the past three 
months (from a mental health nurse, counsellor, psychologist, or psychiatrist). 
Although Improving Access to Psychological Therapies(IAPT) have extended their 
remit to include people with physical health problems
18, 19
 the current uptake by stroke 
survivors is unknown. 
 
Among the several psychological approaches to the treatment of depression, 
Cognitive Behaviour Therapy (CBT) is the most widely used psychological treatment 
for depression in clinical practice
20
 and may be appropriate for those with stroke.
21, 22
 
There is evidence from single case design studies that some patients with post-stroke 
depression improve following CBT.
23, 24
 However, a randomised controlled trial of 
CBT for post-stroke depression found no significant difference in those participants 
who received CBT, an attention placebo or usual care.
25
 One of the possible reasons 
for the lack of efficacy was that psychological treatments need to be tailored for 
people with aphasia and cognitive impairment.
22, 25
 A systematic review of the 
modifications to cognitive behaviour therapy that were required for people with 
cognitive impairments due to acquired brain injury
26
,  included promoting an 
understanding of how specific changes to cognition, affect and behaviour occur as a 
result of brain injury and the use of memory aids.
27
However, a randomised trial of 
augmented CBT ,in which CBT was adapted to suit those with stroke, also found no 
evidence of benefit in comparison with a cognitive training control group. In addition, 
a trial of CBT at different time points after stroke
28
 found no overall effect of CBT in 
comparison with usual care, although there was some evidence that CBT improved 
mood in those who were recruited more than nine months after stroke. There is 
therefore currently little evidence to support the provision of cognitive behaviour 
therapy after stroke. 
4 
 
 
Effectiveness of psychological interventions for depression after stroke  
 
Other psychological interventions that may be appropriate for those with depression 
after stroke include counselling, motivational interviewing and problem-solving 
training. Some of these have been provided early after stroke in an attempt to prevent 
the development of depression,
29-35
 while others have been provided later to those 
who have developed depression.
36, 37
 
 
There is currently limited evidence for the clinical and cost-effectiveness of these 
psychological therapies for treating post-stroke depression.
38
 Towfighi et 
al.
11
identified seven trials (n=775) of psychological interventions for depression after 
stroke and concluded that they suggest that brief psychosocial interventions may be 
useful and effective in the treatment of post-stroke depression. Two of these trials 
evaluated a brief psychosocial behavioural intervention,
36, 37
 but details of the content 
of the intervention are limited. Motivational interviewing
31, 35
 has also been shown to 
reduce post-stroke depression but studies recruited participants early after stroke and 
excluded those with severe communication or cognitive problems, so these findings 
may not be applicable to the broad range of  stroke survivors with post-stroke 
depression. 
 
 
1.3 Behavioural activation 
 
A psychological intervention which may be suitable for stroke survivors is 
behavioural activation (BA) therapy. BA is based on the behavioural model of 
depression, in which depression is believed to result from a lack of response-
contingent positive reinforcement.
39
 Positive reinforcement is dependent on the 
person’s actions40 and reduction in activity can lead to loss of reinforcement. Low 
positive reinforcement can arise from several sources: a deficiency in the individual’s 
skills (e.g. lack of social skills); limited availability of potential reinforcers in the 
environment, and a decreased ability to enjoy pleasant events. The individual may 
engage in few activities that generate reinforcement. These antecedents contribute to a 
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low rate of positive reinforcement, and so there are reduced feelings of mastery, 
esteem in success, which can lead to feelings of depression. As individuals become 
depressed they reduce participation in activities and hobbies, decreasing the level of 
reinforcement further, and so leading to a vicious cycle.
41
 It is proposed that 
depression is therefore maintained by a cycle of depressed mood, decreased activity 
and avoidance.
42
 
 
A stroke can result in a loss or restriction of rewarding activities and interactions 
(such as everyday activities, hobbies and social interactions) and this loss may lead to 
depression.  The symptoms of depression (such as reduced motivation and lack of 
energy), in addition to the consequences of stroke, can mean that some behaviours or 
activities become more difficult and lost the positive reinforcement that they used to 
provide. BA aims to increase activity level, particularly the frequency of valued 
activities, and decrease avoidance behaviours in order to improve mood. In addition to 
its focus on reduced positive reinforcement leading to depression, BA is also 
concerned with addressing avoidance behaviours that contribute to depression. 
Depressed people may use avoidance as a coping strategy.
43
 For example, someone 
who feels low in mood may withdraw from social contacts because they find this 
activity challenging and causing them discomfort. Avoiding this activity provides 
short-term relief and is negatively reinforced thereby increasing the likelihood that 
they will repeat this avoidance again in the future. 
 
BA is effective at treating depression in adults in primary care settings
44-46
and in older 
adults.
47
 It has been found to have comparable effectiveness to CBT in treating 
depression.
48
 In a scale randomised controlled non-inferiority trial, Richards et al.
49
 
found that BA had comparable effects to CBT for people with depression in primary 
care and could be delivered by mental health workers with less intensive and costly 
training than required to deliver CBT, and was thus also more cost effective. 
 
BA is considered a straightforward approach and as such is suitable for those with 
reduced cognitive or communication ability. Stroke patients have cognitive 
impairment and some have communication problems which makes BA an appropriate 
treatment. A multicentre randomised controlled trial, the CALM trial
17
 evaluated BA, 
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delivered by an assistant psychologist, for treating low mood in stroke patients with 
aphasia. This trial found that mood was significantly better at 6 months follow-up in 
those who received BA compared to usual clinical care. In addition, reduced resource 
use suggested potential cost effectiveness.
50
 
 
The transferability of BA to hard-to-reach populations, such as those with aphasia and 
severe cognitive problems
51-54
 adds to its potential as a psychological intervention for 
depression after stroke. Given that the CALM trial demonstrated that it was possible 
to deliver BA to stroke survivors with aphasia, and studies of BA in people with 
dementia indicate it is suitable for those with cognitive impairment
54
 there is 
significant potential for using BA for treating depression in  stroke survivors with 
mild to moderate communication and cognitive impairment’.. 
 
1.4 Rationale and objectives 
 
The Behavioural Activation Therapy for Depression after Stroke (BEADS) trial was 
designed and conducted in response to a commissioned call from the Health 
Technology Assessment (HTA) programme to answer the research question ‘How 
feasible is a study to investigate the clinical and cost-effectiveness of a psychological 
intervention for people with post-stroke depression?’ 
 
BEADS was a multicentre trial designed to test feasibility and clinical outcomes of 
BA for treating post-stroke depression, and its acceptability to patients, carers and 
therapists. We also collected data on the feasibility of delivering the BA intervention 
in the NHS as part of routine clinical practice. This feasibility work was essential in 
informing   a proposal for a definitive (phase III) multicentre RCT evaluating the 
clinical and cost-effectiveness of BA for treating post-stroke depression. However, as 
a feasibility study, BEADSwas not powered to explore any factors that may modify 
the effects of treatment.  
 
Primary objective 
The primary objective was to determine the feasibility of proceeding to a definitive 
trial. 
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Secondary objectives 
The secondary objective was to determine the feasibility of delivering behavioural 
activation to people with post-stroke depression. 
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2 Methods 
2.1 The feasibility trial 
This feasibility trial is reported in accordance with the Consolidated Standards of 
Reporting Trials (CONSORT) statement
55
 and the pilot and feasibility trials 
extension.
56
 The full protocol has been published.
57
 
 
2.1.1 Trial design 
This study used a parallel group, feasibility, multicentre, RCT design with nested 
qualitative research and economic evaluation to compare behavioural activation 
therapy to usual stroke care for patients with post-stroke depression. Participants were 
allocated to behavioural activation or usual stroke care at a ratio of 1:1. 
 
2.1.2 Ethical approval 
Ethical approval was granted on 29
th
 January 2015 by NRES Committee East 
Midlands–Leicester (15/EM/0014). 
 
2.1.3 Important changes to the methods after feasibility trial commencement 
 
Changes made to the essential documentation, during the trial and following ethical 
approval on 29th January 2015, can be found in Appendix 1. 
 
Early in the recruitment phase substantial amendment 2 (Protocol v2.1, REC 
approved 08/07/2015) provided additional options in the recruitment process. This 
allowed the therapists to contact patients directly by phone following initial consent to 
be contacted. This streamlined the recruitment process providing the opportunity for 
the therapist to explain  more about the research and arrange a home visit to complete 
screening measures. This amendment also broadened the recruitment routes to include 
potential participants on acute outpatient caseloads.  
 
In substantial amendment 3 (Protocol v2.2, REC approved 07/09/2015) additional 
exclusion criteria were added to exclude patients that were currently receiving 
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psychological intervention. Five out of the 49 participants were recruited prior to this 
exclusion criteria being added. Furthermore, it was specified that participants in the 
intervention group could be withdrawn from the intervention if it was subsequently 
agreed that the patient needed immediate clinical psychology input. This amendment 
also clarified that participation in the study would not compromise access to other 
services, i.e. psychological input, which were part of usual care.  
 
Minor amendments were also n made including changes in study personnel and 
contact details. Additionally an additional secondary endpoint was added to estimate 
the sample size for a definitive trial and clarification that two or fewer missing items 
within the Patient Health Questionnaire-9 (PHQ-9)
58
 questionnaire could be imputed 
if required. 
 
2.1.4 Participants and eligibility criteria 
Recruitment of participants 
Participants were identified from hospital and community stroke databases at three 
stroke services, as well as the corresponding acute hospital stroke wards, and from 
voluntary support groups. Participants were approached by letter or by clinicians in 
community and acute stroke teams, or by voluntary group leaders. Self-referrals were 
facilitated by advertising the study in newsletters of relevant charities and societies. 
Posters were displayed in local voluntary sector groups, libraries and local community 
centres so that potential participants unknown to local hospital and community stroke 
teams could self-present to the local research team. The methods of identifying 
potential participants were kept broad to allow assessment of the optimum recruitment 
strategy for the definitive study. This also enabled recruitment of a representative 
cross-section of the population. 
 
Participants were recruited from three centres (see 2.1.5).The process for recruitment 
varied depending on where the participant was recruited from: 
 
(i) Hospital stroke database and community stroke team database  
At each site the clinical teams sent invitation letters to those on the hospital or 
community stroke databases of discharged patients.. Patients were sent a postal pack 
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containing a covering letter, participant information sheet, reply slip, PHQ-9, Visual 
Analog Mood Scales (VAMS) Sad item and prepaid envelope. Patients who were 
interested in taking part returned the reply slip and completed PHQ-9 and VAMS Sad 
item to the therapist. Return of completed questionnaires was taken as implied 
consent to be contacted by the therapist i.e. for potential recruitment into the trial. 
Those patients who did not reply were contacted by telephone by the clinical team to 
remind them about the study. The PHQ-9 and VAMS Sad item were used to assess 
whether participants met the inclusion criterion of having depression. Participants 
who returned the reply slip with the completed PHQ-9 and VAMS Sad item were 
contacted by the therapist if they were identified as depressed (as scoring ≥ 10 on 
PHQ-9 or ≥ 50 on VAMS Sad). Those who were identified as not being depressed, 
i.e. scores of less than 10 on the PHQ-9 or less than 50 on the VAMS Sad item, were 
thanked for their interest and informed that they were not eligible. 
 
Therapistscontacted patients classified as depressed to arrange a visit. The purpose of 
the visit was to check the participant met the remainder of the inclusion criteria, to 
explain the study and formally invite eligible patients to take part, obtain signed 
consent and complete baseline assessments. If a patient returned the reply slip to 
express interest in the study but did not return the completed PHQ-9 and VAMS Sad 
item, therapisst offered to visit and support the patient to complete these assessments. 
 
(ii) Patients currently on acute hospital stroke wards 
At each site, Research Nurses visited hospital stroke wards to provide information 
about the research to potential participants and seek their permission to be contacted 
by the research team and therefore, permission for their contact details to be passed on 
to the research team. A screening form was used to collect key demographic and 
contact information from all consented participants, who were then contacted by the 
local therapist three months from the date of consent to be contacted. Before making 
contact, the local Research Nurse or GP were contacted to check whether the patient 
was still alive. 
 
Patients were then contacted by phone to tell them more about the research and 
arrange a home visit during which they completed the PHQ-9 and VAMS Sad item. 
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Those patients who were identified as not being depressed were thanked for their 
interest and were informed that they were not eligible. For patients who were 
classified as depressed, the therapist either a) arranged a subsequent home visit or b) 
continued with recruitment as per the steps at (i) above. Alternatively, instead of a 
home visit or phone call the patient could be sent a pack containing a covering letter, 
participant information sheet, reply slip, PHQ-9, VAMS Sad and a prepaid envelope 
addressed to the therapist for that site. The same steps outlined above at (i) were then 
followed. 
 
(iii) Patients currently on the active caseload of community and acute stroke teams  
BEADS was presented to the community and acute stroke teams at each of the study 
sites. The clinical care teams were asked to explain the study to potential participants 
at the end of therapy or outpatient appointments or between appointments by phone. 
For patients who were interested in taking part, the clinician asked permission for 
their contact details to be passed on to the research therapist. Following this, the 
therapist then sent a pack to the patients and followed the steps outlined at (i) above, 
or arranged a home visit and followed the steps at (ii) above. 
 
(iv) Voluntary sector (stroke and aphasia groups)  
The therapists sought permission to attend stroke and aphasia groups in each site to 
explain the study to members. Those who were interested in taking part were invited 
to provide their contact details to the therapist who then either arranged a home visit 
and followed the steps at (ii) above, or sent them a pack and followed the steps at (i) 
above. 
 
Potential participants were told that entry into the trial was entirely voluntary and that 
their treatment and care would not be affected by their decision. It was also explained 
that they could withdraw at any time but attempts were made to avoid this happening. 
Participants were told that, if they withdrew, their data could not be erased and could 
be used in the final analyses. 
 
Recruitment of Carers and Therapists 
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For those participants with carers, the carer was also invited to take part. Carer 
participants were eligible if they provided informal care to the trial participant. Family 
members, spouses and friends were all eligible to participate as carers. The study 
therapists (staff participants) were invited to take part in the qualitative interviews at 
the end of the study. 
 
The presence of a carer was established by the therapist during the initial telephone 
call to arrange the first home visit. Where the carer was present during the home visit, 
study therapists provided them with a copy of the participant information sheet to 
review and gave a verbal explanation of study participation. Where appropriate and 
relevant, written informed consent was taken from carer participants during this first 
home visit. Where the carer was not present during the home visit, a copy of the 
participant information sheet was provided for the carer and the study therapist 
followed this up with a phone-call to discuss the study in more depth. Where the carer 
was interested in participating, an additional home visit was undertaken to organise 
written informed consent from them. 
 
Staff participants were consented by the study therapist/research, and staff 
participants were consented by the interviewer for the qualitative interview and by the 
trial manager for video recording (fidelity assessment). It was explained that 
participation was voluntary and that they could withdraw at any time.  
 
At consent for recruitment into the trial, all participants opted in or opted out of 
receiving invitations for their treatment sessions to be video recorded as part of the 
fidelity assessment. If a participant declined video recording, they were offered the 
option of audio recording instead. Participants were not excluded from the study if 
they did not want their treatment sessions to be video or audio recorded. We 
documented the proportion of participants who agreed to be video (or audio) 
recorded. 
 
Eligibility criteria 
Inclusion criteria 
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The criteria were designed to identify those who would be suitable for the 
intervention were it to be offered within clinical practice. Participants were included 
in the study if they: 
 
1. Had a diagnosis of stroke  
2. Were aged 18 years or over 
3. Were living in community settings, including home or nursing home 
4. Were a minimum of three months and a maximum of five years post-stroke 
5. Were identified as depressed, defined as: 
a.  Score of ≥10 on the PHQ-9 (Patient Health Questionnaire-9)58(2 or fewer 
missing items within the questionnaire may be imputed), or; 
b.  Score of at least 50/100 on Visual Analog Mood Scales (VAMS) Sad item.59 
 
Exclusion criteria 
Participants were excluded if they: 
1. Had a diagnosis of dementia, based on self-report by patient or carer, prior to their 
stroke 
2. Reported receiving medical or psychological treatment for depression at the time 
at which they had their stroke  
3. Were currently receiving a psychological intervention 
4. Had communication difficulties that would impact on their capacity to take part in 
the intervention, based on assessment with the Consent Support Tool
60
 for people 
with aphasia 
5. Had visual or hearing impairments that would impact on their capacity to take part 
in the intervention based on their therapist’s opinion at baseline assessment. 
6. Were unable to communicate in English prior to the stroke  
7. Did not have mental capacity to consent to take part in the trial. 
 
All reasons for patient exclusion were recorded. 
 
Consent process 
During training by a speech and language therapist experienced in mental capacity 
assessment, all recruiting researchers were taught techniques to identify whether a 
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potential participant was able to understand key information provided about the 
project, retain and weigh this information and methods to assist participants to express 
their decision, adhering to the 4 key aspects of mental capacity according to the 
Mental Capacity Act 2005. 
 
Written informed consent was obtained from all participants who were are able to 
give it. Those who lacked the mental capacity to provide consent were excluded from 
the trial. The therapists explained the details of the trial and provided a Participant 
Information Sheet, ensuring that the participant had sufficient time to consider 
participating or not. For patients who were physically unable to sign the form (e.g. 
weakness in dominant hand due to stroke) then consent could be given using a mark 
or line in the presence of an independent witness (who had no involvement in the 
trial) who would then corroborate this by signing the consent form.  
 
A significant proportion of the stroke population have some degree of cognitive or 
language impairment – aphasia. The level of support required to enable a person with 
aphasia to provide informed consent is dependent upon the severity and profile of the 
aphasia. In order to provide information in a format consistent with each individual's 
language ability, a Consent Support Tool (CST)
60
 could be used. The Consent Support 
Tool provided a means of identifying comprehension levels of people with aphasia or 
cognitive difficulties in order to provide information in a format that was likely to be 
most accessible to the person with aphasia to support their understanding. This tool 
also helped identify methods that support the individual to express their decision. The 
therapist requested verbal consent from the potential participant to carry out part A of 
the CST (10 minutes). The result indicated how appropriate it was to provide the 
accessible information sheet. If the CST indicated that the potential participant 
understood fewerthan two key written or spoken words in a sentence, they would be 
likely to find it difficult to understand all the information required to provide 
informed consent. These participants were thanked for their time but were not eligible 
for the study as, despite the intervention using techniques to support the inclusion of 
those people with reduced language or cognition, the intervention did rely on 
achieving understanding with support and actively participating in therapeutic 
communication.  
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The accessible information sheet was provided to those who understand at least two 
key written and spoken words. This follows standard aphasia-friendly principles with 
one idea presented per page in short simple sentences in large font. Key words are 
emboldened and each idea is represented by a pictorial image to support 
understanding of what the study is about. The therapists were trained to support 
understanding further by reading parts of the information aloud and using supportive 
gestures/actions (as described for information level 3 of the CST and consistent with 
the types of support offered in the intervention under study).  
 
Once the potential participant was been given the information and had sufficient to 
time to ask questions and discuss with family or friends, the therapist checked the 
individual had capacity to provide informed consent. This was done by checking that 
they understood the information could remember what the study was about and 
clearly express their decision in the way in which they usually communicate 
(speaking, writing, using a communication aid). The CST provides information on 
ways people with aphasia might choose to express their intentions.  
 
Where the Consent Support Tool was not needed due to adequate understanding and 
verbal expression in conversation, the researchers were still taught to check the trial 
information provided had been understood by each individual by asking yes/no 
questions about the content of the information and yes/no questions about the 
potential consequences of their involvement to confirm the ability to weigh the 
information.  
 
Participants with capacity to provide informed consent who have used the accessible 
information provision were provided with an aphasia-friendly consent form and asked 
to initial all boxes before signing. Where stroke symptoms prevented initialling of 
boxes or providing written consent, the patient could use a mark or line and a 
relative/friend was asked to witness the fact that the participant was consenting to the 
study, and sign and date the consent form to confirm this on behalf of the participant. 
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As participants may become distressed during the study, and as such, may be advised 
to consult their GPs, consent to notify the GP was sought from all participants. 
Participants’ GPs were notified by letter that their patient was taking part in the 
research and were sent a copy of the Participant Information Sheet for information.  
 
Expected duration of participant participation 
Study participants were expected to participate in the study for approximately 6 
months. 
 
2.1.5 Settings and locations where the data were collected 
 
The University of Nottingham sponsored the trial. Coordination of the trial was 
undertaken by Sheffield Clinical Trials Research Unit (CTRU). Participants were 
identified and recruited from hospital and community stroke services at Sheffield 
Health and Social Care NHS Trust, Derby Hospitals NHS Foundation Trust and Let’s 
Talk Wellbeing at Nottinghamshire Healthcare NHS Foundation Trust. Screening and 
identification of potential participants was supported by Clinical Research Network 
(CRN) staff based at Sheffield Teaching Hospitals NHS Foundation Trust, Derbyshire 
Community Health Services NHS Trust and at Sherwood Forest Hospitals NHS 
Foundation Trust. Baseline data were collected and behavioural activation therapy 
was delivered by the therapists in participants’ own homes. Six month follow up data 
were collected in participants’ own homes for those with aphasia. by blinded outcome 
assessors For those without aphasia, data were collected by post unless help was 
requested. 
 
2.1.6 Interventions 
Intervention – Behavioural Activation Therapy 
 
Behavioural Activation (BA) Therapy is a structured and individualised treatment 
which aims to increase people’s level of activity, particularly the frequency of valued 
activities (pleasant or enjoyable events), and decrease avoidance behaviours, in order 
Comment [AD1]: Six-month 
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to improve mood. Participants randomised to receive BA were treated at their place of 
residence by a research therapist. The research therapists were Assistant Psychologists 
(APs) at two sites and a Psychological Wellbeing Practitioner (PWP) at one site. APs 
are psychology graduates who support the work of a clinical psychologist and work 
under the supervision of a clinical psychologist. Many APs aspireto train to become  
clinical psychologist.s The level of expertise and experience of an assistant 
psychologist can vary but they would need to meet the person and job specification 
for the band at which they would be employed (NHS Band 4 or Band 5). PWPs have 
completed an accredited training course to enable them to deliver low intensity CBT 
based interventions to people with mental health conditions.  
 
The two Assistant Psychologists in the study were therefore Psychology graduates. 
They had no previous formal training in psychotherapy and had not previously 
worked in a stroke service. They were newly appointed to working as an Assistant 
Psychologist in the stroke service at their site; their background and level of 
experience was comparable to the Assistant Psychologists who delivered BA to 
people with aphasia in our previous CALM study.  
 
Participants were offered a maximum of 15 sessions of BA over four months, with an 
expected average of ten sessions. Therapy sessions were delivered face to face on an 
individual basis and lasted about one hour. The intensity and duration of therapy was 
based on a study of CBT with stroke patients
25
and was informed by the CALM study 
in which participants received an average of nine one-hour sessions over three 
months.
17
Experience and criticism of the CBT trial
25
was that three month duration of 
therapy was too short. The trial of BA for treating depression in primary care 
provided 12 sessions over three months
61
 but this was not in a stroke sample and 
patients with communication or cognitive difficulties may require a longer duration of 
therapy. The duration of therapy was therefore four months because the CALM study 
showed that it was difficult to complete sessions in three months due to non-
availability of the participant and short-term illnesses. Four months also allowed 
flexibility to provide therapy visits to support maintenance, as might be provided in 
clinical practice. However, the number of therapy sessions varied according to the 
needs of the individual and their progress in therapy. The intensity of treatment was 
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negotiated between the therapist and the participant, based on their progress in 
achieving their therapy goals, as to reflect usual clinical practice. 
 
A BA treatment manual was developed for the previous CALM trial based on the 
behavioural component of CBT for depression in stroke patients,
23, 25
 behavioural 
therapy with older people
41 
and guidelines on conducting therapy with people who 
have aphasia.
21, 41, 51
 For the BEADS trial, this therapy manual was further revised to 
include BA with stroke patients who did not have aphasia, and provided examples and 
practical guidance relevant to all stroke patients. In revising the manual from the 
CALM trial we drew upon the CBT therapy manuals of Laidlaw
62
 and Lincoln, 
Flannaghan, Sutcliffe and Rother,
23
 behavioural activation manuals of Lejuez, Hopko, 
Acierno, Daughters and Pagoto
63
, Martell, Dimidjian and Herman-Dunn
40
 and 
Mitchell
64
 behavioural activation strategies used in low intensity CBT
65
, and 
guidelines on adapting CBT for people withstroke.
22, 51, 66
 
 
The therapy manual contained session content for ten sessions using the same 
behavioural approaches as the CALM study. Participants could receive up to 15 
sessions to allow for the fact that for some people it may take longer to cover therapy 
content. Additional guidelines were provided for identifying strategies to support 
people with aphasia and materials were recommended to enable guidelines on 
conducting therapy to be followed. 
 
Goals set during treatment to increase enjoyable activities were tailored to the 
individual. BA also included ‘homework’ tasks to be completed between sessions to 
practice exercises and increase activity levels. Behavioural treatment strategies 
focused on maximising mood-elevating activities. The process of BA involved 
identifying how the person currently spends their time, identifying activities that they 
enjoyed doing (this included resuming previous activities, increasing current activity 
levels or introducing new activities) and setting goals to increase the number of 
enjoyable activities. 
 
Behavioural therapy techniques included: 
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Activity monitoring: Therapists identified how participants spent their time to assess 
current activity level, determined what activities they enjoyed and when activities 
could be carried out. Participants were given an activity diary or timetable to complete 
as a homework task. The complexity of the diary varied according to the cognitive 
and communication abilities of the patient. The activity diaries were available in a 
range of formats including the use of word cards, picture cards and photographs. 
 
Activity scheduling: Participants were encouraged to plan realistic activities and goals 
to complete each day. This was intended to increase the likelihood that activities were 
being carried out. The number of activities was gradually increased in order to 
increase the amount of positive reinforcement received. Activities were set according 
to the abilities and goals of the individual. 
 
Graded task assignment: Tasks were broken down into smaller, manageable steps, to 
facilitate practising tasks participants found difficult. This was intended to increase 
the frequency of self-reward and reduce the chances of failure and avoidance of tasks. 
For example, for someone who wanted to go shopping, they started by going to a 
familiar local shop where they knew people already; this was then extended to going 
to a larger shop,further away. 
 
Problem solving: This included focusing on difficulties a participant may have with 
completing activities and using behavioural techniques (such as a graded task) for 
improving success at these tasks. Common problems in carrying out activities or tasks 
were identified and then a problem-solving approach was used to identify and 
practisepossible solutions.  
 
After each session, therapists completed the Therapy Recording form. This included 
the duration and location of the therapy session and whether there was another person 
present. The time taken to travel to the visit was recorded. The Therapy recording 
form also included an estimate of how much time (in 10 minute units) had been spent 
on each component of therapy. The components of therapy were based on the content 
of BA approaches in the manual. 
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The therapist also completed the Therapy Session log. This included the planned 
number of treatment sessions, the number of treatment sessions completed and the 
reasons that sessions were missed. 
 
Ensuring Intervention Fidelity 
 
The therapists attended a two-day workshop led by an NHS Consultant Clinical 
Psychologist and the Chief Investigator. The workshop covered the rationale of 
therapy for treating depression, application of behavioural techniques for treating 
post-stroke depression, and explanation of the therapy manual. The workshop 
included fictional case examples and role play exercises. The workshop also included 
training from a Speech and Language Therapist on communicating with stroke 
patients with cognitive and/or communication difficulties. Communication resources 
were developed during the CALM study (such as picture cards and activity schedules) 
and were provided for each of the therapists. To support between session activities, 
worksheets/information appropriate sheets were developed for varying levels of 
cognitive difficulties or aphasia.  
 
It was important that the therapists delivered the intervention consistently in 
accordance with the therapy manual. Weekly clinical supervision for the therapists 
was provided by a local Clinical Psychologist at each site. In addition, therapists 
delivering the intervention had a monthly teleconference to discuss the content of the 
intervention, share examples of practice and raise any difficulties with the Chief 
Investigator and NHS Consultant Clinical Psychologist.  
 
A sample of therapy sessions were video recorded (see 2.2 Fidelity assessment for 
further details). 
 
Control group – Usual care 
The availability of psychological support in the three sites varied. The content of 
usual care was decided locally by the clinical team, as per local services. In the three 
sites, most stroke survivors are admitted to hospital, usually to a stroke unit. On 
discharge they may receive input from an Early Supported Discharge team or from a 
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community stroke/rehabilitation team.  
Participants in the usual care group followed the current care pathway. Participants 
received all other services routinely available to them as local practice but had no 
contact with the trial therapist. This usual care control group provided a record of 
usual care to inform the design of the definitive trial. 
Concomitant treatment 
Those receiving medical or psychological treatment for depression at the time of 
stroke onset were excluded as we were interested in those who developed depression 
following stroke (as per exclusion criteria in section 2.1.4 above). Those who were 
currently receiving antidepressants were included so we could record how commonly 
this occurs. Receipt of antidepressant medication or other psychological intervention 
for depression was recorded in the CRF. 
 
Compliance 
Compliance with BA was regarded as an outcome measure not as a covariate and was 
measured by recording whether participants allocated to the BA intervention attended 
scheduled therapy session. The completion rates of follow-up questionnaires were 
also recorded. 
 
2.1.7 Feasibility criterion 
Primary Outcome 
The primary outcome measures related to the feasibility of a) proceeding to a 
definitive trial and b) delivering the behavioural activation therapy intervention with 
participants with post-stroke depression. 
 
The primary endpoints were based on: 
a. Feasibility of recruitment  
b. Acceptability of the research procedures and measures 
c. Appropriateness of the baseline and outcome measures for assessing impact 
d. Retention of participants at outcome 
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e. Potential value of conducting the definitive trial, based upon value of 
information analysis 
 
Other feasibility outcomes 
The secondary endpoints were related to the feasibility of the behavioural activation 
therapy intervention, based on: 
a. Acceptability of behavioural activation therapy to participants, carers and 
therapists 
b. Feasibility of delivering the intervention by Assistant Psychologists or 
therapist s under supervision of an experienced mental health practitioner 
c. Documentation of ‘usual care’ using a healthcare resource use questionnaire 
d. Treatment fidelity of the behavioural activation therapy 
e. Feasibility of delivery of behavioural activation therapy within current 
services and within a definitive trial 
f. Estimating the sample size for a definitive trial 
 
Clinical outcomes 
Primary outcomes 
The primary clinical outcome measure at 6 months was the PHQ-9 
Questionnaire.
58
For participants with moderate to severe language problems who 
were unable to complete the PHQ-9,the VAMS Sad item
59
was used – this was a 
single item visual analogue mood measure. The number of participants unable to 
complete the PHQ-9 was recorded, and the VAMS Sad was completed with all 
participants so the relationship between the measures could be explored. This was a 
pragmatic approach, based on self-completion at baseline. 
 
Secondary outcomes 
The secondary clinical outcomes were the questionnaire measures used to assess the 
potential secondary outcomes at six months following BA therapy. These related to 
the feasibility primary endpoints b) and c). The following measures were used to 
assess clinical outcomes at 6 months: 
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 Stroke Aphasic Depression Questionnaire (SADQH-10) – Hospital version 
(observer-rated depression)
67
 
 Nottingham Leisure Questionnaire (NLQ) (leisure activities)68 
 Nottingham Extended Activities of Daily Living (NEADL) (functional outcome)69 
 Carer Strain Index (CSI) (carer-rated level of strain)70 
 EuroQol EQ-5D-5L(health related quality of life) – standard version71 and version 
for people with cognitive problems
72
 for participants and carers 
 Healthcare resource use questionnaire 
 
Participant withdrawal 
Participants had the right to withdraw from the study at any time. The reasons for 
leaving the study, where given,  were recorded on a CRF.. Participants who withdrew 
were still invited to complete the 6 month outcome assessments unless they had 
specified that they wished to have no further involvement in the trial. Individuals 
removed from active participation in the intervention were not replaced. Reason for 
withdrawal from the intervention, if known, was recorded. 
 
Participants were withdrawn from the trial either at their own request or at the 
discretion of the Chief Investigator. The investigator could withdraw a participant in 
the interest of the participant (e.g. if continuation in the trial was considered to be 
causing undue stress) or due to a deviation from the protocol (e.g. where, following 
review, it transpired that a participant was incorrectly deemed eligible at the time of 
consent). Participants could discontinue their allocated intervention or withdraw from 
the study for the following reasons:  
 
 withdrawal of consent,  
 changes to their health status preventing their continued participation,  
 failure to adhere to protocol requirements.  
 
If, during the trial there was a patient allocated to the BEADS intervention who 
subsequently requiredclinical psychology input (as per the protocol of the local 
service) then the BEADS therapist (AP/PWP) discussed this with the clinical 
psychologist or clinical lead and the patient and all agreed what was best for the 
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participant. If it was agreed that the patient needed immediate clinical psychology 
input then they were withdrawn from the BEADS intervention and they saw the 
clinical psychologist, or were referred to alternative provision. The patient was 
therefore withdrawn from the intervention but not the overall trial, and thus outcome 
data was still collected from them. We recorded the number of participants who were 
withdrawn from the BEADS intervention because of a conflict in using clinical 
services. 
 
2.1.8 Changes to trial outcomes after the trial commenced, with reasons 
An additional secondary endpoint, to estimate the sample size for a definitive trial, 
was added to the protocol after the trial commenced, as an inconsistency was 
identified between the SAP and the protocol.  
 
2.1.9 Sample size 
As this was a feasibility study, it was not powered for efficacy and no formal interim 
analyses of efficacy were conducted; the sample size was adequate to estimate the 
uncertain critical parameters (standard deviation for continuous outcomes; consent 
rates, event rates, attrition rates for binary outcomes) needed to inform the design of 
the definitive RCT with sufficient precision. The sample size of 60 participants 
allowed SD for continuous outcomes, such as the PHQ-9 and VAMS Sad, to be 
estimated to within precision of approximately ±19% of its true value (with 95% 
confidence). Allowing for 15% attrition by 6 months post-randomisation follow-up, 
72 participants needed to be recruited. To achieve the target sample size of 72, over 
the 12 month recruitment period, with three centres, we needed to randomise two 
participants per centre per month.  
 
In addition to this, we estimated that we would recruit a total of 65 carers and three 
therapists to the study. The carer estimate was based on the CALM study
17
 where 
approximately 90% of people with stroke had an informal carer present who 
completed the study outcome assessments. The total sample size was 140. 
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Further information on both the quantitative and health economic analysis are 
provided in the Statistical Analysis Plan. This covers both the procedures for missing, 
unused and spurious data and definitions of populations whose data were analysed. 
 
2.1.10 Explanation of any interim analyses and stopping guidelines 
The overall study could have been stopped because of safety concerns or issues with 
study conduct at the discretion of the sponsor. There were no formal statistical criteria 
for stopping the trial early. Decisions to stop the trial early on grounds of safety or 
futility would have been made by the Trial Steering Committee (TSC) on the basis of 
advice from the Data Monitoring and Ethics Committee (DMEC). No early stopping 
was planned, but the study could have been terminated early if, in the view of the 
TSC, no useful information was likely to be obtained by continuing. The criteria for 
assessing this were primarily the feasibility outcomes listed in section 2.1.7. The 
Steering Committee could also have recommended the closure of a centre but that the 
trial as a whole continued, on the same grounds. Unblinded adverse event data were 
reviewed by the DMEC, who could have recommended to the TSC that the trial was 
stopped if, in their opinion, there was evidence of harm in the intervention group. As 
this was a feasibility trial, it would not have stopped early for efficacy. 
 
2.1.11 Method used to generate the random allocation sequence 
Randomisation was conducted using a computer-generated list with random permuted 
blocks of varying sizes, created and hosted by the Sheffield CTRU in accordance with 
their Standard Operating Procedures (SOPs) and was held on a secure server. Once a 
participant had consented to the study, the therapist logged into the remote, secure, 
internet-based randomisation system and entered basic demographic information. The 
allocation for that participant was then revealed to the researcher.  
 
2.1.12 Type of randomisation; details of any restriction (such as blocking and 
block size) 
Block randomisation with randomly varying block size of two, four and six was used 
so that the sequence of allocation could not be predicted. The block sizes were 
determined by the trial statistician and block size was not revealed to any other 
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member of the study team. Participants were allocated to behavioural activation or 
usual stroke care at a ratio of 1:1. Randomisation was stratified by site. 
 
2.1.13 Allocation concealment mechanism 
Access to the allocation sequence was restricted to those with authorisation. The 
sequence of treatment allocations was concealed until interventions had been assigned 
and recruitment, data collection, and analyses were complete. 
 
Neither the participants nor the therapists were blind to which treatment the 
participants were receiving. The outcome assessors (researcher) were blind to the 
treatment received and there was no requirement for them to know the treatment 
allocation at any stage. As a result a procedure for breaking the code was not 
necessary. 
 
2.1.14 Blinding 
Participants were randomised at baseline (after consent and baseline assessments) in 
equal proportions to BA or usual stroke care. It was not possible pragmatically for the 
participant or therapist to be blind to the group allocation, but the researchers 
completing 6 month outcome assessments were blinded and also had no involvement 
in any other aspects of the trial. The researchers were asked to record whether or not 
they thought they were unblinded and werealso asked to guess the group allocation. 
We followed guidelines to minimise unblinding during randomised controlled trials of 
rehabilitation.
73, 74
 
 
The trial statisticians remained blind until data freeze, at which point data checks were 
carried out on unblinded data. 
 
2.1.15 Statistical methods 
As the trial was a pragmatic parallel group RCT, data were reported and presented 
according to the CONSORT 2010 statement.
55
All statistical analyses were performed 
in R version 3.3.1.
75
As a feasibility study the main analysis was descriptive and 
focussed on confidence interval estimation and not formal hypothesis testing. 
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2.1.16 Analysis populations 
The intention to treat (ITT) population includes all participants for whom consent was 
obtained and who were randomised to treatment, regardless of whether they received 
the intervention or not. This is the primary analysis set and endpoints were 
summarised for the ITT population unless otherwise stated. 
 
Baseline Characteristics 
Baseline characteristics were participants’ demographics (age, sex and ethnicity), 
patient and carer reported outcomes (PHQ-9, VAMS Sad, EQ5D-5L, NEADL, NLQ, 
SADQ, CSI and EQ5D-5L carer), stroke history (time since last stroke, lateralisation 
of stroke, stroke type, side of weakness, previous stroke, depression treatment) and 
stroke outcomes (Montreal Cognitive Assessment [MoCA], Frenchay Aphasia 
Screening Test [FAST] and Modified Rankin Scale). 
 
For continuous variables, the number of observations, mean and standard deviation or 
median and interquartile range (IQR) and minimum and maximum observations were 
presented by treatment group and site. For categorical variables, the number and 
percentage of observations in each category were presented.  
 
Imbalance between treatment arms was not tested statistically but was reported 
descriptively. 
 
Feasibility outcomes 
The number of participants screened, eligible and randomised per month per centre 
and overall were presented with relevant percentages. Attrition was examined by 
presenting the number of participants who dropped out by treatment arm, site and 
time since last stroke. The reasons for attrition, where given, were also presented for 
each participant.  
The time of key events including screening, randomisation, baseline, and follow up 
was plotted by participant to check that these were carried out as planned. 
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The number and percentage of participants randomised to the BA arm and who 
received at least two, five, eight and ten therapy sessions were presented. The mean, 
SD, median and IQR number of planned sessions that were missed were presented.  
A summary of missing patient and carer reported outcome measures was also 
presented. In addition to this, we reported the timing of the post randomisation follow 
up assessment. 
As part of the feasibility analysis, the effect size for the 6-month PHQ-9 outcome (the 
probable primary endpoint for the definitive study), the difference in mean scores 
between the BA and control groups was estimated, along with its associated 95% 
confidence interval estimate,
76
 using a mixed effects model including site as a random 
effect and baseline PHQ-9 as a covariate to check that the likely effect was within a 
clinically relevant range as confirmation that it was worth progressing with the 
definitive trial. 
 
The following sensitivity analyses were presented alongside the ITT analysis: 
 Multiple imputation of missing primary outcome data; 
 Unadjusted analysis. 
Although this was not pre-specified, to examine the effect of the treatment we also 
examined the change in PHQ-9 depression categories defined as follows (see  
Table 1): 
 
Table 1 PHQ-9 Depression Categories 
PHQ-9 Score Depression category 
0-4 Minimal depression 
5-9 Mild depression 
10-14 Moderate depression 
15-19 Moderately severe depression 
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20-27 Severe depression 
 
 Individual PHQ-9 score and depression category at baseline and follow up was 
plotted by intervention arm. To assess the level of agreement between PHQ-9 and 
VAMS Sad, scatterplots were generated using baseline and 6 month follow up data. 
Pearson’s correlation coefficient was also calculated using baseline and 6 month 
follow up data. 
 
Sample size calculations for a definitive trial 
We calculated a sample size for a definitive trial comparing BA to usual care in 
participants with post-stroke depression. The primary endpoint used was PHQ-9 at 6 
months post randomisation. The sample size was based on a range of differences in 
PHQ-9 of between 3 to 5 points
77
 and a range of conservative estimates of SD of 7 to 
11 points giving a range of standardised effect sizes between 0.27 to 0.71 allowing us 
to determine the most appropriate option.   Feasibility data was used to calculate the 
ICC in the intervention arm based on clustering by site. Furthermore, the feasibility 
trial attrition rate was used to adjust the final sample size calculation. 
 
Clinical outcomes 
Primary outcomes 
The primary clinical outcome measure at 6 months was the PHQ-9
58
We planned that 
those participants with moderate to severe language problems who were unable to 
complete the PHQ-9, the Visual Analog Mood Scales (VAMS) Sad item
59
would be 
used – this was a single item visual analogue mood measure. However, we did not 
have any participants with moderate to severe language problems who did not 
complete PHQ-9. A comparison of PHQ-9 to VAMS Sad item was carried out as 
described above to inform a potential definitive trial. 
 
To assess the quality of the primary outcome, the follow up window, defined as the 
period between screening and 6 month follow up assessment, was calculated for each 
participant. A mean and SD of follow up time in days was calculated. Timing of key 
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events (screening, consent, randomisation, withdrawal, follow up) were plotted with 
number of days on the x axis and screening number on the y axis. 
 
The secondary outcomes at 6 months post randomisation were analysed using a 
multiple linear regression model on the ITT population adjusting for baseline measure 
and centre to examine the difference between treatment arms. Mean differences and 
their 95% confidence intervals were presented. 
 
 
Missing Spurious and Unused Data 
The number of missing scores for each of the primary and secondary outcomes was 
presented by baseline and 6 months post randomisation and by treatment arm. 
Furthermore, the number and percentage of missing items was presented for each of 
these questionnaires.  
 
Multiple imputation was carried out using the Multivariate Imputation by Chained 
Equations ‘mice’ package in R statistical software.78Missing 6 month post-
randomisation PHQ-9 scores were imputed using chained equations and 30 multiply 
imputed data sets. The multiple imputation model included sex, age, treatment group, 
PHQ-9 score at baseline and/or 6 months, EQ5D-5L at baseline and 6 months and 
SAD-Q at baseline and 6 months as predictors. 
 
Safety outcomes 
The number of Adverse Events (AEs) and Serious Adverse Events (SAEs) was 
recorded and presented by treatment arm. These events were further categorised by 
the type of adverse event (fall, worsening health etc.) and whether they resulted in a 
hospital stay. 
 
2.1.17 Patient and public involvement (PPI) 
The BEADS trial received input from the PPI group (including one patient with 
significant aphasia) for aspects of the design and methods development as well as 
study oversight. Two patients and a carer attended five scheduled meetings to discuss 
feedback on how the study was being conducted including ideas about recruitment, 
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study documents, ensuring the wellbeing of the patients and carers and supporting the 
therapists. The meetings were attended by the PPI members, the trial manager and the 
Chief Investigator. Meetings took place prior to ethical approval when study materials 
were being developed, during recruitment and intervention delivery, and to discuss 
the study results. The meetings each had an agenda that was agreed by the group. A 
summary of the discussions was written up by the trial manager and Chief 
Investigator and was circulated to the group for them to add any points and to ensure 
it was an accurate summary of the meeting. Suggestions were put into practice with 
the creation of a short study summary card and a spiral-bound version of the aphasia-
friendly participant information sheet. At the suggestion of the patient and carer 
representatives, the therapists were invited to join the PPI meetings. In these 
meetings, the PPI members were able to ask the therapists questions and give 
suggestions. Issues discussed included the PPI members asking whether therapists 
found their job difficult and whether there were any challenges with delivering the 
intervention. The therapists explained that they were well supported and that they 
enjoyed their role. The PPI members felt that this was crucial to the success of the 
study. Another question asked by the PPI group was whether the therapists felt that 
having the carer being present during therapy was helpful or not. The therapists 
explained that the carer provided support to the patient. One of the therapists said that 
they made sure they addressed any discussion or questions to the participant directly 
so that they could choose when they wanted their carer to answer on their behalf. 
 
 
2.2 Fidelity assessment 
To ensure the fidelity of the intervention, the content of treatment was described and 
analysed against the manual.  
 
Therapy sessions were videoed to ensure the treatment was being delivered according 
to the manual and potentially be used for future training. The plan was to select 
participants and sessions iteratively using purposive sampling to represent the range 
of severity of depression (mild, moderate, severe from baseline scores) and across the 
phases of therapy (beginning, middle and end). We planned to video up to 24 therapy 
sessions (based on recruiting the target sample size). It was anticipated that more 
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sessions would be recorded in the middle phase of therapy because this covered more 
of the therapy sessions and is where the majority of the BA intervention occurs.  
 
The video recordings were transferred to a secure encrypted device and deleted from 
the video recorder prior to transportation and stored in a secure area on the University 
of Nottingham server. 
 
Practices for video recording drew upon guidance on minimizing intrusiveness of the 
recording.
79, 80
Coding of videos was carried out by an independent researcher using a 
time sampling procedure. Recordings were made on the minute, every minute 
throughout the recording. On each observation, the activity of the therapist and 
participants was given the appropriate activity code.  
 
The assessors analysing the videos applied a customized therapy record form 
designed to capture a variety of key elements spanning all aspects of the intervention. 
The recordings included activities which were expected in all sessions and those 
which were session specific. They also included content derived from the treatment 
manual and other content. The other content included activities which were likely to 
occur but were not specified in the manual, such as social chat and making travel 
arrangements. A sample of recording was checked by another observer and 
discrepancies were resolved by discussion. 
 
The video recording categories are shown in Appendix 2. 
 
Data from coding sheets was entered into SPSS for analysis. 
 
2.3 Health Economic Methods 
 
2.3.1 Background 
The health economic analysis had two key components which related to the primary 
endpoints of the trial. These were: 
 Assessing the feasibility of collecting data that may be used in a health 
economic analysis 
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 Conducting an economic evaluation and a value of information analysis in 
order to provide information on the potential value of conducting the 
definitive trial. 
2.3.2 Overview 
For the feasibility analysis, the number of participants who had complete data for each 
of the key measures is reported for each time-point by treatment group and overall. 
For patient and carer questionnaires, the item response rate at each visit (baseline and 
6 months) are reported. Response rate was measured as a fraction of the total number 
of items. This provides an analysis of the feasibility of collecting data required to 
complete a health economic analysis. For the health economics analysis, the data of 
most relevance are: 
 EQ-5D-5L – standard version (completed by participants who are able) 
 EQ-5D-5L – aphasia accessible version (completed by all participants) 
 EQ-5D-5L – completed by the carers of participants for themselves 
 EQ-5D-5L – completed by the carers of participants on behalf of the 
participant 
 Resource use questionnaire 
 
For the economic evaluation a series of cost-effectiveness analyses were conducted: 
 
 Within-trial analysis from an NHS and Personal Social Services perspective 
 Within-trial analysis from a societal perspective 
 Model-based analysis from an NHS and Personal Social Services perspective 
 Model-based analysis from a societal perspective 
 
Due to the importance of carers for people with post-stroke depression it was 
important to include analyses undertaken with a societal perspective to supplement 
the NHS and Personal Social Services (PSS) analyses.  
 
The within-trial analyses were undertaken both with and without multiple imputation, 
which was used to estimate values for missing data. Patient-level costs and outcomes 
were assessed over the full length of the feasibility study, and this was supplemented 
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with the construction of a simple economic model to examine the longer-term cost-
effectiveness of treatment and priorities for future research. Costs and utilities were 
estimated for individual patients using data collected at baseline and follow-up, based 
upon responses to EQ-5D-5L and resource use questionnaires, combined with 
standard cost and valuation sources.
81, 82
 Differences between costs and quality 
adjusted life years (QALYs) in the two groups were described and the incremental 
cost effectiveness ratio (ICER) was calculated. 
 
The main aim of the BEADS study was to assess the feasibility of conducting a future 
definitive randomised controlled trial to investigate the clinical and cost-effectiveness 
of BA therapy for people with post-stroke depression. Therefore, our analysis cannot 
provide conclusive cost-effectiveness results. However, early cost-effectiveness 
modelling remains of value because it provides insight on the likely cost-effectiveness 
of the intervention and demonstrates the value of pursuing further research, 
particularly when value of information analyses are included.
83, 84
 The value of 
information framework allows the maximum value of further research to be estimated, 
taking into account the uncertainty in the parameters included in the economic 
model.
85, 86
 We estimated the expected value of perfect information (EVPI), 
representing the maximum value of further research on all uncertain parameters in the 
economic model, and also estimated the expected value of perfect partial information 
(EVPPI), representing the maximum value of obtaining more information on each 
specific parameter (or group of parameters) included in the model.  
 
2.3.3 Resource use 
Costs were estimated for each participant, including intervention costs (based on staff 
time and number of sessions), and health care resource use. Questionnaires were 
tested as a method for collecting resource use data. The resource use questionnaire 
included questions about a participant’s use of health services over the previous three 
months, representing the final three months of the follow-up period. As data were 
required for the entire 6 month follow-up period, we assumed that costs for the first 
three months were the same as for the final three months. In the questionnaire 
resources were split by services, such as inpatient, outpatient, primary care and 
community services, and where necessary included average appointment length. 
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Participants were also asked to record dosages of medication relating to depression, 
and information about carer time and employment. This information was used to 
calculate total medical costs and societal costs.  
 
2.3.4 Unit costs 
Resource use data were combined with unit cost data from the latest versions of the 
personal social services research unit (PSSRU) unit cost publication,
87
Reference 
costs
81
 and the British National Formulary
88
 in order to calculate costs for inclusion in 
the economic analysis. When appropriate values were not available from the latest 
version of the PSSRU unit costs publication, earlier versions were consulted
89-91
 and 
prices were inflated using the hospital and community health services index.
87
 
 
The unit costs used to estimate the costs associated with the resource use observed in 
the trial are presented in Appendix 3. 
 
2.3.5 Outcomes 
Participants who did not have moderate or severe language problems were asked to 
complete the standard version of the EQ-5D-5L as well as an amended (and as yet 
unvalidated) accessible version (based upon pictures).
57
 Participants who 
hadmoderate to severe language problems were asked to complete the accessible 
version of the EQ-5D-5L. In addition, for participants who had carers, the carer was 
asked to complete a standard EQ-5D-5L by proxy. This allowed us to test alternative 
methods for collecting data from which to calculate QALYs.  
 
2.3.6 Analysis 
Within-trial analysis 
Utility scores, based on EQ-5D-5L responses, were calculated for participants at 
baseline and follow-up. Differences between costs and QALYs in the two groups 
were estimated over the 6 six month trial period using Seemingly Unrelated 
Regression (SUR). SUR allows for correlation between costs and utility data.
92-94
The 
SUR model was specified to adjust for baseline EQ-5D-5L as suggested by Manca et 
al.
95
 and also adjusted for baseline (pre-randomisation) costs. The regression was run 
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for participants with no missing data (complete cases) and also for all participants 
including imputed values for costs and utilities. 
 
For missing EQ-5D-5L data multiple imputation was used as described in 2.1.16. 
Predictive mean matching was used to impute the missing data for costs using a 
chained regression.
96
 Thirty imputations were generated for each missing value, and 
the mean of these was used in the final imputed dataset analysis. Differences between 
costs and QALYs were summarised using the incremental cost-effectiveness ratio 
(ICER) and confidence intervals were algebraically determined by using the variance-
covariance matrix.  
 
A supplementary societal perspective analysis involved costing carer time associated 
with each participant (collected using the resource use questionnaire) using the human 
capital approach.
97
 The resource use questionnaire also collected data on employment 
changes and private care costs, which were incorporated in the societal analysis.  
 
Model-based analysis 
The trial-based analysis was supplemented with an analysis using a simple decision 
analytic model, used to estimate the cost-effectiveness of the intervention over the 
lifetime of participants. This was populated using the trial data combined with unit 
costs and mortality rates as well as assumptions regarding the maintenance of the 
treatment effect over time. The base case analysis was undertaken from an NHS and 
PSS perspective, but a supplementary societal analysis was also undertaken. 
 
The structure of the model (see Figure 1) was based on that used to estimate the cost-
effectiveness of computerised aphasia treatment compared to usual stimulation in the 
CACTUS study.
72
 A simple three-state Markov model was used to extrapolate the 
data from the trial to a simulated cohort over a lifetime horizon. Participants entered 
the model in the no response state. Each month, they could remain in this state or 
transition to the good response state or death. Once in the good response state 
participants could remain in this state, move back to the no response state, or to death. 
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Transition probabilities were primarily based on the trial data. The primary clinical 
outcome measure was the PHQ-9, and therefore we based our definition of “good 
response” on PHQ-9 scores. Specifically, participants moved from the “no response” 
state to the “good response” state if they achieved a 4.78-point decrease in PHQ-9 
score from baseline to follow-up. This definition of a response was chosen based upon 
the minimum important clinical difference of PHQ-9 reported by Löwe et al.
77
 In the 
model we assumed that the intervention would be given over four months, as in the 
trial, and a response (if achieved) would occur after three months. As the trial only 
had one follow-up time point it was not possible to estimate a relapse rate for a good 
response. Hence, in the base case it was assumed that the relapse rate was zero. A 
sensitivity analysis was carried out to estimate the effect on cost-effectiveness of 
changing the relapse rate – in this analysis it was assumed that participants in the 
“good response” state could move back to the “no response” state after 6 months. 
Transitions from the “no response” and “good response” states to death were based 
upon evidence on long-term survival following stroke,
98
combined with background 
mortality rates from the Office of National Statistics,
99
 reflecting the approach taken 
in a previous economic evaluation of an intervention for people with aphasia.
72
 The 
same mortality rate was used for the “no response” and “good response” states. 
 
The HRQoL utility scores applied to each health state were reduced over time 
according to multipliers estimated by Ara and Brazier.
100
 QALYs were estimated for 
each cycle of the model by combining utility scores with life years, allowing the total 
QALYs associated with each treatment strategy to be calculated. Costs and QALYs 
were discounted at a rate of 3.5% each year, in line with recommendations made by 
the National Institute for Health and Care Excellence.
101
 
No 
response 
Good 
Response 
Dead 
Figure 1 Markov model 
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Distributions were placed around each of the uncertain parameters included in the 
model for use in probabilistic sensitivity analysis (PSA), which allowed the estimation 
of cost effectiveness acceptability curves (CEAC) and a value of information analysis. 
Gamma distributions were used for costs, log normal distributions for utilities, and 
beta distributions for probabilities, with dispersions based upon numbers observed in 
the trial. The PSA was supplemented with deterministic scenario analysis on the 
relapse rate as this was not observed directly in the trial.  
 
The EVPI and EVPPI analyses were undertaken assuming a cost-effectiveness 
threshold of £20,000 per QALY gained (based upon NICE decision rules
101
) over a 
period of 10 years (assuming that it might take 10 years before a new treatment for 
these patients is developed), using a 3.5% discount rate. The Sheffield Accelerated 
Value of Information tool
102
 was used to estimate the EVPI and EVPPI. 
 
2.4 The qualitative research 
A series of qualitative interviews with a sample of participants and carers (from both 
the intervention and control arms of the study), as well as all three therapists were 
completed by an independent researcher to provide a description of the acceptability 
of the design and procedures used in the trial and the BA intervention. We 
interviewed 16 participants and ten carers. The participant and carer interviews were 
completed in their homes (or agreed convenient private location) and the therapist 
interviews were completed in private locations, as agreed with the researcher. 
Participants and carers were interviewed after 6 month outcome assessments had been 
completed. Therapists were interviewed after they had completed all therapy sessions 
for the study. The interviews took between 10 to 55 minutes. All participants were 
provided with information concerning the purpose of the study, issues relating to 
confidentiality and anonymity of the data, and their rights as a participant. All 
participants provided informed consent to participate in the interview, which was also 
audio recorded on an encrypted digital recorder and transferred to a secure area on the 
University of Nottingham server. The researcher transcribed all of the interviews; the 
transcripts did not include any personal identifiers and the recordings were deleted 
upon completion of the transcription. 
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2.4.1 Interviewer characteristics 
Three women and one man conducted the interviews with patient and carer 
participants. They were PhD students and research assistants who were registered 
allied health professionals (one was a speech and language therapist) or working 
towards gaining professional registration as an allied health professional 
(psychologist). They had experience of working with people with neurological 
conditions and had been trained to conduct interviews with patients and carers, 
including those with reduced language and cognitive ability. Dr Gogem Topcu, who 
has expertise in health psychology and research into long-term conditions, conducted 
the therapist interviews. She is an experienced qualitative researcher who adopted a 
realist pragmatic approach to research; she had no previous experience of conducting 
BA therapy. 
 
 
2.4.2 Relationship with participants 
The interviewers’ role was to guide and facilitate the interview, rather than imposing 
how the interview proceeded. The interviewers had no involvement in the delivery or 
provision of care for the patient-participants, and participants were aware of this. The 
person who interviewed the therapists did not have any prior relationship with the 
therapists. The interview analysts did not have a personal view on the benefits or 
limitations of the intervention or about participants’ experience of taking part in the 
study. 
 
2.4.3 Theoretical and thematic framework 
A Framework Approach was adopted, which is a hierarchical, matrix-based method 
for ordering and synthesising qualitative data.
103, 104
 This approach enables in-depth 
exploration of the data while simultaneously maintaining an effective and transparent 
audit trail.
103, 105
 Adopting this approach consolidated the rigour of the analysis and 
the credibility of the findings.  
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The thematic framework was constructed iteratively from the interview objectives and 
existing literature (e.g., previous trials of BA) as well as the issues the participants 
raised during the interviews. We followed Ritchie and Spencer’s104approach in 
arriving at the final thematic framework, which began with familiarisation of the 
transcripts and audio recordings of the interviews to gain an overview of the data, 
noting salient points and recurrent ideas. The thematic framework was further 
consolidated by amalgamating the notes taken during the familiarisation process and 
the a priori issues covered in the interview schedule and extant literature. We did, 
however, keep an open mind to incorporate material that did not fit within our pre-
defined structure, and iteratively checked whether additional themes were warranted 
or whether some pre-defined themes needed to be minimised in terms of importance 
or relevance, based on the interview (see Appendix 4 for a worked example of an 
audit trail of how a? framework was developed and amended).  
 
2.4.4 Participant Selection 
We used a purposive, maximum-variation sampling strategy to select participants and 
their carers for the interview phase. We attempted to recruit a heterogeneous sample 
based on their demographic and stroke characteristics. The selection strategy was 
designed to balance the sample of participants in the following categories:  
1) Recruitment site 
2) Treatment arm 
3) Gender of participant 
4) Level of depression (mild, moderate or severe) 
5) Aphasia status 
6) Recruitment (early or late to the study) 
As there were a large number of stratification factors, we prioritised selecting 
participants by site and treatment arm, and then the other factors. The sample size was 
guided by our previous experiences of soliciting feedback about trials from stroke 
survivors and patients with neurological conditions (e.g., das Nair & Lincoln
106
) 
whereby we felt we were able to achieve sufficient detail related to each construct 
under investigation, and the categories had ‘conceptual depth’.107. We were also 
guided by the limits placed by the recruitment process of the main trial and our 
framework analysis method. Our primary criterion for conceptual depth related to the 
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question: ‘Do we have sufficient data for each key question that represents rich, 
nuanced, wide ranging experiences, that resonate with (agree or depart from) the 
extant literature?’ (cf., Nelson108). Therefore, we did not seek to achieve ‘data 
saturation’ per se. The trial therapists from each participating site were invited to take 
part in interviews about their experiences of working on the trial and delivering the 
intervention. 
 
2.4.5 Data collection 
The interviewers had sufficient knowledge of the interview schedule to loosely follow 
the questions in line with interests and views offered by the participant. While a pre-
determined and structured schedule was used to conduct the interviews, the interviews 
were flexible allowing the emergence of issues relevant and important to interviewees 
that were not in the initial schedule. This allowed participants to say what they felt 
was important to them, while maintaining a basic framework of inquiry at the same 
time. Prompts were used throughout interviews to provide cues when participants had 
difficulties, to clarify questions or encourage responding.  
 
The interview schedule included general questions for all participants and carers 
concerning their experiences of participating in the study, and specific questions to 
those who had received the intervention and those who were in the control group (see  
and Appendix 6). An accessible version of the interview questions were also 
developed for participants with aphasia. The interview schedule for therapists 
included questions relating to therapists’ experiences of delivering the therapy and 
views on the trial procedures, and practical aspects of delivering the therapy (see 
Appendix 7). Interviews were transcribed verbatim. The transcripts did not include 
any personal identifiers and the recordings were deleted upon completion of the 
transcription. 
 
2.4.6 Data analysis 
Data analysis was undertaken by GT using the framework approach,
103, 104
 where the 
data were mapped onto the constructed thematic framework. If required, the 
framework was amended to include new concepts or themes introduced during the 
interviews. To map the data onto the theoretical framework, we relied on indexing 
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various sections of the data to specific thematic constructs. This again, was an 
iterative process, requiring GT to go back to previously analysed transcripts to check 
whether the newly emerged construct was also evident in ‘older’ transcripts. After 
mapping all the data, a matrix was generated in which the data were charted to 
summarise each main theme. This matrix was then used in the interpretation of the 
data in addition to the notes made during the coding process. The interpretation 
process, like the other processes, was iterative and relied on consultation between GT 
and RdN regarding the viability and relevance of a theme, to interrogate theoretical 
constructs, and to unpack nuances within the data.  
 
To ensure rigour and credibility of the findings, RdN reviewed the generated matrix 
and checked the quotations for their relevance to the themes. Disagreements were 
resolved by discussion. We provided information regarding the context in which the 
interviews were conducted, some pertinent descriptions of the interviewers and 
interviewees, and some verbatim quotes from our participants, to ensure transparency. 
To ensure quality of study reporting, we used the Consolidated Criteria for Reporting 
Qualitative Research (COREQ) Checklist (see Appendix 8 ). 
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3 Results of the feasibility trial 
 
3.1 Implementation of intervention and trial 
3.1.1 Implementation summary 
The trial was due to start recruitment at the beginning of May 2015 but due to delays 
in set-up,  recruitment did not start in Site 3 until the 27 May 2015, in Site 1 until the 
20 August 2015 and in Site 2 until the 3 September 2015. This resulted in a total of 27 
recruitment months available rather than the planned 36. Recruitment ended as 
planned on the 30 April 2016. Follow-up was completed in November 2016.There 
were a number of issues in regards to recruitment, data collection and delivery of the 
interventions which are discussed below.  
 
Please note that in order to maintain anonymity the sites will be referred to as Site 1, 
Site 2 and Site 3 rather than by their geographical name. 
 
3.2 Recruitment and participant flow 
3.2.1 Recruitment to the trial 
The study set out to assess feasibility of recruitment by utilising a number of different 
recruitment routes including hospital database, community database, stroke ward, 
community caseload, voluntary group, self-referral and outpatients. The CONSORT 
flow diagram (see  
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Figure 2) shows the flow of participants through the trial. See section Feasibility 
criterion2.1.7for the primary endpoints referred to in the analysis section ( 
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Figure 2). 
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Figure 2 Study CONSORT Flow Diagram 
 
Table 2 displays a summary of recruitment flow by screening route and Table 3 shows 
the number identified by the different screening routes for each site. The number 
randomised signifies the success of each route,  however it is necessary to discuss 
each method in turn to fully understand its individual efficiency. Overall we 
randomised 49 participants to the trial in 27 centre months of recruitment (1 
participant was randomised in error and was not included in analysis and 1 participant 
withdrew consent 5 days after randomisation and was included in analysis). 
Recruitment by centre can be seen in Table 4 and numbers recruited by the 
recruitment route can be seen in Table 5. 
47 
 
 
48 
 
Table 2 Summary recruitment flow - by screening route 
 Hospital database 
Community 
database Stroke ward 
Community 
caseload Voluntary group Self-referral Outpatients 
Identified 444 8 183  80 9 4  28 
 n % n % n % n % n % n % n n 
Pack 
sent/Home 
visit arranged 
444  100.0 8  100. 64 35.0 24 30.0 9  100.0 3 75.0 22 78.6 
Pack 
received/Home 
visit conducted 
156  35.1 2  25.0 12 6.6 22 27.5 9 100.0 3 75.0 21  75.0 
Questionnaires 
completed 
74  16.7 1  12.5 11 6.0 20 25.0 9 100.0 3 75.0 20 71.4 
Initial 
eligibility met 
29  6.5 1  12.5 3 1.6 13 16.3 4 44.4 3 75.0 16  57.1 
Eligibility 
appointment 
conducted 
25  5.6 1  12.5 2 1.1 10 12.5 3 33.3 3  75.0 13 46.4 
Eligible 21  4.7 1  12.5 1 0.5 8 10.0 2 22.2 3 75.0 13 46.4 
Consent 
obtained 
21  4.7 1  12.5 1 0.5 8  10.0 2 22.2 3  75.0 13 46.4 
Randomised 21  4.7 1  12.5  1  0.5 8 1 0.0 2  22.2 3  75.0 13 46.4 
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Table 3 Number identified by screening route
a 
Route Site 1 Site 2 Site 3 Total 
 n % n % n % n % 
Community 
caseload 
10 2.6 63 22.7 7 7.9 80 10.6 
Community 
database 
0 0.0 8 2.9 0 0.0 8 1.1 
Hospital 
database 
198 50.8 193 69.7 53 59.6 444 58.7 
Out 
Participants 
4 1.0 7 2.5 17 19.1 28 3.7 
Self-referral 2 0.5 1 0.4 1 1.1 4 0.5 
Stroke ward 176 45.1 5 1.8 2 2.2 183 24.2 
Voluntary 0 0.0 0 0.0 9 10.1 9 1.2 
a 
1 participant from the hospital database was randomised in error 
 
Table 4 Participants randomised by centre and by month
a
 
 
Jul 
15 
Aug 
15 
Sept 
15 
Oct 
15 
Nov 
15 
Dec 
15 
Jan 
16 
Feb 
16 
Mar 
16 
Apr 
16
b
 Total 
Site 1 0 0 1 5 5 0 4 0 3 6 24 
Site 2 0 0 0 0 0 1 2 0 2 2 7 
Site 3  1 1 2 1 1 2 3 2 2 3 18 
a 
Recruitment start dates: Site 1- Opened 20/08/15, Site 2-Opened 3/9/15, Site 3-
Opened 27/05/15; 
b
1 participant was randomised in error at Site 2 
 
Table 5 Number recruited by the recruitment route 
 Site 1 Site 2
a
 Site 3 Total 
 n % n % n % n % 
Community 
caseload 
4  16.7 1 14.3 3  16.7 8  16.3 
Community 
database 
0  0 1  14.3 0 0 1 2 
Hospital 
database 
14  58.3 4  57.1 3 16.7 21  42.9 
Outpatients 3  12.5 0  0 10 55.6 13  26.5 
Self-referral 2 8.3 1  14.3 0 0 3  6.1 
Stroke ward 1  4.2 0  0 0 0 1 2 
Voluntary 0  0 0  0 2 11.1 2 4.1 
a 
1 participant from the hospital database was randomised in error 
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Table 6 shows that 28 out of a possible 33 carers were recruited to the study. These 
carers were evenly spread across treatment arms and centres. Table 7 shows the 
reasons that a small number of carers (n=5) refused consent to the trial. 
 
Table 6 Number of carers recruited to BEADS trial by treatment arm and site 
  Participants with carers Carers recruited 
 n % n % 
Overall 33 68.8% 2 84.8 
Treatment arm     
Intervention 17 68% 15 88.2 
Control 16  73.9 13 81.2 
 
Table 7 Reasons for non consent given by carers 
Reason for carer non consent n % 
Carer not present at time to give consent 3 40 
Carer does not speak English 1 20 
Carer does not have enough time and is not interested in participating in 
research 
1 20 
 
Hospital database 
The highest number of participants were recruited through the hospital database. This 
therefore could be considered the most efficient method as it only required minimal 
staff time. However uptake seemed to be even more effective if a potential participant 
is approached by a clinician and given the opportunity to discuss the study and ask 
questions. It is worth noting that the success of this route varied between the sites; in 
Site 1 the hospital database was their most effective route of recruitment. However, 
the therapist in Site 1 was based in the hospital setting and worked closely to support 
the CRN nurse to identify and recruit participants. By comparison the therapists at 
other two sites were based more at different hospitals from the CRN nurse and 
therefore were able to work less closely.  
 
Stroke Ward 
Based on the figures in Table 3 the stroke ward seemed to be the least effective 
recruitment route. Although research nurses had the opportunity to approach 
inpatients on the stroke ward to discuss the study, participants did not become eligible 
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to take part until three months after their stroke. The protocol indicated that the 
therapists should perform a mortality check prior to n contacting patients at three 
months post-stroke to establish if they were still interested in taking part. However 
this follow up might not always have taken place. Furthermore, in this early stage 
some stroke patients were more focused on dealing with practical issues, such as 
walking and talking, rather than with their mood. 
 
Community database 
Identifying patients through the community stroke databases was not used 
consistently across the three sites. Community stroke services varied between Trusts 
and records were kept less consistently than in secondary care. For a definitive study 
it would be important to discuss the composition of community services available to 
improve understanding of specific recruitment routes at the outset.  
 
Community caseload 
This route was used by the study therapists to identify current community patients. 
Approaching patients by phone or face to face was more effective than the community 
database effective as it allowed the patients an opportunity to discuss the study, albeit 
was more time consuming for staff.  
 
Voluntary Group 
The protocol specified that the therapist could attend stroke and aphasia groups to 
explain the study and to collect contact details of those interested, although this route 
was time consuming and not successful in recruiting many participants. However, if 
the protocol had been less prescriptive and allowed for the people that run the 
voluntary groups to discuss the study and collect contact details on behalf of the 
therapists, it may be possible to make this route a more efficient method for a 
definitive study. Site 3 was the only site that recruited through this route. The 
therapist in Site 2 reported that recruitment from voluntary groups was unfruitful as 
many members were not eligible,  few had low mood and many were more than five 
years post-stroke.  
 
Self-referral 
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According to Table 3 this route appears very effective however there were few 
participants recruited this way. This route could be more efficient if the study had 
been advertised more widely in the press and through social media. 
 
Outpatients 
It could be suggested that this route was successful because patients were screened 
and identified by clinical care teams in outpatients’ settings allowing for the 
opportunity of face to face discussions with patients about the study. This route was 
particularly successful at one site (Site 3) with the PI and therapist based in the 
community team with patients being referred post-stroke. This outpatients route were 
community based patients and not hospital outpatients. Outpatients differed from 
community caseload as this is a longer term service identifying participants that were 
longer after their stroke. 
 
3.2.2 Protocol non-compliances 
Table 8 shows protocol non-compliances reported by site and category. All of the 
issues identified as non-compliances could be incorporated into site staff training for a 
future definitive trial.  
We also reported a non-compliance relating to the inconsistency in using the consent 
support tool during recruitment; this is discussed in further detail in 3.6.2. 
 
 
Table 8 Non compliances reported in the trial 
  Site 1 Site 2 Site 3 Total 
Delegation log 2 0 0 2 
Eligibility 0 1 0 1 
Intervention delivery 0 0 1 1 
Failure to report SAE 0 1 0 1 
 
In addition to the non-compliance reports, there was one instance of unblinding 
occurring at a 6 month outcome visit where a participant revealed their allocation to 
an outcome assessor.  
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3.2.3 Losses and exclusions after randomization 
Table 9 shows the number and percentage of participants who dropped out of the trial 
by treatment arm, site and length of time since stroke. Attrition is defined here as the 
number of participants who did not complete the primary outcome (PHQ-9) at 6 
months post randomisation. See Appendix 9 for an outline of the reasons, where 
given, for drop out. A total of nine participants dropped out of the trial during the 6 
month follow up period. Of these nine participants, seven of these were in the 
intervention arm. All of the participants who dropped out of the study had their most 
recent stroke between three and 12 months ago. 
 
Table 9 Attrition presented by treatment arm, site and time since stroke.  
    Number 
Withdrew 
Consent  
Intervention 
withdrawal 
& decision 
not to FU  
Investigator 
decision- 
patient too 
ill  
Lost to 
Follow 
up
a
 
Overall 
attrition  
   n % n % n % n % n % 
Overall  48 1 11 1 11 1 11 6  67 9 18.8 
Treatment Intervention 25 1 11.1 1 11.1% 0 0 5 55.6 7 28 
 Control 23 0 0 0 0 1 11.1 1 11.1 2 8.7 
Site Site 1 24 0 0 0 0 1 11.1 4 44.4 5 20.8 
 Site 2 6 0 0 0 0 0 0 0 0 0 0 
 Site 3 18 1 11.1 1 11.1 0 0 2 22.2 4 22.2 
Time 
since 
stroke
b
 
3 months to 
1 year 
30 1 11. 1 11.1 6 66. 1 11.1 9 30 
 1-2 years 12 0 0 0 0% 0 0 0 0 0 0 
 2-4 years 6 0 0 0 0 0 0 0 0 0 0 
a 
One participant completed follow up but did not complete the PHQ-9 questionnaire. 
This participant did not have aphasia. 
b 
Mean (SD) number of days since last stroke in participants who dropped out is 231.6 
(76.1) with a minimum and maximum of (108,343) 
 
Lost to follow up  
Table 10 shows the method for completion of 6 month follow up data. Reminders 
involved a phone call to the participant or carer. We aimed to test the feasibility of 
collecting 6 month outcome data by post versus in person using a blinded outcome 
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assessor. For a definitive RCT it may be necessary to implement additional measures 
to further? minimise loss to follow up e.g. reminder phone calls rather than the initial 
reminder letter to identify those who need a home visit to complete the questionnaires 
sooner, sending regular newsletters to participants during the follow up period to 
maintain engagement with the study, and offering vouchers to participants to 
encourage return of postal questionnaires. 
 
Table 10 Number of participants who completed follow up by home visit and postal 
pack.  
 Home Visit Postal Pack 
Total 17 (37%) 29 (63%) 
Visit arranged/ Pack sent 16 (94.1%) 28 (96.6%) 
Visit conducted/ Pack returned 14 (87.5%) 24 (85.7%) 
At least 1 reminder contact 1 (6.2%) 11 (39.3%) 
Mean (SD) no. of reminders 0.1(0.2) 0.8(1.5) 
Reminder resulted in completed questionnaires 1 (100%) 8 (72.7%) 
Other method used 0 (0%) 2 (6.9%) 
 
3.2.4 Dates defining the periods of recruitment and follow-up 
Data collected outside of data collection window 
It was agreed that data would be accepted within four weeks before or after the 6 
month time point. However data from four participants was collected outside of this 
data collection window as it was delayed due to illness 
 
Delay in randomisation following initial eligibility measures 
During the analysis there were some delays between completion of the initial 
eligibility measures and randomisation. In most cases there was a delay of between 7 
to 30 days between completing the initial eligibility and randomization, which was 
probably due to availability of the therapist and the patient in arranging a home visit 
(see Appendix 10). However nine participants had a delay of greater than 30 days. 
Each therapist could only deliver the therapy to a limited number of participants at 
one time and therefore some participants had to wait for therapist availability. The 
PHQ-9 score collected at initial eligibility is considered the baseline PHQ-9 and 
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therefore due to these delays the time point between baseline and 6 month PHQ-9 is 
not always the same. For a definitive trial we would suggest setting a timeframe 
between collecting initial eligibility and full eligibility at baseline.
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3.3 Baseline data 
 
Demographic, patient and carer reported outcomes and stroke related outcome data 
for randomised participants by intervention arm can be seen in Table 11, Table 12, 
Table 13 and Table 14.  
 
Twenty-five participants were randomised to the intervention arm and 23 were 
randomised to the control arm. The mean age of participants was 65.6(SD=13.6) and 
most participants were men (60.4%). Site 1 recruited 24 participants, Site 3 recruited 
18 participants and Site 2 recruited seven participants. 
 
Mean scores were consistent across treatment arms. Most participants had a time 
since stroke of 3 months to 1 year (62.5%). More participants in the control arm had 
had a previous stroke (47.8%) as compared to in the intervention arm (24%). 
 
There was a greater proportion of men in the intervention arm (72.2%) than in the 
control arm (52.4%). 
 
Table 15 and Table 16 show the baseline demographics and baseline outcome 
measures for participant included in the primary effectiveness analysis. 
 
Table 11 Baseline demographics by treatment arm 
 Intervention Control Overall 
Age    
N 25 23 48 
Mean(SD) 62.6(14.5) 68.8(12.1) 65.6(13.6) 
Median(IQR) 65 (53 ,72) 67 (60, 75) 66 (55, 75 ) 
Min,Max (31, 88) (40, 97) (31, 97 ) 
Sex    
Man 17 (68 %) 12 (52.2%) 29 (60.4%) 
Woman 8 (32 %) 11 (47.8%) 19 (39.6%) 
Ethnicity/Nationality    
English / Welsh / Scottish / Northern 
Irish / British 
25 (100%) 22 (95.7%) 47 (97.9%) 
Pakistani 0 (0 %) 1 (4.3%) 1 (2.1%) 
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Table 12 Baseline outcome measures by treatment arm 
 Intervention Control Overall 
PHQ-9 Score    
N 25 23 48 
Mean(SD) 16.3(4.7) 17.3(4.8) 16.8(4.7) 
Min,Max (10, 25 ) (10, 27) (10, 27) 
PHQ-9 Category    
n 25 23 48 
Moderate (10-14) 12(48.0) 7 (30.4) 19(39.6) 
Moderately severe (15-19) 6 (24.0) 9 (39.1) 15(31.3) 
Severe (20+) 7 (28.0) 7 (30.4) 14(29.2) 
VAMS SAD Score    
n 25 22 47 
Median(IQR) 51 (39, 74) 52 (41, 83) 51 (39, 82) 
Min,Max (3, 100) (0, 96) (0, 100) 
SADQ Score    
n 15 12 27 
Mean(SD) 25.3(7.6) 18.8(8.1) 22.4(8.4) 
Min,Max (8, 35) (5, 29) (5, 35) 
NLQ Score    
n 24 23 47 
Mean(SD) 16.2(6) 13.1(5.4) 14.7(5.9) 
Min,Max (4, 29) (5, 24) (4, 29) 
NEADL Score    
n 24 23 47 
Mean(SD) 12.3(7.2) 11.7(6) 12(6.6) 
Min,Max (2, 22) (0, 21) (0, 22) 
CSI Score    
n 13 11 24 
Mean(SD) 7.2(3.6) 6.5(2.7) 6.9(3.2) 
Min,Max (1, 13) (3, 11) (1, 13) 
EQ-5D-5L Score    
n 24 23 47 
Mean(SD) 0.5(0.3) 0.5(0.3) 0.5(0.3) 
Min,Max (0.045, 0.924) (-0.218, 0.951) (-0.218, 0.951) 
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PHQ-9 had a range of 0 to 27, low scores mean low level of depression. VAMS Sad 
has a range of 0 to 100, low scores mean low mood. EQ5D-5L Standard score can 
range from -0.281 to 0.951, with 0, 1, and negative values corresponding to death, full 
health, and health states worse than death, respectively. NLQ scores ranged from 0 to 
60 with a low score indicating a low level of leisure activity. NEADL scores ranged 
from 0 to 22 with low scores corresponding to lower independence. SADQ scores 
ranged from 0-63 on the SADQH-21, with low scores indicating low level of 
depression. This questionnaire wascompleted by carers. CSI scores ranged from 0 to 
13 with low scores corresponding to low level of strain on the carer. 
 
Table 13 Stroke characteristics by treatment arm 
 Intervention Control Overall 
Modified Rankin Score    
n 24 23 47 
Mean(SD) 3.2(0.9) 3.2(0.9) 3.2(0.9) 
Min,Max (2, 4) (2, 5) (2, 5) 
FAST Score    
n 24 23 47 
Median(IQR) 27 (22, 29.5) 27 (22, 29 ) 27 (22, 29) 
Min,Max (18, 30) (12, 30) (12, 30) 
FAST category    
n 24 23 47 
Aphasia (below cutoff) 10(41.6) 11(47.8) 21(44.7) 
MoCA Score    
n 24 23 47 
Median(IQR) 22 (17.5, 25) 22 (17, 26) 22 (17, 25) 
Min,Max (11, 30) (4, 29) (4, 30) 
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Table 14 Stroke history by treatment arm 
 Intervention Control Total 
Time from stroke    
Less than 3 months 0 (0%) 0 (0%) 0 (0%) 
3 months to 1 year 16 (64%) 14 (60.9%) 30 (62.5%) 
1 to 2 years 7 (28%) 5 (21.7%) 12 (25%) 
2 to 4 years 2 (8 %) 4 (17.4%) 6 (12.5%) 
Lateralisation of stroke    
Left 11 ( 44 % ) 9 (39.1%) 20 ( 41.7 % ) 
Right 12 (48%) 10 (43.5%) 22 (45.8%) 
Unknown 2 (8%) 4 (17.4%) 6 (12.5%) 
Stroke type    
Ischaemic 19 (76%) 18 (78.3%) 37 (77.1%) 
Haemorragic 6 (24%) 4 (17.4%) 10 (20.8%) 
Side of weakness    
Left 13 (52%) 10 (43.5%) 23 (47.9%) 
Right 10 (40%) 7 (30.4%) 17 (35.4%) 
Bilateral 0 (0%) 2 (8.7%) 2 (4.2%) 
Unknown 2 (8%) 4 (17.4%) 6 (12.5%) 
Previous stroke    
Yes 6 (24%) 11 (47.8%) 17 (35.4%) 
No 19 (76%) 12 (52.2%) 31 (64.6%) 
Depression treatment    
Yes 10 (40%) 12 (52.2%) 22 (45.8%) 
No 15 (60%) 11 (47.8%) 26 (54.2%) 
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Table 15 Baseline demographics of the participants who completed baseline and 6 
month follow up by treatment arm (n=39) 
 Intervention Control Overall 
Age    
n 18 21 39 
Mean(SD) 63.4(11.8) 67.9(10.7) 65.8(11.3) 
Median(IQR) 62.5 (54, 72) 67 (64, 75) 66 (56, 75) 
Min,Max (47, 85) (40, 89) (40, 89) 
Sex    
Man 13 (72.2%) 11 (52.4%) 24 (61.5%) 
Woman 5 (27.8%) 10 (47.6%) 15 (38.5%) 
Ethnicity/Nationality    
English / Welsh / Scottish / Northern 
Irish / British 
18 (100%) 20 (95.2%) 38 (97.4%) 
Pakistani 0 (0%) 1 (4.8%) 1 (2.6%) 
 
Table 16 Baseline outcome measures of the participants who completed baseline and 
6 month follow up by treatment arm (n=39) 
 Intervention Control Overall 
PHQ-9 Score    
n 18 21 39 
Mean(SD) 16.2(4.9) 16.9(4.6) 16.6(4.7) 
Min,Max (10, 25) (10, 27) (10, 27) 
VAMS SAD Score    
n 18 20 38 
Median(IQR) 59.5 (39, 82) 52 (35.5, 82.5) 56 (39, 82) 
Min,Max (3, 100) (0, 96) (0, 100) 
SADQ Score    
n 11 11 22 
Median(IQR) 25 (22, 32) 19 (13, 28) 22 (14, 29) 
Min,Max ( 8 , 35 ) ( 5 , 29 ) (5, 35) 
NLQ Score    
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 Intervention Control Overall 
n 18 21 39 
Median(IQR) 17.5 (10, 20) 14 (10, 17) 16 (10, 19) 
Min,Max (7, 29) (5, 24) (5, 29) 
NEADL Score    
n 18 21 39 
Median(IQR) 12.5 (5, 20) 11 (10, 18) 12 (8, 18) 
Min,Max (2, 21) (2, 21) (2, 21) 
CSI Score    
n 9 10 19 
Median(IQR) 7 (5, 8) 5.5 (4 , 9 ) 6 (4, 9) 
Min,Max (1, 13) (3, 11) (1, 13) 
EQ5D-5L Score    
n 18 21 39 
Median(IQR) 0.466 (0.3, 0.7) 0.599 (0.4, 0.7) 0.563 (0.4, 0.7) 
Min,Max (0.045, 0.893) (0.206, 0.951) (0.045, 0.951) 
    
 
3.4 Clinical Outcomes and estimation 
Primary clinical outcomes 
Thirty-nine of the 48 randomised participants had valid PHQ-9 outcome at follow-up 
(18 intervention arm: 21 control arm). Table 17 shows a summary of the results of the 
primary effectiveness analysis. Following adjustment for baseline and centre, we 
observed a mean difference in PHQ-9 of -3.8 (95% CI -6.9 to -0.58) at 6 months post 
randomisation. This represents a reduction in depression in the BA arm.  
Multiple imputation by chained equation was used to impute this missing outcome 
data ; this was a sensitivity analysis which increased the sample size back up to 48 (25 
BA: 23 control). Adjusting for baseline and centre, we observed a mean difference in 
PHQ-9 score of -3.4 (95% CI -7 to 0.094) at 6 months post randomisation. This is 
shown in Figure 3. Adjusted models included baseline measure and centre as a 
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random effect. (n=39 in unadjusted and adjusted analysis, n=48 in MI adjusted and 
unadjusted analysis). 
 
Table 17 Primary effectiveness analysis on PHQ-9 adjusted for baseline PHQ-9 and 
centre as a random effect. 
 
Intervention 
n 
Median 
(IQR) 
Mean 
(SD) 
Control 
n 
Median 
(IQR) 
Mean 
(SD) 
Mean 
Diff in 
PHQ-
9b 95% CI 
Unadjusted 18 6.5 (5, 
15) 
10.1 
(6.9) 
21 14 (10, 
17) 
14.4 
(5.1) 
-4.3 (-8,-
0.5) 
Adjusted       -3.8 (-6.9,-
0.58) 
MI 
Unadjusted
a
 
25   23   -3.9 (-7.7, -
0.0041) 
MI 
Adjusted
a
 
25   23   -3.4 (-7, 
0.094) 
a 
PHQ-9 score was imputed using chained equations and 30 multiply imputed data 
sets. The multiple imputation model included sex, age, treatment group, PHQ-9 at 
baseline and/or 6 months, EQ5D-5L at baseline and 6 months and SAD-Q at baseline 
and 6 months as predictors. 
b 
A negative mean difference implies the intervention group had lower scores. 
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Figure 3 Results from unadjusted and adjusted Primary analyses showing mean 
difference between Intervention and Control at 6 months.  
 
Previous research has suggested that the minimum clinical important difference or 
change for the PHQ-9 is 4.78 points on the scale.
77
The 95% CI for the mean 
difference in PHQ-9 scores between the groups includes a difference of five or more 
suggesting that the likely treatment effect is within a clinically relevant range. 
 
Figure 4 shows that more participants in the intervention arm reduced PHQ-9 
category (horizontal dotted lines) from baseline to follow up. Horizontal dotted lines 
represent the cut-off scores for depression categories. This information is also 
presented in Table 18. Most participants in the intervention arm were in the 'Moderate 
depression' category at baseline (n=9), whereas participants in the control arm are 
distributed across three depression categories: 'Moderate'(n=7), 'Moderately Severe' 
(n=8) and 'Severe' (n=6). Most of the participants in the intervention arm reduced 
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level of depression by one (n= 7) or two categories (n=7) at 6 month follow up 
compared to baseline. Most participants in the control arm stayed in the same 
category (n=9) or reduced by one category (n=6). 
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Figure 4 Plot showing
Comment [LM2]: To be deleted and 
replaced with new figure 
66 
 
 
Figure 4: Line plot showing individual participant change in PHQ-9 score from 
baseline to follow up by intervention arm.  
Table 18 shows that a greater number of intervention arm participants decreased by 
one or two categories) than in the control arm. 
 
Table 18 Summary of changes in PHQ-9 category by intervention arm 
 Intervention n Control n 
 n % n % 
Increased by 1 category 2  11.1 3  14.3 
No change in category 2  11.1 9  42.9 
Decreased by 1 category 7  38.9 6  28.6 
Decreased by 2 categories 7  38.9 2  9.5 
Decreased by 3 categories 0  0 1  4.8 
 
Figure 5 shows the mean PHQ-9 score in the intervention and control arms at baseline 
(n=48) and 6 months (n=39). Despite the intervention arm having a lower mean score 
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at baseline, the decrease in PHQ-9 score overall was greater in the intervention arm. 
The dotted lines represent the cut-offs for PHQ-9 depression categories and show that 
mean score in the intervention arm has reduced by one depression category. 
 
 
Figure 5 Mean PHQ-9 score at baseline and 6 month follow-up by randomised group 
by treatment arm [n=48] 
 
Figure 6 shows the relationship between PHQ-9 and VAMS Sad item at baseline and 
6 months post randomisation. Correlation was found to be moderate at both baseline 
and follow up (r= 0.45, r=0.57). The level of agreement would be considered too low 
for VAMS Sad to be used to impute PHQ-9.
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Figure 6 Scatterplot showing correlation between standardised PHQ-9 and VAMS 
Sad at baseline and 6 month follow up [n=48 at baseline and n=39 at 6 months] 
 
Secondary clinical outcomes 
Table 19 shows the analysis of patient reported secondary outcomes and Table 20 
shows the analysis of carer reported secondary outcomes. Of all of the patient 
reported secondary outcomes, most of the differences suggest that the intervention has 
a small positive effect. 
Table 19 shows the adjusted mean differences and their relative 95% confidence 
intervals for the patient reported outcomes including VAMS SAD, NLQ, NEADL and 
EQ5D-5L. VAMS Sad and NLQ both suggest that the intervention has a positive 
effect although the 95% confidence intervals include a difference of zero. NEADL 
does not demonstrate any difference between intervention and control arms. EQ5D-
5L is lower in the intervention arm which suggest a small negative effect.
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Table 19 Secondary effectiveness analysis on patient reported outcomes adjusted for baseline and centre 
 
Intervention 
 n Median (IQR) 
Mean 
(SD) Control n Median (IQR) 
Mean 
(SD) Mean Diff 95% CI 
VAMS SAD 
Unadjusted 
19 39 (10, 64) 39.8 (28.5) 21 54 (34, 69) 48.6 (24.7) -8.8 (-26, 8.2) 
VAMS SAD 
Adjusted 
      -8.6 (-25, 7.7) 
NLQ Unadjusted 18 17.5 (14, 26) 20.5 (9.1) 21 15 (12, 20) 15.6 (5.5) 4.9 (0.087, 9.7) 
NLQ Adjusted       3.2 (-0.96, 7.3) 
NEADL 
Unadjusted 
18 12 (5, 18) 12 (7.1) 19 11 (6, 17) 11.6 (6.1) 0.37 (-4,4.8) 
NEADL Adjusted       -0.032 (-2.2,2.1) 
EQ5D-5L 
Unadjusted 
18 0.6 (0.33, 0.71 ) 0.5 (0.3) 20 0.7 (0.47, 0.82) 0.6 (0.2) -0.12 (-0.29, 0.054) 
EQ5D-5L Adjusted       -0.04 (-0.17, 0.092) 
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Table 20 shows the carer reported outcomes. CSI was lower in the intervention which 
represents a positive effect. EQ5D-5L Carer was lower in the intervention arm which 
suggests a small negative effect of the intervention. SADQ showed very little 
difference between groups. Confidence intervals are wider due to smaller numbers of 
carers than participants. Confidence intervals around the adjusted mean differences 
for carer reported outcomes are very wide due to low numbers of carers who 
completed 6 month follow up (n=22). 
 
Standardised mean differences and their confidence intervals can be seen in Figure 7 
where arrows indicate the direction of a positive intervention effect. Arrows on the y-
axis indicate the direction of a desired effect. Outcomes have been standardised onto a 
0-100 scale. 
 
 
 
Figure 7 Results from Secondary analyses showing mean difference between 
Intervention and Control at 6 months adjusted for baseline and centre.  
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Table 20 Secondary effectiveness analysis on carer reported outcomes adjusted for baseline and centre 
 Intervention n Median (IQR) 
Mean 
(SD) Control n Median (IQR) 
Mean 
(SD) 
Mean 
Diff 95% CI 
SADQ Unadjusted 10 23.5 (20, 27) 23.5 (8.7) 11 17 (13, 25) 17.6 (7.4) 5.9 (-1.5,13) 
SADQ Adjusted       -0.55 (-6.5,5.4) 
CSI Unadjusted 9 4 (1, 7) 5.1 (4.5) 10 7.5 (2, 9) 6 (3.5) -0.89 (-4.8,3) 
CSI Adjusted       -2 (-4.9,0.84) 
EQ5D-5L Carer 
Unadjusted 
12 0.8 (0.67, 
0.87) 
0.7 (0.2) 10 0.8 (0.75, 
0.87) 
0.8 (0.2) -0.062 (-0.23,0.11) 
EQ5D-5L Carer Adjusted       -0.052 (-0.24,0.14) 
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3.4.1 Decision on the primary endpoint and sample size for a definitive trial 
Sample size calculations 
We calculated a range of sample sizes for a definitive scale trial comparing BA to 
usual care in patients with post -stroke depression. The primary endpoint used was 
PHQ-9 at 6 months post randomisation. PHQ-9 has a range of 0 to 27, low scores 
mean low level of depression. We assumed a target difference in PHQ-9 scores of 
approximately 5 points,
77
 would be clinically and practically important but also used 
lower estimates of 3 and 4 points so as to produce a range of scenarios. A range of 
estimates of SD (7, 9 and 11 points) were used,  roughly based on the SD observed in 
the pilot,  which are subject to considerable uncertainty. These scenarios give a range 
of standardised effect sizes of 0.27 to 0.71. From the feasibility study, data was used 
to calculate the ICC of 0.06 in the intervention arm based on clustering by site. We 
also assumed an average cluster size of around 20 participants per therapist/site. 
Furthermore, the attrition rate of 18.8% was rounded up to 20% over 6 months and 
was used to adjust the final sample size calculation. 
A sample size of 580 participants would be required to detect a difference of 4 points 
(SD of 9) on the PHQ-9 scale with 90% power and 5% significance (see Table 21). It 
would take approximately 24 months of recruitment in 16 centres assuming a 
recruitment rate of 1.5 participants per centre per month which is similar to the rate of 
1.8 participants per month observed in BEADS. 
A sample size of 623 participants would be required to detect a difference of 3 points 
(SD of 7) on the PHQ-9 scale with 90% power and 5% significance (Table 21).  
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Table 21 Sample size estimation for a definitetrial.  
Outc
ome 
Signific
ance 
Pow
er 
(%) 
Targe
t 
differ
ence SD 
Standa
rdised 
Effect 
Size ICC 
Ave. 
cluster 
size 
Samp
le size 
per 
group 
Total 
sample 
size 
(adjust
ed for 
20% 
attritio
n) 
PHQ
-9 5% 90% 
5 
points 7 0.71 0.06 20 93 233 
PHQ
-9 5% 90% 
4 
points 7 0.57 0.06 20 142 355 
PHQ
-9 5% 90% 
3 
points 7 0.43 0.06 20 249 623 
PHQ
-9 5% 90% 
5 
points 9 0.56 0.06 20 150 375 
PHQ
-9 5% 90% 
4 
points 9 0.44 0.06 20 232 580 
PHQ
-9 5% 90% 
3 
points 9 0.33 0.06 20 409 1023 
PHQ
-9 5% 90% 
5 
points 11 0.46 0.06 20 221 553 
PHQ
-9 5% 90% 
4 
points 11 0.36 0.06 20 343 858 
PHQ
-9 5% 90% 
3 
points 11 0.27 0.06 20 608 1520 
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3.4.2 Delivery and receipt of the intervention 
Table 22 shows the attendance at BA sessions in participants who were randomised to 
the intervention. Attendance of participants to therapy sessions was high. The mean 
number of therapy sessions received in the intervention arm was 8.1 (SD 3.4). 92% of 
participants randomised to the intervention arm received at least 2 sessions. 88% 
received at least 5 sessions, 64% received at least 8 sessions and 40% received at least 
10 sessions. The mean number of missed sessions was 0.9 (SD 1.3) with 52% of 
participants missing at least one scheduled therapy session.  
 
 
 
 
 
Table 22 Number of sessions attended for participants who were randomised to the 
intervention 
  Site 1 Site 2 Site 3 Overall 
N 12 3 10 25 
Total number of sessions completed 110 23 69 202 
Mean (SD) number of sessions 
attended 
9.2 (2.2) 7.7 (1.2) 6.9 (4.6) 8.1 (3.4) 
Median (IQR) number of sessions 
attended 
10 (2.25) 7 (1) 8.5 
(7.75) 
9 (3) 
No. of participants attending at least 2 
sessions 
12 
(100%) 
3 (100%) 8 (80%) 23 (92%) 
No. of participants attending at least 5 
sessions 
12 
(100%) 
3 (100%) 7 (70%) 22 (88%) 
No. of participants attending at least 8 
sessions 
9 (75%) 1 
(33.3%) 
6 (60%) 16 (64%) 
No. of participants attending at least 
10 sessions 
7 
(58.3%) 
0 (0%) 3 (30%) 10 (40%) 
Total number of planned sessions not 
completed 
6 (5 ) 1 (4%) 16 
(19%) 
23 
(10.2%) 
Mean (SD) number of sessions not 
completed 
0.5 (0.9) 0.3 (0.6) 1.6 (1.5) 0.9 (1.3) 
Median (IQR) number of sessions not 0 (1) 0 (0.5) 1 (1) 1 (1) 
75 
 
completed 
No. of participants missing at least 1 
session 
4 
(33.3%) 
1 
(33.3%) 
8 (80%) 13 (52%) 
 
Probably due to a higher number of withdrawals, Site 3 had a higher rate of missed 
sessions. Figure 8 shows that participants who withdrew from the intervention had a 
low number of sessions attended. There were also three participants who attended 
eight or more sessions and were lost to follow up. 
 
Figure 8 Number of sessions attended by participants who were randomised to the 
intervention arm [n=25] 
 
The timing of therapy sessions was fairly regular (see Figure 9) with sessions 
generally occurring weekly.  
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Figure 9 Timing in days of screening, randomisation (at zero), therapy sessions and follow up in the intervention arm [n=25] Comment [LM3]: To be removed 
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3.4.3 Number of missing values/incomplete cases 
Missing data in the outcome measures and missing items within these outcomes are 
presented in Table 23. Baseline completion rate was high in all outcomes. The six 
month follow up rate was around 80% in most outcomes. Two participants had two or 
fewer missing items for PHQ-9 at 6 months post randomisation. Imputation was used 
on these missing items as specified in the statistical analysis plan (SAP).  
 
Table 23 Summary of non-missing scores and items within questionnaires 
  Time Total % 
Median 
(min,max) 
Intervention 
Median 
(min,max) 
Control 
Median 
(min,max) 
Overall 
PHQ-9
a 
Baseline 48 100 % 9 (7, 9) 9 (8, 9) 9 (7, 9) 
9 items 6 months 39 81.2 % 9 (0, 9) 9 (0, 9) 9 (0, 9) 
VAMS 
Sad
b
 
Baseline 47 97.9 % NA NA NA 
1 item 6 months 40 83.3 % NA NA NA 
EQ5D 
Standard 
Baseline 47 97.9 % 5 (5, 5) 5 (5, 5) 5 (5, 5) 
5 items 6 months 38 79.2 % 5 (0, 5) 5 (0, 5) 5 (0, 5) 
NLQ Baseline 47 97.9 % 30 (30, 30) 30 (30, 30) 30 (30, 30) 
30 items 6 months 39 81.2 % 30 (0, 30) 30 (0, 30) 30 (0, 30) 
NEADL Baseline 47 97.9 % 22 (22, 22) 22 (22, 22) 22 (22, 22) 
22 items 6 months 37 77.1 % 22 (0, 22) 22 (0, 22) 22 (0, 22) 
SADQ Baseline 27 96.4 % 21 (21, 21) 21 (20, 21) 21 (20, 21) 
21 items 6 months 21 75 % 21 (0, 21) 21 (0, 21) 21 (0, 21) 
CSI Baseline 24 85.7 % 13 (10, 13) 13 (12, 13) 13 (10, 13) 
13 items 6 months 19 67.9 % 13 (0, 13) 13 (0, 13) 13 (0, 13) 
a 
2 participants had two or fewer missing items for PHQ-9 at 6 months post 
randomisation. Imputation was used on these missing items as specified in the 
statistical analysis plan (SAP). 
b 
VAMS Sad is a one item measure so cannot have missing items. 
 
Summary of risks and benefits 
 
This study was not an investigation of a medicinal product (IMP) and entailed no 
invasive procedures. No participants had any existing treatments withdrawn. There 
was a risk that participants may have experienced some distress from being asked 
about their mood, but all researchers and therapists were trained to deal with these 
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situations. If at any point during the baseline assessment, intervention or outcome 
assessment the researcher or therapist was concerned about a participant, for example 
they had severe distress or reported feeling suicidal, then the necessary referrals were 
made. This process is explained in section 3.5 and 3.6. 
 
3.5 Adverse events 
For the purposes of this study, adverse events were defined as suicidal intentions. 
Researchers asked participants about any adverse events at the 6 month follow-up. 
This information was collected on outcome questionnaires, or recorded in person for 
those participants who required help at a home visit. Any adverse events that were 
self-reported by participants in the intervention group during the delivery of the 
therapy sessions were also recorded by the therapist on the CRF and database. 
Adverse events have been summarised by treatment arm (see Table 24 Error! 
Reference source not found.). There were a total of 13 adverse events experienced 
by ten participants. Serious adverse events are presented in  Table 25 Error! 
Reference source not found.. There were three adverse events experienced by three 
separate participants. None of these SAEs were related to the intervention.  
 
Table 24 Summary of adverse events 
 Intervention Control All 
No. and % of 
participants who 
experienced >= 1 AE 
4 15.4% 6 26.1% 10 20.4% 
No of AEs 5  8  13  
Type of Adverse Event       
Fall 0 0% 2 25% 2 15.4% 
Health Worsened 1 20% 3 37.5% 4 30.8% 
New Health Condition 2 40% 0 0% 2 15.4% 
Suicidal Intentions 2 40% 3 37.5% 5 38.5% 
Hospital Stay       
No 1 20% 8 100% 9 69.2% 
Yes 4 80% 0 0% 4 30.8% 
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Table 25 Summary of serious adverse events 
BEADS 
ID Description 
Was the SAE 
intervention related? 
Outcome of 
SAE 
C7/014 Admitted to A&E following 
suicide attempt. 
No Ongoing 
C6/004 Admitted to hospital 
following a heart attack 
No Improved 
B4/016 Repair to hernia No Recovered 
 
 
3.6 Challenges with implementation 
 
3.6.1 Challenges with the delivery of the intervention 
Based on the experiences of delivery of the intervention, we have gained some 
important insights for a definitive trial.  
 The therapists delivering the intervention identified that participants in the early 
days post-stroke had more practical goals, such as walking and speaking, and were 
less concerned with their mood.  
 It was difficult to find activities for participants with limited mobility.  
 Getting participants to adapt their goals was challenging and one therapist felt that 
at this stage a talking therapy to deal with acceptance would be more beneficial. 
 One of the therapists had experience of delivering cognitive behavioural therapy 
in a previous role. It may  therefore be important to tailor therapist training for 
those that are inexperienced in delivering psychological therapies and those that 
are experienced in delivering psychological therapy but not specifically 
behavioural activation therapy. This would ensure that both experienced and 
inexperienced therapists deliver the therapy according to the manual.  
 This feasibility study only recruited participants who were mildly affected by 
aphasia and therefore did not provide us with knowledge of delivering the 
intervention to those with aphasia and cognitive impairments. 
 
3.6.2 Challenges with recruitment and data collection 
There were a number of issues experienced with recruitment which resulted in lower 
than planned recruitment rates. However, the final sample recruited was sufficient for 
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this feasibility study which was not powered for efficacy but to inform the design of 
the definitive RCT. The original recruitment target of 72 participants was based on 
three sites recruiting two participants per month over 12 months giving a total of 36 
recruitment months. However, due to delays in site set up none of the sites were able 
to utilise the full 12 month recruitment period. Instead a total of 27 recruitment 
months were available across the three sites.  
 
There were three main challenges for the delays in site set up - approval of Excess 
Treatment Costs (ETCs); the knock-on effect on appointment of study therapists in 
the NHS (as advertisement of the posts was contingent on ETCs) and a change to the 
IAPT provider close to the time that the study was due to open. While we under-
recruited slightly, this had little impact on determining the feasibility of the trial. 
Recruitment challenges included the fact the therapists had a dual role which meant 
they were recruiting participants in addition to delivering the intervention. This also 
meant that they were limited to only being able to recruit the number of participants to 
whom they had capacity to deliver the intervention to at one time.  
 
A second recruitment challenge was the inevitable competition in highly engaged 
clinical research centres for the resources to recruit participants. The CRN research 
nurses at sites were able to assist in screening participants from the hospital database 
and stroke wards. They issued invitation packs to participants they identified as fitting 
the initial eligibility criteria but this then required further time to follow up potential 
participants to discuss the study after issuing the invitation packs.  
 
The third recruitment challenge was the centres being in different settings and 
therefore encountering different problems with recruitment. Recruitment was 
particularly successful where the therapist was based in the hospital setting and so 
was able to work closely with the CRN nurse in recruiting from the hospital database 
and stroke wards. In contrast, for the therapist based in a community setting the bulk 
of their recruitment was gained through the outpatient, community caseload and 
voluntary group routes as there was limited resourcing to recruit from the hospital 
database. The therapist based in the IAPT (Improving Access to Psychological 
Therapies) service was heavily reliant on the participants identified from the hospital 
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database and stroke ward by the CRN nurses and so was constrained by the resourcing 
available. For a definitive RCT it would be beneficial to fund more Research 
Assistant/Research Nurse time to support recruitment. 
 
Use of the Consent Support Tool 
Eighteen of the 48 participants recruited had aphasia which represents one third of 
this cohort of stroke survivors as expected. The intervention was designed to be 
suitable for people with mild and moderate aphasia with adaptations being made to 
support reduced language ability. Only those with aphasia severe enough to make 
participation in the intervention difficult, even with support, were excluded. The 
Consent Support Tool was recommended to identify those who were not eligible due 
to not having mental capacity to provide informed consent, and those whose aphasia 
was too severe to participate in the intervention with support (those with two key 
written or spoken word comprehension or below). The Consent Support Tool was also 
recommended to help identify which participants required accessible information and 
to identify strategies to support the individual’s communication needs during the 
intervention. The Consent Support Tool was only used with five of the 18 participants 
with aphasia. The Frenchay Aphasia Screening Test (FAST) scores for these 
participants show that they had mild-very mild aphasia, confirming that they were all 
eligible for the study. The therapists described having a conversation with potential 
participants and if they seemed to be communicating well and understanding what 
was being said to them, then they did not feel the need to use the Consent Support 
Tool.  
 
Problems with data collection: 
There was an occasional need to visit some participants twice to collect data outcome 
due to health and tiredness. Aalthough this was not common, it did impact on 
therapist time.  
 
The main problems experienced were with outcome data collection. The postal 
method proved to be challenging and it was necessary to chase some participants to 
return their questionnaires, which resulted in four participants (8%) having their 
outcome data collected outside of the data collection window. This may have been 
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due to the nature of the patient group requiring more support to complete the 
questionnaires. For a definitive trial the response rate may be more prompt or 
improved by issuing regular newsletters to participants to keep them engaged, or by 
planning for visits to those who request them 
 
During the trial the therapists were only funded till the end of therapy. However at 
this stage, 6 month data collection was still ongoing and therefore adverse events 
could still be reported and study completion/discontinuation forms required 
completion. For a definitive trial it may be beneficial to extend contracts a couple of 
months beyond the end of treatment completion. Furthermore, organising regular 
teleconferences with the PIs could improve PI engagement throughout the trial.  
 
Reporting of adverse events 
The protocol specified that all adverse events were to be assessed for seriousness, 
expectedness and causality. In addition, the therapists and researchers completed a 
Serious Adverse Event (SAE) form for additional events that were classed as serious, 
including death; suicide; a life-threatening adverse event; inpatient hospitalization or 
prolongation of existing hospitalization; disability or incapacity. For other adverse 
events, the researcher completed an Adverse Event form. Further stroke related events 
were not reported as SAEs because these were expected within this population. 
However it was later identified that it was not always possible to assess all adverse 
events for their relationship to the stroke and to the intervention. For example a score 
of 3 ‘nearly every day’ on question 9 ‘Thoughts that you would be better off dead or 
of hurting yourself in some way’ on the PHQ-9 questionnaire would trigger the 
suicide protocol and be reported as an adverse event. When this occurred this was 
referred back to the site to follow their local procedures to ensure the safety of the 
participant. They were also asked to assess if the event was related to the stroke and to 
the intervention (where applicable). This proved difficult for a number of reasons. 
Firstly, based on a response to the questionnaire it is not possible to assess these 
criteria without asking the participant -which may seem inappropriate and insensitive. 
Secondly, as participants were recruited from various routes they were not always 
known to the immediate team and therefore did not have an established rapport with 
the therapists. Thirdly, in cases where the study team were based in community 
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psychology services they did not always have access to the patient’s hospital records 
specifically for admissions to general hospital and therefore found it difficult to 
identify and report detail of serious adverse events.  
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Summary of usual care 
A summary of the provision received by participants in the study by treatment arm 
can be seen in Table 26. The provision is consistent across treatment arms, however 
one participant who was in the intervention arm received significantly more services 
than other participants.  
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Table 26 Summary of other resource used in the previous 3 months at 6 months post randomisation by intervention arm 
  
Int. 
Total n>=1 
Mean 
(SD) 
Median 
(IQR) 
Mean (SD) 
duration 
Control 
Total n>=1 Mean (SD) 
Median 
(IQR) 
Mean (SD) 
Duration 
Inpatient Hospital services 1 1 0.038(0.2) 0(0,0) NA 0 0 0(0) 0(0,0) NA 
Outpatient hospital services 35 3 1.3(4.7) 0(0,0) NA 2 1 0.087(0.42) 0(0,0) NA 
A&E or Day hospital 
attendance 
9 4 0.35(1.2) 0(0,0) NA 4 3 0.17(0.49) 0(0,0) NA 
Doctor or Nurse contact 64 14 2.5(3.2) 1.5(0,5) 19(26) 96 17 4.2(4.9) 2(0,8) 27(38) 
Occupational therapist 32 5 6.4(5.1) 3(3,12) 66(33) 12 2 6(5.7) 6(2,10) 42(25) 
Physiotherapist 42 4 10(9.5) 7.5(4,17) 60(0) 29 5 5.8(4.9) 3(3,10) 44(16) 
Speech and language therapist 1 1 1(NA) 1(1,1) 60(NA) 13 4 3.2(3.3) 2(1,5.5) 45(17) 
Home help/ Care worker 522 3 170(81) 180(90,252) 68(75) 540 3 180(160) 90(90,360) 32(13) 
NHS Counseller, psychologist 
or psychotherapist 
8 1 0.31(1.6) 0(0,0) 3.5(18) 6 1 0.26(1.3) 0(0,0) 2.2(10) 
Community nurse, social 
worker, Case manager or 
Wellbeing practitioner 
9 1 0.35(1.8) 0(0,0) 50(17) 2 1 0.087(0.42) 0(0,0) NaN(NA) 
CBT therapist 13 3 4.3(2.9) 6(1,6) 1.5(7.8) 0 0 NaN(NA) NA(NA,NA) 2.6(13) 
Day care centre 24 2 12(0) 12(12,12) 120(85) 13 2 6.5(7.8) 6.5(1,12) 240(NA) 
Private counsellor, Psychologist, 
Psychotherapist or Psychiatrist 
24 1 0.92(4.7) 0(0,0) NA 0 0 0(0) 0(0,0) NA 
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4 Fidelity assessment results 
The mean number of sessions attended was 8.5 (SD 4.4) with a range from zero to 14 
sessions. Over all 90% of scheduled sessions were attended. The main reason that 
sessions were missed was a change in participant's availability (n=14, 61%), illness 
(n=4, 17%) and change of therapists’ availability (n=3, 13%). In addition, two 
participants (9%) withdrew from treatment.  
 
Table 27 shows the proportion of time (in 10-minute units) spent on individual 
components of therapy, as reported by therapists.  
 
Table 27 Frequency of 10 minute units of time spent on the subcomponents of therapy 
Main 
component  
Subcomponent of therapy Number 
of 10 
minute 
units 
Percentage 
Explanation of treatment rationale 117.8 10.2 
 Explain research project 13.0 1.1 
 Explain behavioural activation 45.2 3.9 
 Set and agree session agenda 59.6 5.2 
Assessment 104.5 9.0 
 Background information 14.0 1.2 
 Current problems or difficulties 46.0 4.0 
 Depression symptoms, mood 28.0 2.4 
 Effects of stroke 16.5 1.4 
Communication and cognitive difficulties 9.0 0.8 
 Establish communication skills and 
difficulties 
1.0 
0.1 
 Developing communication resources 2.0 0.2 
 Practice communication skills 0 0 
 Identify strategies for coping with cognitive 
difficulties 
6.0 
0.5 
Goals 117.0 10.1 
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Main 
component  
Subcomponent of therapy Number 
of 10 
minute 
units 
Percentage 
 Set and agree goal 48.5 4.2 
 Review progress of goals 68.5 5.9 
Activities 209.5 18.1 
 Activity monitoring 75.0 6.5 
 Identify enjoyable activities 69.5 6.0 
 Activity scheduling 56.0 4.8 
 Practice skills or task 9.0 0.8 
Graded task 240 2.1 
 Explain graded task principle 10.5 0.9 
 Set and agree graded task 10.0 0.9 
 Carry out part of the task in therapy 3.5 0.3 
Problem solving 44.0 3.8 
 Identify problems or obstacles arising 24.0 2.1 
 Identify and plan solution(s) to a problem 20.0 1.7 
Between-session tasks 212.4 18.3 
 Set and agree between-session tasks 89.0 7.7 
 Review between-session tasks 123.4 10.6 
Summary and review 149.1 12.9 
 Recapping information 54.3 4.7 
 Discuss therapy ending 36.0 3.1 
 Summarise session 58.8 5.1 
Generalisation 52.0 4.5 
 Summary of skills learned during therapy 31.5 2.7 
 Plan for future scenarios 20.5 1.8 
Other 118.5 10.2 
 Discussion with carer 29.5 2.5 
 General conversation 52.0 4.5 
 Other (specify) 37.0 3.2 
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Most time was spent on between-session tasks (18.3%), which included setting and 
agreeing new between-session tasks (7.7%) and reviewing the previous between -
session tasks (10.6%). The second most frequent component was activities (18.1%). 
This included activity monitoring (6.5%), identifying enjoyable activities (6.0%) and 
activity scheduling (4.8%) with relatively little time spent on practicing skills or tasks 
(0.8%). The least amount of time was spent on communication and cognitive 
difficulties (0.8%). Also the use of graded tasks (2.1%) and problem solving (3.8%) 
were relatively infrequent.  
 
All participants received an explanation of the treatment rationale, assessment, 
discussion of between-session tasks and summary and review. Two (8%) did not 
receive any goal setting or activity scheduling. Twelve (50%) did not receive graded 
task assignments and eight (33%) did not receive training in problem solving. This 
indicates that some core components of behavioural activation were missed with some 
participants. The therapy relied heavily on between-session tasks and activities. 
 
The proportion of components of therapy according to session number is shown in 
Table 28. This shows that explanation of the treatment occurred across most sessions 
and that assessment was mainly concentrated in the first two. Goals, activities, graded 
task assignments and problem solving were spread across most sessions. In all 
sessions most time was spent discussing between session tasks and on summary and 
review. Discussion of generalisation occurred mainly in later sessions.  
Checked tables and %! 
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Table 28 Proportion of components of therapy by Session Number 
Component of 
therapy  
Session number 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
 n % n % n % n % n % n % n % n % n % n % n % n % n % n % 
Explanation of 
treatment 
rationale 
60  29 21 14 16 10 17 10 17 11 13 8 15 10 8 8 8 9 4 7 3 9 1 4 0 0 1 17 
Assessment 84  40 20 13 8 5 2 1 2 1 2 1 3 2 2 2 3 3 1 2 1 3 0 0 0 0 0 0 
Communication 
and cognitive 
difficulties 
3 1 0 0 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 0 0 0 0 0 0 0 0 
Goals 0 0 20 13 6 4 8 5 7 5 13 8 19 13 16 15 16 18 9 15 2 6 3 13 1 17 1 17 
Activities 5 2 9 6 44 26 46 28 34 22 36 23 22 15 11 10 8 9 4 7 2 6 1 4 1 17 0 0 
Graded task 0 0 2 1 3 2 5 3 6 4 9 6 1 1 2 2 0 0 1 2 2 6 2 8 0 0 0 0 
Problem solving 0 0 3 2 11 7 9 6 12 8 4 3 9 6 8 8 2 2 0 0 1 3 0 0 0 0 0 0 
Between-session 
tasks 
22 11 39 25 43 26 42 26 38 25 34 22 31 21 17 16 12 13 5 8 4 12 4 17 0 0 0 0 
Summary and 
review 
29 14 23 15 25 15 22 14 22 14 30 19 26 17 23 22 23 26 15 25 6 18 4 17 2 33 2 33 
Generalisation 0 0 0 0 0 0 0 0 2 1 5 3 13 9 8 8 9 10 16 26 6 18 4 17 0 0 1 17 
Other 6 3 18 12 10 6 10 6 11 7 9 6 9 6 10 9 8 9 5 8 6 18 5 21 2 33 1 17 
Total  209  155  168  162  152  156  149  106  90  61  33  24  6  6  
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We were unable to video as many therapy sessions as planned. The main difficulty was that 
there was only one video camera for the study to be shared between the three therapists who 
were geographically based in three different sites. The therapists has to take turns in having 
the video camera and record available sessions depending on whether the participants they 
were treating at that time had consented to be videoed. 
 
Video recordings of treatment session were analysed for eight participants, who were age 47 
to 76 years (mean 62.6, SD 10.8) and 6 were men. PHQ scores ranged from 11 to 23 (mean 
15.8 SD 4.6) and VAMS Sad item scores from 22 to 88 (mean 59.3, SD 29.5). Ten treatment 
sessions were recorded from across the three sites. There were no recordings for sessions 1, 5, 
8 and 9. 
 
The frequency of components of therapy were calculated separately for those components of 
the manual that were applicable on all sessions and those which were session specific. See 
Appendix 11  and Appendix 12 for the results.Most components of the manual that were 
intended to be delivered on all sessions occurred. However, there were four sessions in which 
no session summary was observed. In addition the recording of session ten comprised almost 
exclusively social chat and few of the components of treatment that should apply to all 
sessions.  
 
The components of treatment that were specific to individual sessions were observed in the 
appropriate sessions. However, the recoding of session four did not show any discussion on 
how enjoyable activities improve mood, nor a list of enjoyable activities being created, and 
no identification of barriers to engaging in identified activities. These were all components 
listed in the manual for session 4. In addition the recording of session ten showed that the 
session comprised entirely question and answers and did not include a review of problems 
addressed during therapy, a summary of successful strategies and skills used, a discussion of 
generalisation of skills to future situations or a reminder about the 6 month follow up. 
See Appendix 13 for a summary of the frequency of therapist and participant activities. Most 
therapist activities occurred on most sessions. The only notable omission was the lack of 
reference to previous sessions by the therapist. The participants’ activities were similar across 
sessions. However, there were no observations of participants asking for information or 
asking questions
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Discussion of fidelity results 
 
Overall, for the assessment of fidelity, the results of the therapy records indicate that 
most of the components of therapy described in the manual were delivered to 
participants. Importantly each session included essential components of therapy and 
the distribution of time was as expected. This suggests that outcomes reflect the effect 
of the intervention as described in the manual. However there were some components 
of therapy that were not recorded as being delivered to some participants. There was 
little use of graded task assignments and training in problem solving, even those that 
are core components of BA. This may be a reflection of the coding used, as graded 
task assignments were often used as between session tasks. The record form may need 
to be modified to reflect the content of the between session tasks, as well as the 
content of therapy. 
 
The video recordings also indicated that therapy was mainly delivered according to 
the manual. The main limitation of the video analysis is that recordings were 
incomplete and some sessions were not covered. The results therefore demonstrated 
the extent to which video analysis could be reported in a definitive trial. The 
recordings highlighted that the content of the sessions that were recorded did not 
cover all aspects of therapy expected from the manual. However, the intervention was 
designed to be delivered flexibly and it may be that the missed content was delivered 
in other sessions.  
 
Both methods of checking the fidelity of the intervention were feasible and both 
highlighted potential ways that the therapy received deviated from the treatment as 
described in the manual. The records kept by therapists were simpler to use and more 
complete. However, the lack of therapeutic content in the video recording of session 
ten was not picked up in the therapist records, suggesting that the two methods may 
complement each other.
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5 Health economic results 
5.1 Feasibility Outcomes 
The percentage of items of complete data for each key outcome measure is presented 
in Table 29. At baseline, the response rate for the standard and pictorial versions of 
the EQ-5D-5L and resource use questionnaire was over 90%. There was a lower 
response rate for the proxy version of the EQ-5D-5L which was completed by carers, 
and for the carers EQ-5D-5L about their own health (75.8% and 84.8% respectively, 
as a proportion of those participants who had carers). At the 6-month follow-up time-
point the response rate was slightly lower for most outcome measures for participants 
in the intervention group than in the control group. Overall, at follow-up, the response 
rate for the standard version of EQ-5D-5L and the resource use questionnaire was 
around 80%. Of the ten participants who did not have standard version EQ-5D-5L 
data at 6-months; eight participants had withdrawn from the study or were lost to 
follow-up, one participant did not return the questionnaire and one participant 
returned the questionnaire but only had a response for four out of the five domains so 
an EQ-5D-5L score could not be calculated. The resource use questionnaire response 
rates were analysed by item. At baseline there was 2% missing data and at 6-months 
there was 16% missing data. The larger proportion of missing data at 6-months was 
generally due to a small number of participants not completing any part of the 
questionnaire, rather than due to missing items within otherwise completed 
questionnaires. 
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Table 29 Response rate by outcome measure 
 Baseline 6-months 
 Control Interventio
n 
Overall Control Interventio
n 
Overall 
EQ-5D-5L 
(Standard 
version) 
100.0% 
(23/23) 
96.0% 
(24/25) 
97.9% 87.0% 
(20/23) 
72.0% 
(18/25) 
79.2% 
EQ-5D-5L 
(Aphasia 
friendly 
version) 
95.7% 
(22/23) 
92.0% 
(23/25) 
93.8% 82.6% 
(19/23) 
72.0% 
(18/25) 
77.1% 
EQ-5D-5L 
(Proxy)* 
81.3% 
(13/16) 
70.6% 
(12/17) 
75.8% 68.8% 
(11/16) 
58.8% 
(10/17) 
63.6% 
EQ-5D-5L 
(Carer)
a
 
87.5% 
(14/16) 
82.4% 
(14/17) 
84.8% 56.3% 
(9/16) 
70.6% 
(12/17) 
63.6% 
Resource 
use 
questionnair
e 
100.0% 
(23/23) 
96.0% 
(24/25) 
97.9% 91.3% 
(21/23) 
76.0% 
(19/25) 
83.3% 
a 
Percentages based only on participants with carers 
 
5.2 Within trial analysis 
Quality of life 
The standard version of the EQ-5D-5L was used to calculate quality adjusted life 
years (QALYs) due to no participants having severe aphasia. All participants were 
able to complete the standard version including the five participants with moderate 
aphasia. At the 6-month follow-up, EQ-5D-5L utility scores were slightly higher in 
the control group compared to the intervention group (See Table 30.  
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Table 30 EQ-5D-5L by group at both time points 
 Mean Standard Error 95% Confidence 
Interval 
EQ-5D-5L at baseline 
Control  0.51 0.06 [0.40, 0.63] 
Intervention 0.50 0.06 [0.38, 0.62] 
EQ-5D-5L at 6-months 
Control 0.60 0.06 [0.46, 0.73] 
Intervention 0.51 0.07 [0.35, 0.67] 
 
As a supplementary analysis, the pairwise correlation between the different utility 
measures was calculated. There was a strong correlation (Pearson’s correlation 
coefficient 0.91) between values of the aphasia accessible version of the EQ-5D-5L 
and standard version. The correlation between responses to the EQ-5D-5L completed 
by carers on behalf of the study participant (carer proxy) and the standard version 
completed by the participants was moderate (Pearson’s correlation coefficient 0.59). 
 
Costs 
The cost of the intervention was estimated to be £57 per hour.
87
 This was based on the 
intervention being provided on a one-to-one basis by a grade 5 agenda for change 
(Afc) mental health nurse, using estimates from the PSSRU. PSSRU incorporate 
training and clinical supervision costs in this estimate and therefore the training and 
supervision received in the BEADS study was not costed separately. Direct 
intervention costs were calculated by multiplying the hourly intervention cost by the 
average number of sessions for each individual patient.  
 
There were two participants in the control group and seven in the intervention group 
with missing cost data at follow-up. One of these participants also had cost data 
missing at baseline. As there were the same level of missing data across resource use 
categories, data was imputed on the total cost level. The missing data at 6 months was 
imputed separately based upon whether or not the participant had achieved a “good 
response” as measured by the PHQ-9. Analyses that incorporate imputed data are 
95 
 
referred to as “full dataset (with imputation)” analyses. Analyses that do not use 
imputed data are referred to as “complete case” analyses.  
 
Average costs at follow-up for the whole trial period (6 months) are shown in Table 
31; these figures contain no imputed data. For all of the categories except societal 
costs the average cost per patient in the intervention group was higher than in the 
control group (though no differences were statistically significant – see Table 32). 
Inpatient costs were incurred by two participants in the intervention group, compared 
to none in the control group. It is possible that these were chance events rather than 
being related to the intervention. For outpatient hospital services, two participants in 
the intervention group had costs over £1000 whereas there were no such outliers in 
the control group. These costs were associated with psychiatry and psychology 
outpatient visits. It is unclear whether these were related to the intervention. 
 
Table 31 Intervention costs and average costs from resource use questionnaire 
(complete case) 
 Inpatient 
hospital 
services 
Outpatient 
hospital 
services 
Primary 
and 
community 
care 
Community 
day based 
services 
Intervention 
costs 
Societal 
Control £0 £225.12 £1,123.02 £111.46 £0 £24,133.84 
Intervention £466.16 £954.78 £2,175.92 £217.96 £460.56 £19,292.29 
 
Home help was the main factor which caused the difference between the control and 
intervention groups in primary and community care costs. Four participants in the 
intervention group received home help compared to three in the control group. The 
intervention group received 295.5 hours more home help than the control group over 
the last 3-months of follow-up. There was one participant in the intervention group 
who received the equivalent of approximately one visit a day for 3 hours per day, 
which was more than that received by any other participant in the trial. See Appendix 
14 for the distribution of costs relevant to the NHS and PSS perspective for the 
control and intervention groups. 
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The human capital approach was used to estimate societal costs. The societal 
component of costs consisted of work hours lost, carer time, travel expenses, private 
healthcare costs and charity provided services. These were added to the costs from the 
NHS and PSS perspective to form costs for the societal perspective. Due to the nature 
of the population, there were only two participants in the control group and three 
participants in the intervention group either working or looking for work. In addition, 
three carers were reported to have lost work hours due to their caring responsibilities. 
However, data was incomplete with some carers not recording whether they worked 
or not, and some carers not recording if they lost any time from work. For this reason, 
we allocated a cost to all carer time reported for the societal perspective analysis, 
whether or not it resulted in time being taken off work. Carer time accounted for 
93.3% and 78.0% of societal costs for the control and intervention group respectively. 
See Appendix 15 for the distribution of costs relevant for the societal perspective for 
the control and intervention groups. Aggregated costs for the 6 months of the trial are 
presented in Table 32. 
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Table 32 Estimated average health care and societal costs for the 6-month trial period 
 N Mean 
(£) 
Std. 
Error 
95% CI Differenc
e 
(£) 
Std. 
 Error 
95% CI 
Full dataset (with imputation): Health care costs (including intervention costs) 
Control 23 1,961.18 800.49 [234.37, 
3688.01] 
   
Intervention 25 3,547.46 1072.8
3 
[1316.47, 
5778.44] 
1,586.27 1,357.62 [-1164.24, 
4336.77] 
Full dataset (with imputation): Societal costs (including health care and intervention 
costs) 
Control 23 26,549.3
6 
6078.0
9 
[13801.07, 
39297.65] 
   
Intervention 25 22,991.1
8 
6056.1
3 
[10275.64, 
35706.72] 
-3,558.18 8724.13 [-21249.47, 
14133.1] 
Complete case: Health care costs (including intervention costs) 
Control 21 1,391.90 318.38 [727.77, 
2056.03] 
   
Intervention 19 3,875.64 1307.2
2 
[1129.27, 
6622.01] 
2,483.74 1286.12 [-119.88, 
5087.36] 
Complete case: Societal costs (including health care and intervention costs) 
Control 21 25,525.7
4 
6039.6
8 
[12927.19, 
38124.29] 
   
Intervention 19 23,167.9
2 
6470.6
1 
[9573.67, 
36762.18] 
-2,357.817 8842.79 [-20259.11, 
15543.48] 
 
Results from the within trial analysis 
The within trial analysis was undertaken on both the complete case and imputed 
datasets. Results are presented in Table 33. Based on the imputed dataset, when 
including all costs relevant to the NHS and PSS (labelled “NHS & PSS perspective 
1”) costs were £1,316 higher in the intervention group than for the control group over 
the course of the study. To illustrate the influence of inpatient hospital stays we re-
analysed the data excluding inpatient costs if the hospital stay was for more than one 
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night (labelled “NHS & PSS perspective 2”). In this analysis the incremental cost 
associated with the intervention reduced to £980. The 95% confidence interval for 
both these estimates includes negative values, indicating that there was not a 
statistically significant difference in costs between the intervention and control 
groups.  
 
For all analyses incremental QALYs were negative meaning that participants in the 
intervention group accrued fewer QALYs over the 6-month trial period than 
participants in the control group. Again, differences were not statistically significant. 
Therefore, based upon an NHS and PSS perspective and a within-trial analysis, the 
intervention is expected to be dominated by the control – that is, it results in higher 
costs and lower QALYs than usual care.  
 
It was estimated that there would be -£8,281 lower costs per patient in the 
intervention group than in the control group, when taking a societal perspective and 
valuing all carer time regardless of whether it resulted in the carer taking time off 
work. This results in an ICER of £539,917 saved per QALY lost based on the 
complete case analysis, and an ICER of £400,048 saved per QALY lost based upon 
the imputed data analysis. The interpretation of these ICERs is different to the 
standard interpretation because the intervention is situated in the south-west quadrant 
of the cost-effectiveness plane (see Figure 12) – it results in cost savings but fewer 
QALYs. 
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Table 33 Results from within trial analysis 
 Incrementa
l costs (£) 
Standar
d error 
95% 
Confidenc
e Interval 
Incrementa
l QALYs 
Standar
d error 
95% 
Confidenc
e Interval 
Complete case (38 participants) 
NHS & 
PSS 
perspectiv
e (1) 
1,634 1174.0 [-667.39, 
3934.63] 
-0.0107 0.015 [-0.04, 
0.02] 
NHS & 
PSS 
perspectiv
e (2) 
1,228 951.9 [-638.13, 
3093.27] 
-0.010 0.015 [-0.04, 
0.02] 
Societal 
perspectiv
e 
-6,479 7727.6 [-21625.08, 
8666.45] 
-0.012 0.015 [-0.04, 
0.02] 
Full dataset (Including imputed data; 48 participants) 
NHS & 
PSS 
perspectiv
e (1) 
1,316 1275.15 [-1191.66, 
3823.16] 
-0.0204 0.021 [-0.06, 
0.02] 
NHS & 
PSS 
perspectiv
e (2) 
980 1245.94 [-1469.93, 
3430.61] 
-0.0205 0.021 [-0.06, 
0.02] 
Societal 
perspectiv
e 
-8,281 7945.87 [-23879.93, 
7318.81] 
-0.0207 0.021 [-0.06, 
0.02] 
Note: Incremental costs differ from those presented in Table 32 due to the covariate 
adjustment used in the SUR. 
 
Figure 10 and Figure 12 show the point estimate of the (ICER) and confidence 
intervals around this based upon the “NHS & PSS perspective (2)” analysis and the 
societal analysis respectively using the full dataset with imputation. Figure 11and 
Figure 13 show the corresponding probabilities of the intervention being cost 
effective at different cost effectiveness thresholds for these two analyses. 
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Figure 10 Confidence ellipses for “NHS & PSS perspective (2)” analysis, full dataset 
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Figure 11 Cost-effectiveness acceptability curve for “NHS & PSS perspective (2)” 
analysis, full dataset 
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Figure 12 Confidence ellipses for the societal perspective, full dataset 
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Figure 13 Cost-effectiveness acceptability curve for the societal perspective, full 
dataset 
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5.3 Model-based analysis 
5.3.1 Model Inputs 
Transition probabilities 
Transitions from the “no response” health state to the “good response” health state 
were based upon response rates observed in the trial. In the intervention group, 68% 
of participants achieved a 4.78-point decrease in PHQ-9 from baseline to follow-up 
and were therefore assumed to transit into the “good response” state. In the control 
group, 22% of participants achieved this response. Model parameter values for all 
parameters included in the model, their confidence intervals and the distribution used 
to characterise them in probabilistic sensitivity analysis are presented in Appendix 17. 
 
It was not possible to discern relapse rates from the trial and therefore these were 
assumed to be zero in the base case, but a range of possible relapse rates were 
considered in sensitivity analysis. 
 
Brønnum-Hansen et al.
98
 estimated that the annual risk of death from stroke is 18.1% 
and 10% between 4-weeks to 1 year and after 1 year since stroke respectively. In the 
BEADS trial, 60% of participants had a stroke up to one-year prior to randomisation, 
with mean time since stroke for this group being approximately 7 months. Hence for 
the first five months of the model the mortality rate was weighted between 18.1% and 
10%, according to the proportion of participants who had a time since stroke of more 
or less than 1 year. This mortality rate was applied to both the “no response” and 
“good response” health states – hence we assume that the intervention does not affect 
survival. From month 6 up to the start of year 6 the transition probability for death 
was based on the 10% annual risk estimated by Brønnum-Hansen et al.
98
 From year 6 
onwards death from other causes was added to the annual mortality rate based on 
mortality data from the Office of National Statistics
99
 and the age and gender split 
observed in the BEADS trial.  
 
Quality of life 
We calculated utility scores at baseline and at 6-months separately for participants 
who achieved a “good response” and those who did not, in order to estimate the 
increase in utility associated with achieving a good response using a difference-in-
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differences approach. We found that achieving a good response was more beneficial 
than not responding, such that achieving a good response was associated with an 
increase in utility score of 0.066 at 6 months. 
 
It is notable that the increase in utility score in responders was much more substantial 
in the control group than in the intervention group (see Appendix 16). However, we 
assumed that this was due to chance and in the economic model simply used the 
utility benefit estimated using all responders in the study, irrespective of their 
randomised group.  
 
In the economic model, the utility score for the “no response” health state was 0.52 
and the utility score in the “good response” health state was 0.59 (see the table of 
parameter values in Appendix 17). These were based on average utility for each 
response group at 6-months. 
 
Costs 
Health state costs were estimated separately for the “good response” and “no 
response” states. Outlying costs were observed in the trial analysis – in particular, 
inpatient hospital costs were only observed in the intervention group, and these were 
not deemed to be associated with the intervention. These costs were a 17 night 
inpatient orthopaedics episode and a 10 night inpatient episode for a myocardial 
infarction. In order to avoid these costs skewing our model-based analysis, we 
excluded them from the economic model. Costs associated with the response and non-
response health states used in the economic model are presented in the table of 
parameter values in Appendix 17). Costs were slightly higher in the “good response” 
health state from the NHS and PSS perspective, but were lower from the societal 
perspective.  
 
The direct cost of the intervention was estimated to be £460.56, based upon an 
average number of behavioural activation sessions completed in the intervention arm 
of the trial of 8.08. This cost was only added to the intervention arm of the model and 
included in the probabilistic sensitivity analysis (see table of parameter values, 
Appendix 17). 
104 
 
 
Probabilistic sensitivity analysis 
For the probabilistic sensitivity analysis, we assumed that utility in the response group 
could not fall below the utility of the non-response group. The difference method was 
used
110
 rather than simple (and biased) techniques that involve resampling or 
adjustment if the desired ordering is not achieved. It seems reasonable to assume that 
a participant with a lower level of depression (i.e. a “good response”) would have a 
higher utility than a participant with a higher level of depression, all else remaining 
equal. Without a larger dataset of observations of utility values of responders and non-
responders it is impossible to rule out the possibility that this assumption does not 
hold. 
 
Our base case analysis incorporated a zero relapse rate. We felt that this was likely to 
lead to misleading probabilistic sensitivity analysis and value of information results. 
Therefore, in a supplementary analysis a hypothetical relapse rate of 10% per month 
was added to the model. This followed a beta distribution with a standard error of 0.2, 
and lower and upper bounds of 0.01 and 0.8 respectively. The standard error was 
chosen based upon an inflation of the standard error observed for the response rates 
for each treatment group (0.09 in the intervention group and 0.08 in the control 
group). 
 
5.3.2 Results from the model-based analysis 
Deterministic Results 
Based on an NHS and PSS perspective the economic model predicted that over a 
person’s lifetime costs would be £3,852 higher in the intervention group than in the 
control group. It is notable that this represents a substantial difference compared to the 
QALY loss estimated using the within-trial analysis. This is because there was a 
higher response rate in the experimental group, and the utility score was higher in the 
“good response” health state, and is driven by the fact that we assume that the utility 
of a responder is not dependent upon whether they received the intervention or usual 
care. This point is re-visited in Section 5.4. A QALY gain of 0.2 was estimated for 
participants in the intervention group. From these results the ICER was estimated to 
be £19,187. Typically, in the United Kingdom, interventions are classed as cost-
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effective if the ICER is below £20,000 per QALY gained.
101
 Under a societal 
perspective, the intervention was estimated to dominate the control treatment – 
producing higher QALYs and cost savings. Results are presented in Table 34. 
 
 
Table 34 Results from the deterministic analysis 
 Per person treated    
 Cost QALYs Incrementa
l costs 
Incrementa
l QALYs 
ICER 
NHS Perspective 
Control £33,590 3.57    
Intervention £37,441 3.77 £3,852 0.2 £19,186.88 
Societal Perspective 
Control £363,127 3.57    
Intervention £319,449 3.77 -£43,678 0.2 Intervention 
dominates 
 
Deterministic Sensitivity Analysis 
Cost-effectiveness analysis results are often more sensitive to the values of certain 
parameters than others. A one-way sensitivity analysis allows us to see how changing 
one parameter and keeping other parameters constant would influence the ICER. Due 
to the relapse rate not being included in our base case analyses (as it was not possible 
to calculate it directly from trial data), the base-case ICERs may be optimistic. Figure 
14 demonstrates that when a relapse rate was incorporated within the model, the ICER 
increases above £30,000 per QALY gained for relapse rates over 7% per month, 
under an NHS and PSS perspective. 
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Figure 14 ICER vs. relapse rate per month, NHS and PSS perspective 
From a societal perspective, the intervention continues to dominate for all possible 
relapse rates, with all else remaining equal. 
 
Probabilistic Sensitivity Analysis 
The results of the deterministic analysis have to be interpreted with caution as they do 
not account for parameter uncertainty. Probabilistic sensitivity analysis (PSA) assigns 
distributions to parameters and runs the model many times, each time selecting a 
value from the distribution of each parameter. Estimates from each run of the model 
are combined and averages are taken to calculate the probabilistic ICER. Cost-
effectiveness acceptability curves (CEACs) are estimated, which represent the 
proportion of simulations in which the intervention was associated with an ICER 
below a defined cost-effectiveness threshold. We ran the model a total of 10,000 
times in a Monte Carlo simulation. The result of each simulation is presented on the 
cost-effectiveness plane in Figure 15, for the analysis that took an NHS and PSS 
perspective and incorporated imputation. The probabilistic ICER was £18,979.82 per 
QALY gained.  
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Figure 15 Model-based analysis – probabilistic results on the cost-effectiveness plane, 
NHS and PSS perspective 
 
Due to the substantial uncertainty around monthly costs associated with each health 
state, incremental costs for each model run varied widely with approximately 70% of 
runs estimating the control group would have lower costs, and approximately 30% 
estimating that the intervention group would have lower costs. CEACs, showing the 
probability of the intervention being cost effective at various thresholds for the NHS 
and PSS perspective, are plotted in Figure 16. At a threshold of £20,000 per QALY 
gained the intervention had a 51% probability of being cost effective, and at a 
threshold of £30,000 the probability was 60%. Due to a small number of model runs 
producing a QALY decrement for the intervention group, the probability of the 
intervention being cost-effective does not reach 100% irrespective of how high the 
threshold is. For cost-effectiveness thresholds of over £19,000 per QALY gained it 
was estimated that the intervention would be most likely to be the cost effective 
treatment option. 
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Figure 16 Cost effectiveness acceptability curves, NHS and PSS perspective 
 
From the societal perspective, the probabilistic analysis estimated that the intervention 
was dominant – the vast majority of model runs resulted in cost-effectiveness 
estimates that lay in the south-east quadrant of the cost-effectiveness plane (see 
Figure 17). The probability that the intervention was cost-effective at a threshold of 
£20,000 per QALY gained was 82.8% (see Figure 18) 
 
 
 
Figure 17 Model-based analysis – probabilistic results on the cost-effectiveness plane, 
societal perspective 
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Figure 18 Cost effectiveness acceptability curves, societal perspective 
 
Supplementary analysis 
It is important to reiterate that the base case deterministic and probabilistic results 
incorporated a relapse rate of zero, with no uncertainty around this. We conducted a 
supplementary analysis that incorporated a hypothetical relapse rate of 10% per 
month, with a beta distribution with a standard error of 0.2, and lower and upper 
bounds of 0.01 and 0.8 respectively. Clearly this is an important assumption. The 
standard error represents an inflation of the standard errors associated with the 
response rate in the experimental and control groups, which were 0.09 and 0.08 
respectively. This resulted in a probabilistic ICER of £21,626.49 per QALY gained 
for the NHS and PSS perspective. From the societal perspective the model continued 
to estimate that the intervention would dominate, leading to cost savings and QALY 
gains. The cost-effectiveness plane scatters and the CEACs for these analyses are 
presented in Figure 19, Figure 20, Figure 21 and Figure 22. At a cost-effectiveness 
threshold of £20,000 per QALY gained, the probability of the intervention being cost-
effective was 42.6% under an NHS and PSS perspective, and 81.0% under a societal 
perspective. 
 
110 
 
 
Figure 19 Model-based analysis – probabilistic results on the cost-effectiveness plane, 
NHS and PSS perspective with relapse rate 
 
 
 
Figure 20 Cost effectiveness acceptability curves, NHS and PSS perspective with 
relapse rate 
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Figure 21 Model-based analysis – probabilistic results on the cost-effectiveness plane, 
societal perspective with relapse rate 
 
 
Figure 22 Cost effectiveness acceptability curves, societal perspective with relapse 
rate 
 
5.3.2 Value of information 
We conducted our value of information analysis based upon the supplementary 
probabilistic analysis that incorporated a non-zero relapse rate, as it was considered to 
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be unrealistic to assume a zero relapse rate with no uncertainty. We estimate that the 
per-patient value of perfect information is £1,348.85, given a cost-effectiveness 
threshold of £20,000 per QALY gained and taking an NHS and PSS perspective. 
 
We extrapolated the per-patient value of information estimates to a population level 
by estimating the number of Participants that would be likely to receive the treatment 
over a 10-year time period. It is estimated that there are 1,202,053 stroke survivors in 
the UK.
111
Approximately 29% of these people will also have depression.
1
 To be 
conservative in our estimation of the population size that could benefit from 
behavioural activation therapy we assumed that the intervention would not be suitable 
for people with severe depression. No published estimates of the proportion of stroke 
survivors who had mild, moderate or severe depression was found. Hence, to estimate 
this we used the proportion of participants with severe depression in the BEADS trial 
(29.2%) – thus, 70.2% of stroke survivors with depression were estimated to have 
mild or moderate depression and therefore be eligible for the intervention. In total, we 
estimate that the prevalent population in the UK that could benefit from the 
behavioural activation intervention is 246,922 (1,202,053*0.29*(1-0.29)).  
 
In addition, it is estimated that approximately 152,145 people in the United Kingdom 
have a stroke each year,
112
 with 67-75% of these estimated to be first (i.e. not 
recurrent) strokes. 78% of people experiencing a stroke are expected to survive for 
longer than 6 months.
113
 Again, approximately 29% of these people will also have 
depression and we estimate that 70.8% of these would have mild or moderate 
depression and be eligible for the intervention. To be conservative, taking the lower 
bound of the stroke proportion that represents a first stroke, we estimate that the 
incidence population in the UK that could benefit from the intervention is between 
16,333 per year (152,145 * 0.67 * 0.78 * 0.29 * 0.70). 
 
In total, we estimate that 410,251 people in the UK could be eligible to receive the 
intervention over a 10 year time period (246,922 + 10 * 16,333), with, on average 
41,025 treated per year. Based on this, we estimate a population level EVPI of £552.6 
million.  
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The EVPI was higher when undertaking the analysis from a societal perspective. The 
per-patient EVPI was £1,881.00 at a cost-effectiveness threshold of £20,000 per 
QALY gained and the population-level EVPI was £771.8 million 
 
Expected Value of Perfect Parameter Information 
A further analysis was undertaken to gain an insight into which areas would deliver 
the most value for further research. The Sheffield accelerated value of information 
tool
102
 was used to estimate the value of obtaining perfect information for one 
parameter or group of parameters. The following parameters where included in the 
analysis:  
 Health care costs in the ‘response’ state 
 Health care costs in the ‘no response’ state 
 Utility in the ‘response’ state 
 Utility in the ‘non-response’ state 
 Probability of good response (control group) 
 Probability of good response (intervention group) 
 Relapse rate 
 Number of behavioural activation sessions 
 Probability of death 
The results of the analysis taken from the NHS and PSS perspective suggest that the 
parameters which have the highest value for further research were health costs in both 
response states (see Table 35). For health costs in the response state the EVPPI was 
£926 per person, giving a population EVPPI of £379.8 million over ten years, for the 
NHS and PSS perspective. For health costs in the non-response state the per person 
EVPPI was £891, and for the population was£365.4 million over ten years. The next 
most important parameter was utility for a non-response, with an estimated per person 
EVPPI of £108. A zero value for EVPPI suggests that whichever value a parameter 
takes within its defined distribution would not affect the probability of the 
intervention being cost effective at a threshold of £20,000 per QALY gained.  
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Table 35 Results from EVPPI, NHS and PSS perspective 
 Per person 
EVPPI (£) 
Standard 
Error 
EVPPI for UK 
over 10 years (£) 
Health costs (response) 925.84 21.77 379,800,000 
Health costs (no response) 890.61 20.3 365,400,000 
Utility (response) 0 2.1 0 
Utility (no response) 108.42 20.33 44,480,000 
Probability of good response 
(intervention) 13.99 11.44 5,741,000 
Probability of good response 
(control) 0 3.32 0 
Relapse rate 21.77 22.86 8,932,000 
Number of BA sessions 8.24 11.72 3,381,000 
Probability of death 0 0 0 
 
Results of the EVPPI analysis from the societal perspective are presented in Table 36. 
The EVPPI was zero for all parameters except societal costs for both response groups. 
 
Table 36 Results from EVPPI, societal perspective 
 Per person 
EVPPI (£) 
Standard 
Error 
EVPPI for UK 
over 10 years (£) 
Health costs (response) 0 0.69 0 
Health costs (no response) 0 0 0 
Societal costs (response) 734.77 58.69 301,400,000 
Societal costs (no response) 420.6 53.15 172,600,000 
Utility (response) 0 0 0 
Utility (no response) 0 0 0 
Probability of good response 
(intervention) 0 0 0 
Probability of good response 
(control) 0 0.59 0 
Relapse rate 0 6.25 0 
Number of BA sessions 0 0 0 
Probability of death 0 0 0 
 
Given the difficulties associated with collecting accurate data on “indirect” costs – 
that is, NHS, PSS and societal resource use not directly related to the actual receipt of 
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the intervention, details on these are not always collected and included in economic 
evaluations. For this reason, we re-ran the NHS and PSS perspective EVPI and 
EVPPI analyses only including in the economic model the direct costs associated with 
the delivery of the intervention. This resulted in a per-patient EVPI of £50.39, a 
population-level EVPI of £20.7 million, and EVPPI results as presented in Appendix 
18. I’m still reading here!! 
 
5.4 Summary of health economics findings 
The primary objectives of our analysis were to assess the feasibility of collecting data 
that may be used in a health economic analysis in the context of the BEADS trial, and 
to conduct an economic evaluation and a value of information analysis in order to 
provide information on the potential value of conducting the definitive trial. Hence, 
the primary aim of our analysis was not to conclude whether or not the intervention 
was likely to represent a cost-effective use of NHS resources, but to conclude whether 
it is feasible to collect the data required to make such conclusion based upon a full 
trial, and whether it appears to represent good value for money to conduct a full trial. 
 
The collection of data required for the economic evaluation was successful in the 
BEADS trial– it would be feasible to collect similar data in a full trial. The data 
collection completion rate was 97.9% at baseline for the standard EQ-5D 
questionnaire and for the resource use questionnaire, and was 79.2% and 83.3% for 
the EQ-5D and resource use questionnaire respectively at the 6 month time-point.  
 
Our analyses suggest that there would be a very high value to obtaining further 
information on key parameters within the economic model – this value is likely to far 
exceed the cost of running a full trial whether an NHS and PSS perspective is taken 
(for which the population-level EVPI was estimated to be £552.6 million) or a societal 
perspective is taken (for which the population-level EVPI was estimated to be £771.8 
million) in the economic model. The model parameters that are estimated to be the 
most valuable to obtain more information on are the NHS and PSS costs associated 
with “no response” and “good response” health states.  
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Our aim was not to definitively estimate the cost-effectiveness of the BA therapy. 
However, our results suggest that the behavioural activation therapy is likely to be of 
borderline cost-effectiveness from an NHS and PSS perspective given a cost-
effectiveness threshold of £20,000 per QALY gained, but may be cost saving from a 
societal perspective. However, our analysis is exploratory and the results should be 
interpreted with care given the small sample size in the BEADS trial.  
 
It is important to note that the results of our model-based analyses differed 
substantially from those of the within-trial analysis. The within-trial analysis 
estimated QALY losses for the intervention group, whereas the model-based analyses 
estimated QALY gains for the intervention. This is because the model was response 
based; response rates were higher in the intervention group and utility scores were 
higher in responders – and were assumed to be equal irrespective of the treatment that 
had been received. We feel that this is a reasonable assumption, but highlight it here 
as it is the reason for the difference between the within-trial and model-based analyses 
of QALY gains/losses. In fact, the average increase in utility reported by responders 
in the control group was larger than in the experimental group (see Appendix 16). On 
average, non-responders in the control group also reported a small utility gain, 
whereas there was a small decrease in utility in non-responders in the intervention 
group. This explains why the within-trial analysis resulted in a QALY loss for the 
intervention, whereas the modelled analysis resulted in a QALY gain.  
 
We could have assumed that utility scores for the “no response” and “good response” 
health states were treatment arm specific, which would have led to modelled QALY 
losses for the intervention. However, the confidence intervals for the utility scores in 
the “no response” and “good response” health states overlapped for the control and 
intervention groups, and were based on very low numbers – for example, EQ-5D-5L 
data at 6 months were only available for 4 control group participants who achieved a 
good response, and for 6 intervention group non-responders. We therefore decided to 
calculate health-state utility scores that were not treatment arm specific, therefore 
assuming that the utility scores in each response state were not related to treatment 
received. We feel that this is a reasonable assumption, but highlight it here as it is the 
reason for the difference between the within-trial and model-based analyses of QALY 
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gains/losses. This also highlights that there is considerable uncertainty around the 
impact of the intervention on quality of life, and it is possible that the intervention 
could lead to reductions in quality of life.  
 
5.5 Discussion of health economics findings 
Costs were collected on all health care resource use in the BEADS trial and the ranges 
of incurred costs varied widely between trial participants. Based upon the data 
collected in BEADS, it is highly uncertain as to whether a “good response” leads to a 
reduction in health care costs, or an increase – yet the answer to this is highly 
influential to the results of the economic evaluation. Similar is true when the analysis 
takes a societal perspective – the societal costs associated with “no response” and 
“good response” health states are highly uncertain and highly influential, and hence in 
a definitive trial it would be particularly valuable to obtain more information on these. 
 
Given the importance of carer costs in the societal analysis, it is relevant to further 
consider how these were estimated. Resource use questionnaires were used to collect 
data about informal care and trial participants were asked at baseline and the end of 
the trial ‘Over the last 3 months have you been helped and/or cared for by a relative or 
friend because of your health?’ If the answer was ‘yes’ participants were asked to 
record how many hours in the last week the person who helped them most spent 
caring for them, and how many hours resulted in the carer not attending work. 
However, there were many missing responses for how many hours attending work 
were lost and therefore all carer time was costed equally. The total cost of carer time 
over the 6-month trial was estimated by extrapolating the data for 1 week over the 6 
month period and applying an hourly cost based upon median hourly earnings using 
Office for National Statistics figures (see Appendix 3). Due to the majority of societal 
costs being composed of carer costs, we believe that any future trial should aim  to 
improve the collection of data on carer time. Carer diaries could be incorporated in 
the trial, or participants could be asked to complete questionnaires more regularly, to 
reduce the need to extrapolate information from one week over a six month time 
period. 
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Whilst societal costs were much higher than NHS and PSS costs, home help costs 
were a key driver of the analysis undertaken from the NHS and PSS perspective. 
Therefore, for a definitive trial, care should be taken to collect information on this as 
accurately as possible. In fact, in our study home help costs were higher in the 
intervention group, whereas carer costs were lower – in a definitive trial a potential 
relationship between these resource uses should be further explored. 
 
Due to the difficulties associated with obtaining accurate and precise estimates of 
health state costs when all NHS and PSS (and societal) resource use is included, it 
may be argued that value of information analyses that estimate the value of obtaining 
perfect information on these costs are likely to vastly over-estimate the value of 
further research – because perfect information will never be obtained and high levels 
of uncertainty are likely to remain even after a full trial has been completed. For this 
reason, we re-ran our value of information analyses excluding all but direct 
intervention costs from the economic model. This resulted in a population EVPI over 
ten years of £20.67 million. This suggests that it would still be worth conducting a full 
trial to obtain further information on other parameters such as the relapse rate, utilities 
and response rates, even if other resource use costs were ignored. These data are best 
collected in a randomised controlled trial. 
 
Whilst our economic model suggests that the BA therapy is potentially cost-effective, 
it is important to re-iterate that the within-trial analysis resulted in QALY losses for 
the intervention. These were highly uncertain and were not statistically significant, 
but it is possible that the intervention could reduce quality of life. 
 
5.6 Limitations of the health economics analysis 
It should be noted that there are limitations with value of information analyses. The 
EVPI represent the value of obtaining perfect information, which is unlikely to occur 
in reality. It also assumes perfect uptake of the intervention, which may be unrealistic 
(although by assuming that people with severe depression would not receive the 
intervention we have attempted to estimate the eligible population size 
conservatively). Therefore, the EVPI figures may be argued to represent maximum 
values of obtaining further information. Conversely, our EVPI estimates only account 
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for parameter uncertainty in our economic model – they do not account for structural 
uncertainty. A very simple model structure was used because it was unlikely to be 
possible to populate a more elaborate model using data collected in BEADS. For 
instance, different categories of response could be modelled, as well as potential 
future neurological events which would be expected to impact upon the long-term 
effectiveness of the treatment. We believe that a more elaborate model would not 
substantially alter the results of our analysis, particularly our supplementary 
probabilistic analysis that incorporated a relapse rate to account for long-term 
effectiveness. However, a more complex model structure may be appropriate if and 
when further data become available. Overall, given that our estimated EVPI values 
were consistently very substantially higher than the likely costs of undertaking a full 
trial, it seems reasonable to conclude that conducting such a trial would represent 
good value for money.  
 
It may be considered that our assumption of equal mortality rates in the “no response” 
and “good response” health states is overly conservative, given the evidence of an 
association between depression and mortality.
1,8,9 
However, the model states are based 
upon response, not upon whether or not a patient still has depression – a responder 
could still be classified as having depression. An alternative model structure could use 
health states defined around depression instead of response, but this may miss benefits 
to patients who respond favourably to the treatment but still have depression. 
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6 Qualitative research results 
In this chapter we begin by providing an overview of the emerging themes and sub-
themes. At this stage, we have split the themes based on the data derived from the 
patient- and carer-participant interviews and the therapist-participant interviews, 
which are brought together in the Discussion chapter to offer a more comprehensive 
view of similar issues from a patient, carer and therapist perspective.  
 
The major themes covered in this section focus on patient- and carer-participants’ 
views of the intervention and trial procedures, and therapist-participants’ views of and 
practical aspects of delivering the therapy, and their views on the trial procedures. 
While both groups of participants were asked to comment on some of the same 
aspects (e.g. trial procedures), both groups also responded to questions that related to 
their unique experiences. For instance, patient-participants commented on their 
experience of receiving the intervention, while the therapist-participants commented 
on their experience of the training they received to deliver the intervention.  
 
The findings from these themes are brought together in a brief summary of the themes 
at the end of this chapter. 
 
In this chapter we attribute quotes to ‘patients, ‘carers’ or ‘therapists’, so as to 
distinguish which participant group each individual was from. Patient and carer 
quotations are labelled as A, B or C to denote the study site anonymously. We only 
had three therapists in the trial. To protect their identity, we do not attribute quotations 
to specific therapists. We use the term ‘they’ so as to not gender the therapist. 
 
Interviews were completed with 16 participants and 10 carers as well as the three 
study therapists. See Appendix 19 for a summary of participant characteristics. 
 
6.1 Patient views of the interventions and trial 
6.1.1 Gains and changes 
General changes and gains (not-therapy-related) 
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None of the control participants reported that they experienced any changes in their 
lives as a result of undertaking the study. As might be expected, most patients in the 
control group explained that they had only completed questionnaires in the study, thus 
still could not find a way to deal with their problems.  
I: Has being involved in the research study changed anything for [participant] 
or for yourself at a, at a greater level? 
C: Not really I said because there’s (laughs) all you’re filling it 
[questionnaires] in isn’t it, nobody’s highlighted the, oh you answered this and 
you know, can we help you [Carer C1/009 – control] 
However, some control participants found being able to talk to someone about their 
experiences helpful and cathartic. Moreover, they reported that answering 
questionnaires encouraged them to think about their feelings and experiences. One 
participant also found the study helpful because it provided useful information about 
stroke.  
It give me information that I didn’t understand about strokes and that properly 
‘til I came into your study and it gave me a lot more information about them 
that I didn’t know [Patient A6/001 – control] 
 
Therapy-related changes (intervention group only) 
 
I. Perceived changes in participants’ mood since undertaking therapy 
Some intervention participants found it difficult to tell whether they felt any changes 
in their mood since undertaking the therapy as their mood was still changing with 
several ‘ups and downs’. However, some participants reported feeling better and less 
stressed due to having the therapy and engaging in activities, even though they still 
experienced some ‘bad days’. 
Well it was quite uplifting really because [therapist] gave me some good 
points you know to what to do because I think I was down in the y’know 
sometimes I was quite nasty, not intentionally, I didn’t know I was doing it 
y’know but [therapist] gave me some positives, positive ideas what do to do 
like. […] y’know sometimes I’d be just like I am now and then the next 
minute me mood’d just gone to the floor so it was ideas how to get over that 
and it did and then we found this stroke place didn’t we which has been good 
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as well so but the therapy has been really good. [Patient B1/087 – 
intervention] 
 
It’s difficult with [patient] because he changes so much with each… even 
though you’re with him 24 hours a day but he is changing so much. Probably 
sometimes he sinks a little bit more before he either shouts you to get up in the 
middle of the night or gets angry, you know. [Carer C7/017 – intervention] 
 
Some participants perceived no changes in their moods since undertaking the therapy. 
One participant provided conflicting accounts on whether they perceived any changes 
in their mood since undertaking the therapy.  
P: It was good, definitely, yeah. Definitely [therapist] made me feel better. 
[…] 
I: Do you think you have changed since, after those sessions?  
P: Ah well, I don't know really. I can't think if I have. [Patient A1/084 – 
intervention] 
In one case, the participant reported that the therapy had a positive impact on his 
mood while it lasted. However when  it came to an end, he had not been feeling as 
good as before.  
P: I think my mood’s all over the place anyway at the minute. Yeah, I think, 
yeah, ‘cause it makes me feel a bit more positively and plan it has a bit more 
positive impact on my mood, which it had done, but I think that might be to do 
with the fact that course came to an end.  
I: So you think it improved your mood but then maybe it’s not carried on or it 
has carried on? 
P: It has. It’s only recently I’ve been, I’ve not been as good. I’ve been 
meaning to ring [psychologist], to be honest. [Patient C7/017 – intervention] 
 
II. Other perceived benefits of therapy 
Participants described benefits in terms of reassurance, engaging in more activities, 
looking at the bigger picture and thinking about the future, learning skills to break up 
tasks into manageable bits, and having more realistic goals and expectations. The 
therapy was described as a trigger for planning and setting realistic goals, as well as 
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engaging in activities to occupy their mind and keep their mood up instead of doing 
nothing.  
I think it was, it was the thought that you weren’t being abandoned altogether, 
that somebody was there to care for you. […] somebody did come and make 
various suggestions to do things. So that was quite useful. […] I think the 
thing that gave her ideas of things to do, to occupy her mind, not just to sit and 
vegetate but to try and get things done. Which she has done, I mean she’s 
enjoyed the drawing, for instance, and she very much, and she’s made a good 
job of it […] So it’s give her an idea of something to do. [Carer A1/084 – 
intervention] 
 
Moreover, some participants reported that the therapy helped them to think about their 
needs and reflect on their feelings, and giving them new and positive ideas on things 
to do. They expressed an understanding of the relationship between thoughts, mood 
and engaging in activities. 
Um, I don’t feel as if I did anything during the trial that I wouldn’t have been 
doing anyway. Um, but it did help me reflect on how activities were affecting 
my latest mood, certainly. […] I think it was the reflective process and I think 
just recording some of the things down to be quite cathartic. […]I think I 
learned to accentuate the positive maybe. And what I realised was that it 
would be very very easy to get down and depressed if I concentrated more on 
the things I can’t do now. [Patient A6/002 – intervention] 
 
Some participants reported feeling a sense of achievement for being able to do tasks 
and engage in activities despite the stroke. They become more aware of their 
capabilities and realised that they can still perform certain tasks by setting realistic 
goals. 
[Working voluntarily at the museum] helped me realise just what a gap it was 
filling in my life. It sort of grew and it made me feel useful […] it’s these 
weekly sessions discussing what I was doing did help me appreciate what a 
difference it was starting to make to my life. […] Um, I think it gave me a 
sense of achievement to actually physically get out. Um, I think generally 
where I have a day where I haven’t gone anywhere or done anything, then I 
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think I’m feeling a bit down by the end of the day because I feel I’ve wasted 
the day. […]And I think that’s something that I realised during the sort of 
weekly reflections, that that’s the life attitude that really fights off downs. You 
know, my really giving myself a pat on the back for what I have done, rather 
than concentrating on what I feel I can’t do. [Patient A6/002 – intervention] 
 
Some participants in the intervention group found also just merely talking to the 
therapist during the sessions was helpful and cathartic. 
I used to get very emotional about it [stroke] and I didn’t like talking about it, 
I used to bottle it all up. But I’ve found it helps if you do talk about it […] It’s 
like a pressure release valve. It lets a bit of steam off [Patient C7/001 – 
intervention] 
 
Carers also perceived some benefits of the therapy on their own health and wellbeing 
as the positive changes in participants helped carers have a break from their 
caregiving responsibilities and reduced their burden. Seeing the improvements in 
participants’ mood also made carers feel happier. 
It’s [BA] given me pleasure to think that [patient] enjoys doing things out of it 
[Carer A1/084 – intervention] 
 
III. Activities/tasks undertaken (during and after therapy) 
Participants talked about a range of tasks and activities undertaken during and after 
therapy that they found helpful. For example, participants talked about resuming their 
creative writing, drawing and painting, volunteering in a museum, kit cars, and 
walking amongst other things.  
[Therapist] suggested projects I might do which some of them I’ve not got 
round to changing the box yet and sort of things to do I’ve been doing these 
paint books you know when I’m sat sort of on me own y’know […] I’ve done 
quite a few erm, yeah they help us concentrate [Patient B1/087 – intervention] 
 
6.1.2 Therapy-specific experiences (intervention group only) 
Understanding purpose of therapy 
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Participants had a broad recognition of what the intervention was for and what it 
could achieve. There were some initial concerns about what benefit the therapy might 
offer. 
I didn’t know what really to expect. It’s that not knowing bit, isn’t it? But 
when something like this [stroke] happens to you, everything’s a big question 
mark, every day of your life is a question mark. Whether I can get up in a 
morning, be motivated to do things. [Patient C7/017 – intervention]  
In most cases, however, there was a generally positive assessment of the therapy.  
Different tasks, really trying to get me back into realising that you can do 
things. […] this encourages you to break things down into little bits, rather 
than the whole thing, which is a better way of doing it. [Patient A1/034 – 
intervention] 
Participants felt that it was about making them more active to improve their mood by 
reflecting on self and activities done, and by making them realise that they needed to 
break tasks into manageable bits in order to complete them. 
It’s a big hole out of your life, that. So my days will get pretty boring pretty 
quickly. I suppose with that, what they were doing with me, was to prevent 
them things from happening, getting bored and planning things to do and 
making sure I went through with them. The tasks, which, I suppose, were 
really important. I suppose they were very good with that. That’s the exercise, 
I think, it did have a meaning to it. A meaning and an end, if you like. Before 
that I wasn’t interested in planning nowt, or doing nowt, on a daily basis. 
[Patient C7/017 – intervention]  
 
Reflections or perceptions of therapy 
 
I. Perceived mediators of change (helpful aspects of therapy) 
The identification of different and meaningful activities to perform aligned with goal 
setting was frequently described and presented as an important aspect of the therapy. 
However, in general, participants found it difficult to articulate the mechanisms of 
change, and they did not explicitly distinguish the effect of BA therapy from the 
processes involved in it.  
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Well [therapist] told me how to do drawing and things like that, I hadn't even 
thought of it before [therapist] came. And it's done me good really. Trying to 
do some knitting and crocheting, drawing. Yeah, fine. I think it's good the 
idea, because I hadn't even thought of it. [Patient A1/084- intervention] 
Planning (particularly setting goals which are realistic and manageable) was described 
as an important aspect of the therapy. 
You try to do things and you struggle because you try to do things, you’re not 
cutting the picture down, you’re just trying to look at the whole thing. But this 
encourages you to break things down into little bits, rather than the whole 
thing, which is a better way of doing it. […]I’ve learned how to get round to 
doing it with the problem, which is what it’s teaching you. There’s always two 
ways to get somewhere, which I think you’ve got to remember. [Patient 
A1/034 – intervention] 
Completing the diary was also found to be one of the most helpful aspects of the 
therapy as it allowed the participants to reflect on progress, activities and mood on a 
regular basis. It also acted as a reminder for some participants to do the tasks and 
achieve their goals. 
I made a note of what I did um every day and how I was feeling and we [with 
therapist] talked through it. Um, and I did find it useful, interesting, and it sort 
of um prompted me to reflect on my progress and my activities. […]I came to 
look forward to the sessions because it was a chance to sit and reflect and um, 
and it gave um, it became an activity in itself um, which helped me to focus 
what I was doing over the week. Whereas perhaps if I hadn’t been taking part 
in this, I would have been taking these activities for granted […]. [Patient 
A6/002 – intervention] 
The mere process of having to talk to someone during the sessions about their feelings 
and experiences were found to be helpful by many participants.  
The one thing it does is give you, you know that someone’s gonna come 
round, someone you can have a friendly chat with as well, which makes a 
difference. [Patient A1/034 – intervention] 
The positive characteristics of the therapist (e.g., being ‘friendly’, ‘positive’, trained 
and encouraging) and having a good relationship with the patient were alluded to on a 
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number of occasions, suggesting the therapist’s manner might be a mediator for the 
success or acceptability of the therapy. 
In the beginning it needs somebody trained to get your mind-set to change and 
ask the right questions and get people to think differently. [Carer C7/017 – 
intervention] 
There was also a suggestion that continuity, i.e., having the same therapist attend 
weekly, was important.  
Not a stranger because obviously you do get to feel comfortable with the 
person, with [therapist] and, you know and you kind of, kind of look forward 
to it. [Carer B1/087 – intervention] 
 
II. Challenging aspects of therapy 
Some participants mentioned that the therapy was only useful while it lasted, so they 
felt the need for follow-up sessions to maintain the benefits. Participants highlighted 
some challenging aspects of the therapy even though they found the therapy helpful as 
a whole.  
I’m not 100% certain, I think I did benefit from [therapist’s] weekly visits and 
going through goal setting and things. I suppose that, since [therapist] stopped 
coming, that’s slipped a bit. And I would things, sort of think about doing 
things. I supposed, [therapist] turning up was more of a reminder for me what 
I’m doing. [Patient C7/017 –intervention] 
 
However, participants understood that the sessions were part of a research project and 
that it had to end at some point. 
Well, we always realised there was a timescale on it. So, I mean, we were 
prepared that we knew it wouldn’t last forever. […] [Carer A1/084 – 
intervention] 
 
Some participants highlighted that not every stroke patient is affected in the same way 
and suggested tailoring the therapy based on individual’s needs.  
It’s difficult because just for myself personally, I think it’s been great but I 
would think it depends on the type of person you’re going to see and how it 
has affected them y’know whether they would think ‘oh yeah this is fine’ or ‘I 
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can’t be bothered ’y’know that sort of thing but I accepted that everything that 
was put to me was positive and I did my best to do it. [Patient B1/087- 
intervention] 
 
Few participants reported having some trouble with filling out the diary. One patient 
suggested some improvements in the mood diary by breaking it into 
morning/afternoon/evening as their mood tended to vary during the day.  
His projects that he was supposed to do, I think he found that difficult because 
[therapist] would give him a weekly chart like a diary to fill in what he’s been 
doing in the day and I think he just found that; even when he were at work he 
found it difficult to fill in paperwork so it’s nothing new. [Carer C7/017 – 
intervention] 
 
Two participants found the sessions and the tasks repetitive and boring.  
The only thing that I found, you know doing all that work with [therapist], a 
lot of it repeated itself a lot. It was quite repetitive at times. [Patient C7/017 – 
intervention] 
Some of it I thought were a load of rubbish. On the whole, it was a neutral. 
Some of it was good, some of it I found boring, some of it I found helpful and 
it helped me. [Patient C7/001 – intervention] 
 
Format of therapy 
I. Number, frequency and duration of sessions 
Most participants thought the number and duration of sessions were ideal. However, 
some participants suggested having follow-up sessions to ‘keep the pot boiling’ and 
maintain the positive changes gained in therapy. 
Well, it might be worth sometimes to think about some sort of follow-up on a, 
on a sort of annual basis, sort of thing? See how things were going. […] it may 
be useful to keep in touch with things, I don’t know. You know, to see 
whether things are still working or not. [Carer A084 A1/084 – intervention] 
 
II. Role of carer in sessions 
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The carers’ involvement with the sessions was varied. While some carers reported 
assisting the therapist, others stated that they did not get involved with the therapy and 
only supported the patient (if needed) to do planning. Some carers reported joining the 
sessions (even though not taking part in the sessions), while some stated that they had 
never been to the sessions. However, carers felt happy with the level of their 
involvement. 
Well, I think it was just assisting whatever [therapist] wanted to do. If 
[therapist] wanted me to do something then I would, you know, attempt to do 
it. You know so it was just a sort of, like a, you know, assistant. Assisting 
[therapist] to do whatever she wanted to do with [patient]. Tried not to 
interfere more than necessary, really. [Carer A1/084- intervention] 
 
6.2 Therapist views of delivering the therapy 
6.2.1 Experiences of delivering the therapy 
General views and experiences 
All three therapists found delivering the therapy a positive experience and stated that 
they would recommend the intervention to other therapists and patients because of its 
‘simplicity’ and usefulness. They also found implementing the therapy easy and 
straightforward.  
I found it quite easy to implement the therapy. […] I think they [participants] 
found it really beneficial and they did just you know writing down just the 
initial activity diary and just getting them to see what they do and what they 
don’t do and how they could incorporate more things and I think that just 
really helped so yeah, I’d definitely recommend it.  
However, the therapists were also mindful that the therapy would work better for 
people who had come to terms with having stroke and are ready to put in the amount 
of time and effort. As such, they suggested that the therapy might be more effective if 
provided as a supplementary to other therapies for adjustment and physiotherapy.  
I think it works really well for the people who are kind of at the start following 
their stroke where they are ready to kind of put in the amount of time and 
effort required with behavioural interventions. […] some people I work with 
just seemed to be I guess when, when somebody’s got such a low level of 
hope and they still kind of haven’t really come to terms with how their stroke 
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has changed them and how its changed what they can do especially if 
somebody’s experienced a loss of some kind of role […] those people that 
were really quite resistive to any kind of introduction of activity or identifying 
activity they’d just say I can’t do that I can’t do that. 
For all three therapists, communicating with participants went well as they did not 
have any participants with extreme difficulties (e.g., severe aphasia or cognitive 
difficulties). There were only few participants with such difficulties but they were all 
able to understand, follow the conversation and perform the tasks. One therapist found 
the communication strategies taught as part of the training as useful with everyone as 
most participants had some degree of impairment in communication due to stroke 
even though it was not severe.  
 
6.2.2 Challenges 
The therapists also discussed the challenges they encountered while delivering the 
therapy. Dealing with the individual differences was reported to be one of the most 
challenging parts of delivering the therapy. They did not rigidly follow the session-
by-session plan as not everyone worked at the same speed, and the physical and 
cognitive capabilities and personality of people were varied. Some participants were 
more resistant to change or sceptical, whereas others were open to take on board new 
ideas.  
I had a couple of people where I had to take it a little slower, needed a little bit 
more time or a little bit more time for their writing, again that wasn’t difficult 
it was just something that I had to be aware of […]. I think some people are a 
little bit more resistant to change depending on where they are in their journey 
after stroke. Some people are ready to take on board anything that you want to 
do others are a little bit more sceptical even though they’ve decided to try it 
[…]. So trying to get people to understand the rationale and why we were 
doing it, some people I had to repeat that for a lot more and really y’know try 
and keep them on that frame of mind.  
In order to deal with the individual differences, therapists tried to be responsive to 
individual preferences and tailored the sessions in terms of its structure based on their 
needs. 
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I just tried to be responsive to the individuals as I kind of do in my day-to-day 
therapy and I think again as I mentioned, going back to the rationale of the 
therapy and the protocol to try and remind them what we were trying to do and 
why, […] just thinking around the individual needs and exactly sort of what 
people were frame of mind that they were in at the time. 
Two of the therapists also found the process of identifying meaningful and achievable 
activities difficult in some cases due to the participants’ level of disability and 
unrealistic expectations. 
I‘d say the hardest things was just working round practicalities of what people 
could and couldn’t do now, I think people tended to still get very focussed in 
their initial goals of ‘I just want to be as I was in the past’ and so the hardest 
thing was trying to get people to look at perhaps having to adapt that and 
having a different goal slightly or working with that. 
Keeping people engaged with the therapy-related tasks was also challenging. One 
therapist suggested that this was due to people not being able to come to terms with 
the stroke and being ready to change. They further argued that if they were in a 
clinical situation, they would withdraw the intervention for such people (after a 
collaborative decision). However, as this was a research study they felt the need to 
keep pushing to engage people.  
Quite a few people that I worked with it seemed like they weren’t quite ready 
to be increasing their activity and what they needed more at this stage in their 
recovery was the talking therapy and work on acceptance with kind of the 
stroke and the changes that have happened in their life so there was some 
difficulties there in terms of peoples physical capabilities and also engagement 
with the intervention because they kind of felt like there wasn’t anything that 
they could do.[…]quite a few of the people I worked with were telling me that 
they didn’t really want to plan things out they didn’t want to plan activity and 
plan out their lives […]and I think in a real life clinical situation there would 
have been a couple of points where I think I would have had quite a frank 
conversation with somebody about their level of engagement with the 
intervention and where we’d to go from here and if they really want to carry 
on. 
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6.2.3 Improvements needed/suggestions 
In order to improve the therapy, two therapists suggested having a standardised 
interactive therapy notebook or a folder that might be easier for participants to use and 
might also facilitate their engagement with the tasks.  
I tended to recommend to people or suggest they consider having like I say a 
bit of a therapy book because we would obviously have sheets that I could 
copy for people and things like that and that can become a bit disparate and 
people end up with piles of paper all over. So one thing I’d say perhaps just to 
consider, and a couple of people did, was to have a therapy book, erm a 
notebook that they can make any questions for the session, notes at the end 
and set the goals in it and kind of almost do that together and then they can 
sort of slip their diary in it. And one thing for therapy in the future if that 
wanted to be quite standardised across therapists is that could always be 
something that came with the therapy so perhaps a bit of a workbook for the 
clients that BEADS produce so that all the therapists were doing that in the 
same way. So even if it was just a notebook with like a couple of sections or 
something like that or even just a folder that sheets could go in or just to 
standardise it if that’s something to keep quite the same across a large number 
of people.  
Some therapists also argued that delivering the therapy for people who were three 
months post-stroke was too soon as they were still in the process of adjusting to 
stroke, and behavioural change was not a priority for these participants. Therefore, 
they suggested delivering the therapy to those who are 9- or 12-months post-stroke 
might be more beneficial.  
I thought that maybe having the therapy three months post-stroke was a bit too 
soon, just because people are still adjusting to what’s happened and having to 
adapt their homes […] I felt like it wasn’t so much of a priority for them to do 
the BA. They were always wanting to walk or improve their speech.  
 
6.2.4 Experiences of participants from therapist perspective 
Observed changes in participants 
Therapists observed that some participants made considerable progress in terms of 
increased confidence, engagement in activities and making plans. The level of 
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progress in mood and activity levels varied among participants. However, even in 
those who progressed less, there was an increase in the activity levels. 
There was definitely a couple of people that I worked with that were hugely 
different in what they were describing, so anecdotal things like confidence 
increased, going out more, wanting to speak to other people more. 
The people who really engaged with the therapy and kind of did go through 
this gradual process of introducing a bit more activity, experiencing lift in 
their moods, a bit more energy, a bit more motivation and then it kind of 
snowballed from there and people being more motivated to engage the 
following week because the work they’d carried out had shown benefits for 
them. 
They also observed some secondary benefits of the therapy for participants. Having 
someone to talk to during the therapy was thought to reduce feelings of isolation in 
participants. 
I think having someone who was dedicated to talking to them about how their 
life had changed and what they could do to help them and just that 
acknowledgement was a huge part of it I know that’s kind of the secondary 
benefits of any therapy, it’s not the core of BA to be listening to people but 
that was huge, and most people commented that the stage that they were at 
once they’d had all their discharge support sort of 6months down the line from 
the stroke it was very isolating, so they found that very helpful. 
Therapists also observed that those who engaged less with the therapy benefited less 
than those who were fully engaged.  
[…] then there’d seemed to be some people who don’t carry out the work or 
they do and don’t get, they don’t experience as much of a lift in their mood as 
they were hoping for or they didn’t quite get from it what they wanted then 
engagement would drop off and then things kind of snowball in the other 
direction if you like. 
 
Observed helpful and unhelpful aspects of therapy to participants 
Therapists’ observations of the helpful aspects of the therapy for participants echoed 
the accounts of participants and carers. That is, therapists observed that identifying 
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new and meaningful ideas, reflective process undertaken during the sessions, having 
weekly sessions, and talking to the therapist as the most helpful aspects of the therapy.  
More than anything it seemed to be just having the chance to talk things 
through with someone and some, mainly a lot of things that came out, just 
talking and the ideas that it sort of lead them to think of. So things to do, ways 
round little problems, getting out the house so all the things that we would do 
for the BA activities, people said they’d found that really helpful to do that. 
Therapists also emphasised that completing the activity diary helped participants to 
become aware of the link between being active and their mood. 
I think looking definitely visualising the mood rating and their activity levels 
really helped mine and showing them the progress that they were making and 
how their mood was being marked good when they were doing certain 
activities over other activities so I think visualising that and getting them to 
see it on paper rather than just telling them about it actually really helps. 
Undertaking the therapy at home and the flexibility of the therapy schedule were also 
considered helpful. 
People really thought it was good that the therapy was available in their own 
homes, people seemed to respond really well to that especially when I’d go out 
to and see them and talk about the study and explain that the works carried out 
in their own homes, people spoke positively about that and a couple of people 
had even kind of before I’d even got to that point indicated they wouldn’t be 
able come out and see me so there preference was to be seen at home. 
 
 
6.3 Practical aspects of delivering the therapy from therapists’ perspective 
6.3.1 Support provided to therapists 
Views on the manual 
All therapists found the manual a helpful resource when delivering the therapy as it 
provided them guidance during the ,intervention broke down the material and gave 
examples.  
The manual was really helpful, some really good hints in it like at the 
beginning where it gives you a few more hints about using it with people with 
difficulties in aphasia again just to remind you, and broke it down into all the 
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different sessions. […]I think all the sheets at the back were quite helpful so 
having a choice of different appendix and things were helpful yeah. 
While two therapists described the structure of the manual as flexible, one therapist 
found it somewhat rigid and suggested amending the manual to have a little less 
structure in how the modules are introduced to increase the flexibility. 
So it’s a very good structure and it was always told to me that it was quite 
flexible so I never felt that I was doing that wrong and obviously discussed it 
in supervision as well but yeah just for myself and the clients that I had, we 
didn’t stick very rigidly to that session by session structure. […].  
I did find it tricky at times when you kind of reach a road block in one aspect 
of the therapy like I was saying before if someone doesn’t want to be kind of 
formally activity scheduling with some kind of planner and you’ve tried 
everything to come up with a way to modify the strategy in a way that’s 
acceptable to them but still not getting anywhere and then trying to bring in 
other strategies like graded tasks or problem solving it, the manual in that 
sense felt a little bit rigid it was kind of I think problem solving got introduced 
in session six or seven of the manual and graded tasks around the same time 
but in my head I kind of imagined it being a bit more like a timeline between 
activity monitoring, identifying enjoyable activity and activity planning so 
those are kind of the three stages and graded tasks and problem solving are 
kind of additional strategies that slot in throughout. 
One therapist found the manual ‘a bit dense’, however they had an understanding that 
it needed to be comprehensive to cover people with different needs. They suggested 
providing a brief overview of each session in the manual to help therapists as a quick 
reference.  
I did find the manual a bit, a bit dense to use as kind of a brief reference but I 
understand it needs to be as comprehensive as possible and it was useful to 
have the amount of information that was there but one thing I found really 
useful was (pause) I flicked through the manual and essentially took out all the 
headings for each section within each session and made summary cards for 
each session which fit onto a piece of paper about that big a couple of inches 
long, which I could use just as a reference […] As an additional resource I 
think something like that would have been useful […]. 
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Views on the training received 
The training received was described as useful by all the therapists in providing a good 
foundation to BA therapy. They found it ‘comprehensive’, supportive and responsive 
as they were able to ask for help and get answers to their questions. 
I’ve found it to be very supportive in all the training and everything that I’ve 
had […] the training helped just kind of make sure I was doing everything in 
line with the protocol […]we had plenty of time to go through different 
modules and ask questions and sort of get an idea of how the BEADS wanted 
us to use the therapy, but without it being […] and it was nice to meet the 
other therapists at that stage, doing the training and talk to people, so I think I 
found that really helpful and a good base definitely. 
One therapists also commented that the amount of the training provided was just 
about the right amount and that they had the opportunity to ask for extra support if 
needed.  
I felt very able to ask for help and extra sort of support if I’ve needed it. […] it 
didn’t feel like it was too much, overkill or anything like that it was helpful. 
The speech and language training was found to be particularly useful as it provided 
therapists some useful tips on communication with people with aphasia.  
[The] Speech and Language Therapist […] gave us training on communicating 
with people with aphasia and gave us tools and some resources, that was that 
was excellent as well that was really useful as I said I didn’t really work with 
anyone with very severe communication difficulties but just the strategies in 
general were useful with almost everyone I’ve worked with.  
 
Views on the supervision received 
The overall supervision received (including supervision from the BEADS team, direct 
supervision in service and peer supervision) was also described as useful and 
supportive. Peer supervision was particularly found to be helpful as it reduced their 
feelings of isolation and provided therapists with an opportunity to share their 
experiences and tips on how to overcome certain issues they encountered.  
The supervision was good I think with us being quite all over the country the 
supervision that we had with the team, the BEADS team worked well over the 
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phone so it was really, really good to have that sort of peer supervision here 
we had conference calls because it was, you’re quite isolated in doing this role 
for what you’re doing for the BEADS so it’s very nice to kind of hear and talk 
to the others and sort of share experiences and sort of tips and hints of things 
they’ve overcome so definitely that was a really good way of doing it. […] I 
always had the direct supervision within my service from the sort the PI as 
well which was fine. […] I felt very supported. 
 
Views on the monitoring of practice 
Therapists did not feel being monitored, and felt that there was a good balance on 
people keeping an eye on their practice without making them feel pressured.  
It always felt there was a good balance between erm I would have the support 
where people were keeping an eye on what I was doing so I couldn’t go too 
wrong but there wasn’t sort of hovering over the shoulder and sort of didn’t 
feel too pressured and I could ask if I needed to so, that was good.  
Therapists also discussed the videotaped sessions and whether they felt that these 
sessions were different to unrecorded sessions. All three therapists felt that the 
videotaped sessions as being the same as the unrecorded sessions, however they also 
admitted being self-conscious at first, but this disappeared after 5-10 minutes. They 
also reported that they did not observe any differences in participants during the 
videotaped sessions. 
A little bit self-conscious with kind of the videos […] it wasn’t a huge, huge 
problem at all and once the session got started you kind of forgot it [camera] 
was there. So it didn’t bother me [...]. I was keeping an eye out for them 
[participants] maybe not being too different with the camera on from how I’d 
seen them in other sessions. So I think the biggest thing was yeah, just trying 
to make sure they were okay with that but everyone seemed fine […].  
It was weird having to video yourself but no it was good, most participants 
were happy to be videoed, especially when they knew it was just for training 
purposes and wouldn’t be broadcasted on the news or something. 
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6.3.2 Experience of working on trial within therapists’ department 
Therapists had varying experiences of working on the trial within their department. 
One therapist was autonomous, working completely separately from their clinical 
team. Apart from receiving supervision and updating the team, they mostly worked 
independently from home. 
I think for me it was completely separate. So I had my supervision from a 
clinical lead who was the PI for our site, my team do something very different 
so apart from I kind of let people know what I was doing and sort of gave a bit 
of information, but generally it was just completely autonomous. […].  
One therapist felt integrated within a larger clinical team within the department.  
My team […] were brilliant as well, so yeah I really enjoyed it. I had a lot of 
help from [names person] […] everyone was really supportive and always 
replied to the emails and yeah I got a lot of support so it was really good. 
[…]there was always someone there to help and give you any supervision if 
you needed it and […] so there was always a wealth of knowledge to ask if 
ever I needed it so yeah, I couldn’t have asked for better team to be, to be part 
of.  
In contrast, one therapist did not feel integrated within the clinical service and 
expressed that they were mostly working in isolation.  
I was kind of working in isolation a little bit which isn’t ideal, […] so I didn’t 
really feel integrated into the service in anyway and the way that referrals 
came to me from the service it seemed I wasn’t really involved in the triage 
process or really that involved with the other professionals in that team. 
 
6.3.3 Integrating the trial practice into wider service 
Barriers 
Barriers to integrating the trial practice into wider services included: being in different 
Trusts and difficulty to keep reminding people of the trial in Community teams. 
I think because I had the two different [names settings and place], I think it 
was difficult to keep reminding people of the BEADS trial and that it was 
running.  
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A couple of issues in terms of software I guess and the systems that we use for 
note takings and reports and that was to do with that fact its two separate trusts 
again kind of working across both.  
 
Facilitators 
Therapists found sharing information, support from psychological services and 
regular supervision helpful, and thought this might facilitate the integration of the trial 
practice into wider services. 
Obviously having the clinical psychologist who was fully supportive and on 
board. […] so having someone that was, that knew all the different people and 
could email them and, and tell them about the study was really useful for me 
so that was good.  
Regular supervision was really important and helpful […] I think with a 
second larger study just keeping that in mind, the idea of making the therapist 
feel part of the service by kind of physically locating them in the same place 
as the service would be, quite an important thing.  
 
6.4 Participant views on the trial procedures 
6.4.1 Rationale of the study 
Participants and carers recognised the importance of the study and there was a sense 
of understanding its rationale. 
I think it’s useful information and the only way you can get it is by talking to 
people like me, that’s guide through it. [Patient A6/001 – control] 
You can't move forward in these situations without these projects and things 
[Carer B1/087 – intervention] 
However, there were few concerns about what benefit the study and filling out 
different questionnaires might offer participants on a personal level. 
Well, since this [stroke] has happened I’ve had all sorts chucked at me. 
Different types of questionnaires. Varying different types of questionnaires. I 
thought it was good, it’s got its good points. Erm, but ultimately what do I 
achieve from it? [Patient C7/017 – intervention] 
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6.4.2 Motivation and reason to participate 
Altruism was one of the mostly mentioned reasons to participate. Some joined the 
study as they felt grateful to have been invited. Other participants explained that they 
thought it was better than doing nothing and that there was nothing to lose.  
I went into this open-minded and I thought, I’ve got nothing to lose, I’m only 
sat in the house, I’m not doing anything. If nothing else, it’s somebody to talk 
to [Patient C7/001 – intervention group] 
We said yes, you know it’s the least we can do in return for all the care and 
attention that [patient] had. [Carer C1/047 – control group] 
However, it was evident that some people had specific expectations of the BEADS 
study. Some wanted to find out about their problem and what could be done to 
improve their mood. Others chose to participate to see if the treatment would work, 
while some saw the study as an opportunity to talk to others about their problems.  
But err so I’m interested in you know trying to sort out well for ourselves 
trying to find out what is it frustration or is it depression that [patient]’s got. Is 
there anything that we can do about it? […] But yes I am I am in a way 
desperate or I am keen to try and find a way that we can bring [patient] a little 
bit more back to what she was prior to certainly the last two strokes, if not all 
three strokes. [Carer C1/047 – control group] 
Well I thought, well I'll see what I can do and try and, try and help like, you 
know. And see if it help me to get me head straight a bit. [Patient A4/002 – 
Control] 
Some reported having no expectations regarding the study when they first got 
involved.  
I don't think we had a thought about whether it was going to help or not. And 
I, and I don't think actually, one way or the other [Carer A1/124 – control 
group] 
I didn’t know what to expect, I was just – I’ll do it, I’ll do it, I’m not doing 
anything else. So yeah, I thought yeah, I’ll give it a go [Patient A6/001 – 
control] 
For others, it was the hospital or the health professionals who suggested the trial to the 
patient.  
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It was from [staff name] at [hospital name], and she came out as sort of a 
stroke counsellor to try and help me adjust with you know the stroke. Because 
it's difficult. It's tough when you've had a stroke you know. And she came out 
and it were her that suggested it. [Patient A4/002 – Control] 
 
6.4.3 Understanding the research process 
General 
From the feedback interviews, we established that overall, participants and carers 
reported that the information provided was clear and easy to follow, and the study 
itself was a positive experience in general.  
Well as I say the interviews aren’t unpleasant in any way [Patient C4/005 – 
control group] 
However, some participants had difficulty with remembering details about the study 
due to stroke-related memory problems: 
I can’t remember anything about the study because, apart from everything 
else, the stroke’s affecting my memory and I can’t keep them in my mind 
long, they just disappear after a short while. [Patient A6/001 – control group] 
The follow-ups were highlighted as being useful as they provided participants an 
opportunity to reflect on the intervention and the trial.  
Been very happy, you know I like the fact that you don’t just leave people, 
you do follow it up. You give it a break before you actually come out again, 
and so it gives you time to settle down and review, and all that sort of thing. 
[Carer B1/087 – Intervention group] 
Some participants and carers expressed that they would like to know about the 
findings and receive feedback about the study.  
I know the study’s finished and what’s the final outcome when the final 
study’s done all its conclusions? What’s that? What happens then? [Patient 
C7/017 – intervention group] 
For control group participants, the research process was straightforward, involving 
only the completion of questionnaires. Most control participants (both participants 
and carers) reported not feeling involved with the study and there was a sense of 
disappointment. 
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It’s [study] been quite straight forward as far as I’m concerned. No problems 
whatsoever. […] I’ve had to do nothing, only attend 2 visits from people 
asking me questions. There’s nothing much to say about it really. [Patient 
A1/124 – control] 
 
Recruitment 
When prompted to recall the recruitment process, some participants reported that they 
could not remember the finer details of the process. This could be attributed to: (i) the 
stroke-related memory problems, (ii) feeling overwhelmed due to stroke-related issues 
happening at the time (e.g., many health professionals getting in touch, having had the 
stroke recently), and (iii) their involvement being long time ago.  
I: How did you come to be involved in the study? 
P: I can’t remember haha! It’s that long ago, I can’t I think we got a phone call 
or a letter or something. Or even erm I honestly can’t remember […] I can’t 
you see this is where the stroke has affected I can’t [Patient C1/047 – control 
group] 
In general, participants did not mind being asked to participate in the study and some 
found the process of getting involved in the study easy. 
I: So how did it feel, being asked to do the study? 
P: Ooh I didn’t mind at all. Did I? [Patient A1/084 – intervention group] 
One carer argued that some participants might be discouraged by the use of mental 
health terms and by the perceived intrusive nature of the study. However, she was 
happy to get involved and encouraged the patient to take part: 
I can see why people wouldn't be, because people are often a bit put off by the 
words, you know that are used, the sort of mental health side of it and all that 
sort of thing. But it was clearly very appropriate in this situation. […] I guess 
people might think it's a bit intrusive or you know, quite a bit, not personal 
stuff I don't remember there being a lot of personal stuff, but it's, for the actual 
patient or you know stroke victim if you like, you know you're asking how 
much they can do certain things and all of this. And it's another stranger that's 
coming into the home and all this sort of thing […] But I mean I'm quite, just 
for me, I'm quite an open person and I will take any help of any sort given the 
situation. [Carer B1/087 – Intervention group] 
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Acceptability of randomisation protocol 
In general, intervention group participants felt positive about being allocated to get 
the therapy and some thought this as a ‘privilege’.  
Well I think it was, we thought it was a privilege to have the chance to do it 
rather than be sort of abandoned. [Carer A1/084 – intervention] 
Feelings of disappointment were evident in some control group participants and carers 
for not having the intervention, as they understood from recruitment processes that 
they would be receiving treatment.  
I was a little bit disappointed, to be fair, but I was happy to go along with it 
and see what would happen, but I was a little bit disappointed. I wanted to be 
more involved. [Patient B6/001 – control] 
However, there was also a sense of understanding why there was the need to have a 
control group and a sense of acceptance.  
Yeah, I don’t mind that [being in control] because I think it’s useful 
information and the only way you can get it is by talking to people like me, 
that’s going through it. [Patient A6/001 – control] 
Indeed, some intervention group participants would still have taken part even if 
randomised to the control group. 
But yeah I was fine about it really, either way we would have taken part in it I 
think wouldn't we? [P: Yeah, yeah] Because it's all, it's all useful and how can 
you get, you can't move forward in these situations without these projects and 
things. So you can't lose by it really, we would have gone either way to be 
honest. [Carer B1/087 – intervention] 
However, some uncertainty about the randomisation process were evident; some 
control participants thought they were not taking part in the therapy sessions because 
“they were already doing activities” or that they did not “qualify” to get the treatment. 
I: so your research assistant would have called you to let you know that you 
were part of the control group, so you weren't going to be taking part in these 
therapy sessions- 
P: No. Because I already was doing bits myself, you know. So I was like doing 
a lot of what they were going to do, probably, you know.  
I: So is that why, is that the reason you think that perhaps you weren't chosen?  
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P: I don't know because I have me books you see, and I sit colouring all day, 
well most of day! [Patient A4/002 – control] 
P: Yeah I didn't get the treatment, I didn't qualify for the treatment. [Patient 
C7/013 – control] 
There was also a perception among some intervention group participants that the 
questions they answered were used to “qualify” them for getting the therapy. This 
demonstrates misunderstanding and perhaps lack of clarity in how the trial 
information has been explained to participants: 
Um, I was asked, if I remember right, I was asked certain questions which said 
whether I, to which one [group] I would be going to. [Patient A1/034 – 
intervention] 
 
6.4.4 Participant views of the outcome measures 
Focus of measures 
Overall, participants felt the focus of the measures was good, ‘pertinent’, ‘pretty 
through’ and ‘interesting’, and they felt that we were asking relevant questions to both 
the participants and the carers. 
 
Participants and carers were asked to rate the questionnaires on a scale of 1-10 in 
terms of their content and focus (1 for not capturing important aspects of their 
experiences and 10 fully capturing important aspects of their experiences). On 
average, they gave 7.15 (SD=1.85), indicating that the questionnaires captured 
important aspects that were relevant to their experiences. 
Some participants thought some of the questions were not relevant to their own 
personal situation, but they could see the relevance of such questions for other people 
who experienced different problems, and understood that the questions needed to be 
broad. 
[…] so some might not have been quite so relevant for us, but overall you're 
covering it all for people with stroke. So yeah I don't have a problem with any 
of it, some more relevant than others, but I wouldn't say you should leave 
anything out because you've got to cover it for everybody. [Carer B1/087 – 
intervention] 
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Some participants mentioned that how they answer the questions might depend on 
how they feel and cope on a daily basis and that their answers might be different if 
they completed the questions at another time.  
Sometimes the ones you know, did he feel weak and stuff, not at all this week, 
[…] they do, are different at the beginning to what they are as you get further 
on, it depends how they cope with it [Carer C1/009 – control] 
Participants felt that the questionnaires were useful as they gave them and the 
researchers some indication as to how their mental health was affected by their 
condition and the intervention itself.  
Well yes, yeah. I mean obviously this [questionnaire] gave me some indication 
as what my mental state was at the time [Patient B1/087 – intervention] 
One participant thought there were some missing questions regarding fear and 
confidence that might be relevant to people affected by stroke. 
C: I know one question which was not on there and I know sometimes I do 
think it, people who have had a stroke and got off light, or anybody who’s had 
a stroke, they are frightened they’re going to have another one and that’s at the 
back of their mind […] because the confidence goes and in the back of the 
mind, I might be driving somewhere, have a heart attack because I’ve got AF 
or could have another stroke.[Carer C1/009 – control] 
 
Ease of understanding/completion 
I. General comments  
Most participants and carers had positive views of the questionnaires, in terms of ease 
of completion and understanding. A number of people found the questions fairly 
straightforward to complete. 
I think he was fine answering the questions. And he found that a lot of the, the 
questions that were being asked, or was, well they were asking him when he 
was in the hospital, I think, we've had different people come, different nurses 
and things come in. So a lot of the questions were the same as that. [Carer 
A1/124 – control]  
Some participants felt that a space was needed to express their responses in a bit more 
detail and they suggested providing more space or asking open-ended questions. In 
contrast, others mentioned they preferred ticking boxes, as this was easier. 
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It was pretty easy because you’d got the options rather than having to think 
about what you wanted to say. About how easy things were, how difficult 
things were. You got a, you got an option for each one so, yeah, I would say it 
was pretty easy. [Patient B6/001 – control] 
Few participants found completing the questionnaires difficult. One participant found 
the content of the questionnaires difficult to grasp due to stroke-related problems, 
whereas another participant found it hard to concentrate when questionnaires were 
lengthy.  
Shattered because I had to uh concentrate. And the problem being is, the 
questionnaires are that long winded that when your brain’s been affected, you 
have trouble concentrating, so they could simplify it just a tad. [Patient A1/034 
– intervention] 
For some participants and carers, it was hard to explain their thoughts and feelings, 
particularly in a continuously changing context. However, they also suggested that the 
questionnaires provided them with a specified amount of time. 
C: You know, even though circumstances can change you can only answer 
with, you know it’s like, one of them was about me, how was I getting on that 
particular week. Now that particular week I wasn’t having a good week. If 
you’d have asked me a week before that or a fortnight it might have been oh 
I’m fine, so they are pretty good. 
I: But you, you like that it gave you that defining amount of time? 
C: Yeah. Even as though as I said circumstances can change. [Carer C1/009 – 
control]  
I: did you find that [completing questionnaires] easy or quite hard? 
C: Hard. Hard to explain your thoughts and feelings. [Carer A6/001 – control] 
Some participants explained that they needed help with filling the forms in terms of 
holding a pen, concentrating or remembering. One patient stated that she would not 
complete the questionnaires alone as she would not have the patience and the ability 
to concentrate. Thus, they suggested that if the participants complete the 
questionnaires together with someone, as in having a conversation, it would boost the 
confidence of the patient and completing the questionnaires would be easier. 
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C: The problem with form filling for [patient] she hasn’t got the almost the 
patience to do it. So if you give her something like that and then she’s 
absolutely bored by the time she’s got to the bottom of the first page 
I: Hmm, how did you get around that? 
C: Talked about it, I asked the question […]  
I: How do you think [patient] would have got on if you hadn’t have been 
there? 
C: She wouldn’t have done it […] 
P: I’ve always been frightened of forms, filling a form in, in case, in case I do 
it wrong. In any case so just looking at it I would have thought I can’t cope 
with this, and I would have just ignored it, I really wouldn’t know. [Carer & 
Patient C1/047 – control]  
 
II. Specific outcome measures 
In general, participants reported positive views on each specific outcome measures. 
However, some participants and carers found it difficult to answer questions about 
feelings as how the participants feel fluctuated all the time depending on the shifting 
stroke-affected context.  
I found it ok. The questionnaire that we had that you know that I filled in for 
myself at the end, was ok. Some of the questions were a bit erm, I couldn't say 
how he was feeling. You know, you have to expect that, you want to know 
how he was feeling on that day. Well, you know, as far as I'm concerned some 
days are good days some days are bad days, so you can't really make a 
judgement on each day, because you don't know what each, you don't know 
what each day is going to pan out like. [Carer A1/124- control] 
Participants expressed some issues with the mood questions. For instance, they felt 
that asking about suicidal tendencies was ‘strange’, ‘not appropriate’ and ‘upsetting’, 
and one participant felt that these questions were ‘not valid’ as people might not 
answer them truthfully due to the stigma associated to depression and suicidal 
thoughts. However, there were also a sense of understanding of its purpose and that it 
might be relevant to those who were very depressed.  
I found a bit strange I don't know some people might not, but. It says erm well 
the question, do you ever think that, do you ever wish you were dead? Do you 
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think you'd be better off like, you know. Well that, to me that's a question, a 
strange question. Cos I mean I don't think anything like that, it's probably 
ruddy morbid though […] I certainly don't think it's a relevant question to me. 
[…] I can't understand the purpose of a question like that quite honestly. I 
mean whether it erm, whether the answer relates to a person, to an individual 
state of mind or not I don't know, it may do. Which I suppose it does in a 
sense. Because you know people might get all sorts of strange things when 
they, through frustration and that. Which erm, which is I do feel a lot 
sometimes. [Patient A1/124 – control] 
Several participants found the aphasia-friendly questions with pictures and smiley 
faces helpful as the images made the questions more relatable and they enabled them 
to better express their feelings.  
I feel they sort of, you could put 0-3 but, yeah. They made it, sort of, I felt that 
YOU could see exactly how I was feeling. […]I feel that, again, you can see 
better how I actually feel with the pictures rather than if it was just like before 
with the questions. I feel this one you can see a lot more. [Patient B6/001 – 
control] 
In contrast, one participant was offended by the simplicity of these questions. This 
was also echoed in another intervention participant who declined to complete the 
aphasia-friendly questionnaire as he found these ‘too simplistic’. However, 
participants recognised that for others more severely affected these questions were 
needed.  
I didn't really enjoy it. And then there was one with pictures, and she 
[researcher] said now can you point to what's on these pictures. And I thought 
well, course I can! There was a bridge, and a ship in it, and things, and a fence, 
and things like that! And I thought of course I can! Then you think after, it's 
probably for them people that can't remember, you know, that's brain's got a 
bit, you see. [Patient A4/002 – control] 
Most had difficulty answering the resource use questionnaire as it was hard to recall 
answers due to stroke-related memory problems.  
Quite hard to recall, especially when it’s asking you about the minutes each 
time. But yeah, if you just round it up, it’s not too hard. [Patient B6/001 – 
control] 
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Carers found the caregiving questions relevant and they appreciated being considered 
because they often felt forgotten. 
I was actually quite pleased because in a lot of these types of situations the 
carers do get forgotten about, it's one of those duty things isn't it. But erm I 
was pleased to see the carers were at least considered in the equation really, it 
wasn't just about the person that was ill. [Carer B1/087 – intervention] 
 
Quantity of questionnaires 
Most participants and carers were happy with the number of questionnaires they had 
to complete, and stated that the quantity was ‘just about right’.  
There wasn’t too many. It was fine, it was, yeah, I would have liked more 
(Laughs) […] it wasn’t too short, it wasn’t too long, it seemed to have got all 
the information. [MB/001 Patient – control] 
I: what you thought about the number of times and the number of questions 
we've asked you to complete, whether that's been ok or whether there's been 
too many things? 
C: That's fine, I mean there's got to be a reason for it hasn't there? You know, 
so that's fine. [C7/013 Carer – control] 
Four participants thought there were too many questions.  
It took a long while yeah. […] Well, I did get fed up of answering questions 
(laughs) to be honest, kept going which is more or which is less, or whatever 
and things, and I thought not another page you know! (laughs) [A4/003 Patient 
– control] 
Some people questioned why we were being repetitive and wondered if this was a 
way to ‘trick’ them to respond in a certain way or to see if they are being ‘honest’ 
with their answers. The duplication tempted them to constantly go back and check 
their answers.  
You notice as you filled them in as you’ve gone through them, you notice your 
answering the same question two or three times over […] Now whether this is 
just a trick to sort of get you to put yes on the first page and no five pages later 
I don’t know, but they are a lot of questions duplicated, […] So you can go 
back and rub all the answers out and make them all agree! Haha! […] There’s 
always temptation isn’t there [C1/047 Carer – control] 
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6.5 Therapist views on the trial procedures 
6.5.1 Recruitment 
Each therapist experienced different issues with recruitment depending on the setting 
they were based in and links to recruiting Trusts.  
I think it was quite difficult in that I couldn’t get hands-on and do things. So 
we struggled with getting packs out and recruitment to start with […] so 
having permission to go in and work with the team and the research nurses to 
send out packs and then contact patients and follow that up would be really 
helpful. […] if we could have a few extra staff as it were for the first couple of 
months to really plough out that invites, information contact people and then 
even if that dropped off later because we didn’t need that support, to kind of 
almost do it the other way round that would have helped.  
They also found that recruitment from voluntary groups were ‘unfruitful’ as the 
members were already functioning well or several years post-stroke.  
Tried a number of approaches for different groups so like the voluntary groups 
and things like that, which was completely unfruitful. So that didn’t really 
work because the groups mainly held people who were either functioning 
quite well because they were active in the groups or they were sort of 15 years 
post-stroke so it was a very long time ago. 
One therapist found the process challenging and experienced problems at the start, as 
the sites had not been set up as planned. They felt stressed when targets were not met 
as they believed that it was their responsibility to recruit the target number of people. 
We had a little bit of an issue with recruitment at the start of the study in 
[names place] and other sites weren’t quite set up on according to the schedule 
for the study and that kind of set things back a little bit […]the impression I 
had was that recruitment was and the feeling that I got was that recruitment 
was kind of solely my burden almost it was all my responsibility and kind of it 
was quite stressful at time when targets weren’t, weren’t being met because of 
lack of referrals […] and I think one thing that helped towards the end of that 
was getting some more support from the admin team that I was kind of 
working with, the [name of] admin team which I guess just didn’t figure out 
was available at the start. 
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Where the therapist was integrated into the wider stroke research team at the Trust, 
they reported that this went well as they had access to patient data and were able to 
support all recruitment activity. 
I had a lot of help from the stroke co-ordinator, […] she’d given me a database 
to work from, send out recruitment packs which really helped to kick-start 
recruitment for [names site][…] being able to access that data and managing 
all the recruitment myself and sending out the packs and knowing where was 
at with everything really helped because I wasn’t having to rely on other 
people to do it who had their own jobs to do as well so I think that was a real 
benefit for [names site] because I was able to look at the patient records and 
send out the invitation packs so it was really good. 
Two therapists argued that working part-time limited their ability to recruit more 
people and slowed down the process as they did not have enough time to exhaust all 
the available recruitment routes at the same time as delivering the therapy.  
 
6.5.2 Study procedures 
As it was their first research experience, two therapists had initial concerns with 
following the protocol, but they both felt they were able to ask questions and received 
support from the trial team which they found useful.  
There was a few things that I had questions on so just to check back on, yeah 
as I say I’m very clinical based so a lot of the paperwork it was all new to me 
quite how much paperwork and forms and everything there was. So I was a bit 
terrified of getting something wrong, but I was, I felt able to ask questions and 
anytime something was slightly wrong. 
Two therapists found the protocol comprehensive, easy to follow and useful as a 
reference guide. One therapist thought it needed some amendments to allow for 
flexibility and streamlining in terms of the process of screening, baseline, recruitment 
and consenting.  
It [protocol] seemed to work really well, it was nice having that as a reference 
guide to refer back to, it was very thorough and so yeah I think that worked 
well, I can’t think of anything to change.  
There were a couple of things in terms of recruitment and the recruitment 
routes themselves I think there's a couple of amendments there to be made to 
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allow for that flexibility but I think just a little bit more flexibility being 
inherently more in the protocol would have been useful […] I think the 
process for screening, baselines and recruitment and consent could have been 
streamlined a little bit I think that there were some cases I found that it was a 
little bit disjointed. 
One therapist identified that completing therapy treatment sheets and transferring 
them to online system duplicated effort and was time consuming. 
So, for most of the paperwork, like assessment paperwork, you would do it 
with the client ‘cause you were doing there and then and then you would 
transpose it onto the system when you got home which was fine because you 
can understand that, but the therapy treatment write up sheets just felt like a 
real duplicate of time because you would write up your notes with the patient, 
make some notes as you were going along and then you would do a paper 
copy and then you would do it on the computer. So it was almost like ‘cause 
that was quite time –consuming. 
 
6.5.3 Measures 
Therapists thought all the measures were relevant and comprehensive and fit with the 
purpose of the study.  
Well I know all the different assessments are capturing different bits of data 
for various things that they’re going to be looking at. I think they're all 
relevant […] I think the carer questionnaires were particularly good, I think 
the carers that I worked with really liked being involved in the study and that 
way being invited to take part as well and have their view. […] They seemed 
fit for purpose, there wasn’t any where I was thinking that it was I didn’t 
understand why it was being done or that I was thinking it wouldn’t be useful 
there was just that one where there was a doubling up of the aphasia friendly 
and the standard one.  
One therapist thought that there were too many questionnaires, but felt they were not 
tedious and were relevant for the purpose of the study. Another therapist did not think 
that there were too many measures to complete, and where needed, the assessment 
session was split.  
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There was a lot of them [questionnaires], but I could see why they were there. 
They didn’t feel too tedious, as I say I never had anyone with great difficulties 
sort of aphasia or cognitive, they could have been quite overwhelming if there 
was, it would have taken time.  
I didn’t find that it was too much. I just had one lady who did get tired halfway 
through so we had to split the session up […] I just thought that that was the 
information that was needed to collect […] if participants were struggling I’d 
read the questions out for them and do and the checking and things like that. 
One therapist highlighted the doubling up of the aphasia friendly version and standard 
version of the EQ-5D-5L questionnaire at baseline, and thought it would be more 
efficient and more accurate if people completed them independently at first and got 
help from the therapist if needed. 
There’s one that there was a standard version and an aphasia friendly version 
as part of the baseline booklet which I always kind of felt that it was a bit of a 
confounding variable that some of those baselines were done in person with 
the therapist as opposed to done by the individual themselves because a lot of 
the time the baselines were carried out with me going through them, me 
reading in which case the aphasia friendly version and standard version it kind 
of, it’s a bit meaningless if it was me going through them anyway. 
 
6.6 Qualitative summary 
 
Most participants’ experiences of being involved in the trial were positive. However, 
not all participants understood that they would  not receive therapy for their mood 
problems. Additionally, understanding of reasons for being randomised to usual care 
was variable. These findings suggest that more information should be provided to the 
participants about randomisation before they are consented onto the study, with 
possible reminders during the course of the trial.  
 
The outcome measures were generally felt to be appropriate in terms of content and 
length. However, some participants found questions on death and suicide 
inappropriate, yet there was an understanding of its purpose and its relevance to those 
who were very depressed. Therefore, outcome assessors may need to introduce these 
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questions or questionnaires with care. Some participants thought that it would be 
useful to include questions about fear and confidence. Some questions were thought 
to be duplicated across outcome measures, which is inevitable given that standardised 
questionnaires were used (with some overlap of questions). Images to support 
understanding of questions was found useful by many participants, however there is a 
need to be mindful of participants who may find this childish and insulting. 
Additionally, some participants had memory issues affecting completion of measures, 
particularly the service use questionnaire. Therapists felt the questionnaires could 
have been overwhelming if participants had more significant language and cognitive 
difficulties.  
 
The views of the therapist on trial procedures were generally positive. However, they 
felt the process of screening, baseline assessments, recruiting and consenting could be 
clearer in the protocol. They also felt it was important for them to be integrated within 
the existing clinical teams, where possible, for ease of recruitment and understanding 
site-specific processes. Therapists also found completing therapy forms on paper and 
on electronic database duplication of work that was time-consuming, and suggested 
making this process simpler.  
 
Many patient participants reported benefits of having the BA therapy in terms of their 
improved use of strategies, and increased levels of activities and mood. For many, the 
follow-up appointment was seen to be useful therapeutically and they suggested this 
could be part of the intervention itself. Some therapists felt the timing of therapy 
(three months post-stroke) was too early as people were still in the process of 
adjusting to stroke, and suggested providing the therapy later (nine or 12 months post-
stroke). Therapists also recommended including an interactive therapy notebook to 
facilitate participants’ engagement with the therapy. Training and supervision 
provided for the therapists were found to be useful. However, they found the manual 
quite large and suggested providing an overview summary to refer to as needed. 
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7 Discussion 
 
7.1 Summary of findings 
Feasibility was demonstrated across the majority of the selected outcomes and we 
identified strategies for improvements in a definitive trial. However, the main issue 
outstanding is whether a sufficient number of sites could be recruited which would be 
capable of delivering the intervention and maintain participant numbers over the trial.  
 
Feasibility trial 
We randomised 49 participants to the trial (one in error) in 27 centre months of 
recruitment. Recruitment was lower than the anticipated sample size of 72, although 
this calculation was based on 36 centre months of recruitment. The highest number 
was recruited through hospital databases while recruiting from stroke wards was the 
least effective. Nine participants (19%) dropped out of the study during the 6 months 
follow up; seven of these were in the BA arm. Delivery of the intervention was good 
with high attendance (90%).  
 
Participants received a median of nine and mean of 8.1 BA therapy sessions (range 0-
14), with sessions each lasting a mean of 57.3 minutes. Excluding the participants 
from the BA arm who did not receive the intervention, 75% received at least eight 
sessions. A positive effect was found in the intervention arm for the primary clinical 
outcome the PHQ-9. We did not test for statistically significant differences between 
the groups because this was a feasibility trial but we note that the 95% CI does not 
include zero. On the secondary outcomes the intervention had a positive effect for 
participants on VAMS Sad and the NLQ and for carers on the CSI, although these are 
not considered statistically significant. There was no difference between intervention 
and control groups on NEADL. Small negative effects were found for the patient 
reported EQ5D-5L and SADQ. 
 
Fidelity assessment 
The therapy record forms, which documented the proportion of time (in 10 minute 
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units) spent on individual components, indicate that the components of BA described 
in the manual were delivered to participants. The distribution of time on the different 
components over the course of therapy was as expected. However there was little use 
of graded tasks assignments and training in problem solving documented. This may 
be because graded tasks were often used as a between session task and so were coded 
as such. The video recordings of sessions were an important adjunct to the record 
forms as they highlighted some aspects not otherwise recorded. 
Qualitative 
Therapists, participants and carers observed that the most helpful aspects of therapy 
were identifying new and meaningful activities, reflection during the sessions, having 
weekly sessions and having the chance to talk with someone. Most participants felt 
that the number and duration of sessions were appropriate although some suggested 
that follow up sessions would help maintain the gains made. Interestingly some 
control participants also found participation in the study helpful as it provided 
opportunities to talk about their experiences. However, others were uncertain why 
they had been randomised to usual care. 
 
The therapists found delivering BA a positive experience and would recommend it to 
other therapists because of its simplicity and usefulness. The therapists found the 
manual and training helpful but suggested having a summary of each session and an 
interactive notebook or workbook for participants. The therapists may also benefit 
from having a Quick Reference Guide alongside the full treatment manual. The 
therapists also believed that therapy would be more appropriate for those who had 
come to terms with their stroke so therefore later than three months post -stroke. The 
biggest challenge identified was the variation in individual presentations although the 
therapy and manual allowed sessions to be tailored for individuals’ needs. However 
identifying meaningful and achievable activities was difficult for some due to their 
level of disability and unrealistic expectations. The therapists reported different 
experiences of recruiting participants to the trial, reflecting local site differences. 
 
Health economics 
BEADS has shown that it is feasible to collect the data to conduct a rigorous 
economic evaluation. Uncertainty is high and influential, such that very high values of 
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obtaining further information are estimated, irrespective of the perspective of the 
analysis – but conducting a full trial would appear to represent good value for money. 
 
7.2 Evidence of feasibility and implications for a future definitive trial 
7.2.1 Population/recruitment 
The primary objective of this multicentre feasibility trial was to assess feasibility of 
recruitment in the study population for a definitive trial. A total of 756 participants 
were screened across all sites; screening routes among which 49 were recruited, 
amounting, giving a recruitment rate of 1.8 participants per centre per month. Delays 
in set up meant that we had a reduced number of months of recruitment as we still 
closed the study on the planned date. Had recruitment been open for 36 months rather 
than 27 months at our recruitment rate of 1.8 participants per centre per month we 
would have achieved a sample size of 62. We have identified ways to improve 
recruitment in future studies. The delays in site set up have been outlined in Chapter 3 
and were due to delays in the approval of excess treating costs and the knock on effect 
of appointment of study therapists in the NHS, and a change to the IAPT provider 
close to the time that the study was due to open. This suggests that a longer set up 
time should be scheduled for a definitive trial particularly given the increased number 
of sites needed. 
 
The sample size for a definitive trial was calculated with two main options, one is 
based on a difference in PHQ-9 score of 4 points between treatment and control at 6 
months and the other is based on a difference in PHQ-9 score of 3 points between 
treatment and control at 6 months. Both options represent moderate standardised 
effect sizes which are appropriate for a trial of this kind. If a definitive trial were to be 
powered on the smaller effect size to detect a smaller effect, this would mean that to 
have a total sample size of 580 participants, based on a recruitment rate of 1.5 
participants per centre per month, 16 centres and 24 months of recruitment would be 
required. However recruiting 16 centres, capable of participating and delivering the 
intervention, while maintaining a steady pace of recruitment over 24 months, may be 
a potentially significant challenge. Given the variability in psychological support 
services for people with stroke it is not yet clear whether 16 centres would be 
achievable. Data would need to be collected to explore this aspect further. 
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This attrition rate at 19% was higher than the anticipated 15% and was highest in the 
BA group. The reasons given for dropping out were varied and included not having 
enough time (those in the BA group) and deterioration of health. However people did 
not have to give a reason or may not have given the real reason. The attrition rate was 
higher than studies of CBT for post-stroke depression
25
 and motivational interviewing 
after stroke.
31, 35
 The sample size was too small to allow subgroup analysis to explore 
whether particular characteristics were associated with dropping out. One possible 
factor is that in BEADS we recruited people at a wider range of time points post-
stroke. 
  
Recruitment varied across the three sites. Recruitment was most successful in Site 1 
where the therapist was based in the hospital with the CRN research nurse enabling 
them to work closely together to facilitate recruitment. This was reflected in the 
qualitative interviews where therapists felt that it was important for them to be 
integrated within clinical teams to facilitate recruitment. The therapists were generally 
positive about the trial procedures but suggested that the process of screening, 
baseline assessments, recruiting and consenting could be clearer in the protocol. 
 
From our observations in the feasibility trial, the use of IAPT as a main site for 
recruitment in a definitive study may not be ideal, particularly if this is separate to the 
trust delivering wider stroke services. This is due to the nature of IAPT services 
where participants actively seek their services and it was possible that people would 
be less likely to refer potential participants in case of an unfavourable randomisation 
outcome. The IAPT site had lower recruitment, possibly due to fewer numbers of 
stroke patients available to them compared with the other main sites. This made them 
heavily reliant on patients identified from the hospital database at the companion site. 
This adds to the challenge of recruiting the large number of sites required for a full 
trial. 
 
Recruitment varied across the different routes. The highest number of participants 
(42.9%) were recruited using hospital databases. While this requires a large number of 
potential participants to be contacted, it may be considered an efficient approach in 
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terms of staff time to send out the invitation packs. This approach alone may not be 
sufficient to sustain recruitment over the duration of a definitive trial depending on 
the number of patients on the database and how many years previously the details are 
available (e.g. if recruiting up to five year post-stroke). The highest uptake from the 
number of patients screened was via community caseload (13/28 participants; 46.4%), 
possibly due to the personal approach by the clinician and opportunity to explain the 
study and answer questions, although this is more time consuming than using 
databases. We did not recruit through GP databases and this could be explored as a 
future option in order to approach people longer term post- stroke (e.g. two to give 
years) to reach the large patient population. We would first need to establish the likely 
proportion of people on the database who have had a stroke within the last five years 
and the time and resources needed to send out invitation packs. A further suggestion 
for recruiting more patients who are in the late stages (up to 5 years) ,and therefore 
unlikely to be in contact with stroke services , would be through increasing self-
referral. This could be attempted through advertising the study more widely in the 
press and through social media. 
 
It is possible that equipoise, or lack of individual equipoise, may have affected 
recruitment where we were reliant on clinicians as the gatekeeper notifying potential 
participants about the study. Interviewing the Principal Investigators and key 
clinicians from the sites would have provided insight into how they perceived 
equipoise and to what extent it influenced how they explained the study to 
participants. We did get an indication, however ,that there were issues of equipoise at 
one site early on. At this site objections were raised about the treatment as usual arm 
not receiving any active intervention, and whether this was ethical. This was resolved 
with explanation that it was unknown whether the intervention arm would be shown 
to be beneficial. However additional Guidance for clinicians may help them explain 
equipoise to eligible participants.
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Therapists reported that due to their workloads they could only recruit the number of 
participants that they could deliver the therapy to without undue delay in delivery of 
the intervention in case they were randomised to the intervention arm. At one of our 
sites, the therapist had to delay randomising participants and this meant that there 
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were varied periods of delay between when baseline assessments and randomisation 
were performed. In nine participants this delay was greater than 30 days. Stratification 
by site was used, however this did not alleviate these delays. To increase recruitment 
rate and/or reduce this delay then therapists would potentially need to be employed 
for a greater proportion of the week in order to prevent long delays between consent 
and intervention delivery. 
 
All of the participants with aphasia had mild aphasia which may indicate that people 
with more significant communication support needs may have been missed with the 
identification and recruitment methods used. It is possible that staff referring to the 
study simply did not consider people with significant communication difficulties. In 
addition, the written information was sent out to potential participants (covering letter, 
participant information sheet, reply slip, PHQ-9, VAMS Sad) and may not have 
provided sufficient support for people with more significant aphasia to understand the 
study and demonstrate an interest. For a definitive trial, the presence of these 
difficulties could be one of the factors that help decide whether to send a pack or 
whether to arrange a home visit to discuss the study. 
 
The therapists reported not using the Consent Support Tool with all participants if 
they felt that the potential participant seemed to be communicating well with them. 
Yet t how well a person appears to understand can be misleading and is subject to the 
judgement made by the therapist. If people with more significant communication 
difficulties are identified for a future trial, it will be important for therapists to use a 
tool such as the Consent Support Tool routinely with all participants. This would 
ensure consistency and identify any communication difficulties that need to be 
supported. It is to be noted that the FAST, which was similar in presentation to the 
CST, was completed well as it was part of the CRF. However FAST only indicates 
the presence and severity of aphasia while the CST identifies the levels of 
communication ability and thus eligibility for the study and also links to support 
strategies. These issues could be addressed during staff training in a future study.  
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7.3 Generalisability 
The information gained from this feasibility trial was adequate for informing the 
sample size needed for a definitive trial. Our inclusion criteria were broad to reflect 
clinical practice and address the issue of the generalisability of the results. In order to 
recruit a sample representative of the wider stroke population, we identified 
participants through a range of routes. Most participants (62.5%) had a time since 
stroke of three months to one year although one quarter of participants were between 
one and two years post-stroke. We included people who had their stroke up to five 
years previously because there is evidence that depression is still prevalent after this 
time
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 and to reflect our original PPI feedback. .  
 
The therapists did attend voluntary stroke and aphasia groups in an effort to identify 
people later post -stroke but found that they were less likely to need support for low 
mood and were often more than 5 years post-stroke. For a future study there is the 
potential to access hospital and community databases to include more people between 
2-5 years post-stroke.  
 
It is an important point that people with aphasia have higher rates of depression than 
the rest of the stroke population and it was disappointing that only mildly aphasic 
participants were recruited. Of the 48 participants recruited, 18 had aphasia which 
reflects the incident rates of aphasia in this population
116
 although it should be noted 
that all of these were mild aphasia. This may be a reflection of the recruitment 
approaches used. We have already shown in a previous study
17
 that behavioural 
activation can be delivered to a sample of participants with aphasia and can improve 
mood. At baseline 78.7% of participants scored as having mild cognitive impairment 
on the MoCA which is in keeping with previous research that up to around 75% of 
participants have cognitive impairment after stroke.
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The team discussed the possibility that it is not uncommon for clinical staff to ‘pre-
screen’ patients and not identify those who they believe might struggle with the 
intervention or they feel they want to protect, which is common with patients with 
communication and cognitive difficulties due to their increased vulnerability. A 
possible way to ensure inclusion of a wider range of aphasia severity in a future trial 
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may be to provide training to the clinical teams about ensuring they identify all 
patients who are eligible must be given the choice whether to participate in the trial or 
not irrespective of a personal clinical viewpoint. Additionally, it may be of benefit to 
engage more fully and regularly with the speech and language therapists within each 
clinical team, as they are best placed to identify people with aphasia. 
 
Half of the people (69/138) who completed the PHQ-9 for screening prior to 
recruitment scored as depressed. This is higher than the prevalence of one third 
reported in the literature
11
 and suggests that our recruitment approaches were able to 
identify depressed people who were willing to respond to the invitation for the study. 
The mean PHQ-9 score of 16.8 (4.7) in the recruited sample at baseline falls in the 
category of major depression, moderately severe. In the sample at baseline 39.6% of 
participants scored as moderate depression, 31.2% as moderately severe depressed 
and 29.2% as severely depressed. We excluded people who were receiving medical or 
psychological treatment for depression when they had their stroke and those currently 
receiving psychological intervention. Therefore we would not expect to have many 
people with severe depression. 
 
We recognise that all participants were of British White ethnic background except for 
one participant. We would therefore need to improve the representation of the 
multicultural multi-ethnic UK population in a definitive trial. Approaches to improve 
this representation could be through the selection of a diverse range of study sites and 
also including people from different ethnic backgrounds in our PPI group. 
 
For the purposes of this trial, only English speakers were offered the intervention as 
issues to do with delivering the intervention to non-English speakers are not 
straightforward and this would need to be addressed if the intervention was shown to 
be effective with English speakers initially. It is important to explore methods of 
broadening this intervention out to non- English speakers, for examples, using a 
therapists trained in BA who speaks the same language as the patient, using 
translators or family members (however this would need to be explored with caution 
as translators often do not translate verbatim and therefore the content of the therapy 
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delivered may not always be consistent with that received so careful fidelity 
measurement would be required) 
 
7.3.1 Intervention 
The feasibility of the intervention with regards to delivery was very promising as the 
results demonstrated that the intervention could be delivered as intended across sites 
and was acceptable to participants, carers and therapists. Of the 225 intervention 
sessions scheduled, 202 sessions were completed i.e. 90% of sessions scheduled were 
delivered. Reasons for missed sessions included changes to participant's availability 
(n=14, 61%), illness (n=4, 17%) and change of therapists’ availability (n=3, 13%). 
Overall the therapy seemed to be acceptable by participants, carers and therapists and 
could be delivered by an Assistant Psychologist or IAPT therapist under supervision 
from an experienced mental health practitioner. The intervention was manualised to 
support delivery of the intervention by the therapists, to facilitate consistency across 
sites and therapists, and to allow future replication. The therapists did comment in the 
interviews that the manual was quite large and that an overview summary to refer to 
would be helpful. They also recommended that an interactive therapy notebook might 
facilitate participants’ engagement with therapy. Some participants who received BA 
suggested that follow up therapy sessions would be useful to maintain gains. This 
would be consistent with the booster sessions offered in the study comparing BA and 
CBT for depression in primary care.
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The therapy record forms indicate that the components of therapy in the manual were 
delivered to participants and the distribution of time was as expected. The therapy 
record form may need to be modified to reflect the content of between session tasks, 
as the infrequent coding of problem solving and graded tasks on the record form may 
be because they were covered as between session tasks. This is supported by the fact 
that the therapists and participants did refer to problem solving and graded tasks (i.e. 
breaking down a bigger goal or task into smaller steps) which suggests these 
approaches were used. 
 
In the qualitative interviews therapists felt that the timing of therapy was too early for 
some participants as they were still adjusting to stroke although it is important to note 
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that this was not commented on in participant interviews. Participants had to be a 
minimum of three months after stroke but could be up to five years so we did not 
constrain recruitment to the early months post -stroke. The sample size is not large 
enough to allow subgroup analysis to explore whether time post-stroke was related to 
differences in outcomes. Regarding whether the intervention is adaptable enough for 
patients who perceived to come up with unrealistic goals, we could attempt to address 
this in a definitive trial by including more time in the therapists’ training to provide 
guidance on goal setting, using examples from BEADS. We could also seek feedback 
from our PPI group on how to better explain the purpose of the therapy to patients and 
examples of goals that may be appropriate.  
 
7.3.2 Outcomes 
Follow ups for a definite trial could be done via telephone (where appropriate) which 
may improve follow up rates. We observed that some participants needed to be 
reminded by phone calls a few times to complete and send back outcome assessment 
packs to the central study team, this could be practically challenging in a larger study. 
Postal outcome assessments supported by telephone reminders with the option of 
resending questionnaires, completing questionnaires over the telephone or offering a 
home visit have been used previously
31, 35
 and Parker and Dewey
118
 highlighted that 
administration time was important to maximise the quantity and quality of 
information obtained by postal questionnaires. Follow up home visits could be offered 
to all participants; however this would significantly increase the cost of the study 
particularly considering number of centres/participants needed for a definitive trial. 
Text message reminders could also be used. 
 
Completion rates of individual questionnaires were good and there are no reasons to 
change the outcome measures. The outcome measures were generally felt to be 
appropriate in content and length. 
 
The quality of life measures used in the BEADS trial are worthy of further 
consideration. The standard EQ-5D questionnaire was included, as was a proxy 
version completed by carers on the behalf of participants, an accessible, unvalidated, 
aphasia friendly version of the EQ-5D, and the standard version completed by carers 
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to report their own quality of life. Because nearly 98% of participants were able to 
complete the standard version of the EQ-5D at baseline, this measure was chosen as 
the basis for the economic evaluation, with neither the proxy version nor the 
accessible version used any further. It is relevant to note, though, that data completion 
was slightly worse for proxy measures, and that the agreement between proxy 
measures and patient-completed questionnaires was only moderate – agreement 
between patient-completed standard and accessible measures appeared much higher, 
though this does not represent an appropriate validation of the tool. This reinforces the 
view that proxy measures should be avoided where possible, hence the recognised 
need for accessible preference-based health related quality of life measures for 
participants who are unable to complete the standard EQ-5D questionnaire.
119
 
 
Carer quality of life was collected marginally less successfully in the BEADS trial. 
Completion rates were 84.8% at baseline, and 63.6% at the 6 month time-point. 
Quality of life of carers has rarely been taken into account in economic evaluations 
but not including it may underestimate the value of an intervention due to health spill-
over effects not being incorporated, as the health and wellbeing of a carer can be 
affected by the health of the person they are caring for.
120
 Including these spill-over 
effects can affect the cost-effectiveness of an intervention.
121, 122
 There is currently no 
consensus on how spill-over effects should be incorporated but a conceptual 
framework has been developed to suggest how they could be.
123
 The BEADS trial has 
shown that it is feasible to collect information on the health-related quality of life of 
carers, and this could be incorporated into future analyses to help inform decision 
making on the allocation of scarce healthcare resources. 
 
Due to the small mean difference (and 95% confidence interval) found between the 
intervention and control groups at follow up on the NEADL this measure could be 
omitted from a full trial. Overall the items on the NEADL may not be sensitive to 
detect the changes in the types of activities addressed in BA. In the qualitative 
interviews the therapists commented that some participants showed in increased 
confidence during the therapy. One participant also suggested that questions about 
fear and confidence were missing from the measures they completed. A measure of 
confidence after stroke has recently been published
124
and may be suitable as an 
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outcome measure in a full trial although as it is new its responsiveness to change has 
not yet been determined.  
 
7.3.3 Adverse event reporting 
Trials of non-pharmacological health interventions vary widely in their approach to 
recording AE and making attributions in terms of causality. We recommend that the 
approach taken in any future trial is appropriate to the level of risk and feasible. Given 
appropriate resource ,we would record adverse events but an option would be to avoid 
labelling them as ‘adverse’specifically to avoid the need to assess causality. For a 
definitive trial we would recommend that non serious adverse events are not assessed 
for relatedness to stroke or intervention as these are difficult to attribute to the 
intervention. As access to the hospital admission details is not easily accessible for 
rehabilitation trials and the event cannot always be assessed for its relatedness to the 
intervention or condition we would propose that events are not recorded as adverse 
events instead as safety outcomes that are not assessed in the same way and no action 
is taken. These safety outcomes could then be reported regularly to the DMEC for 
monitoring. We would record and report Serious Adverse Events. 
 
7.4 Strengths and limitations 
7.4.1 The feasibility trial 
BEADS was a multicentre randomised controlled trial. Allocation concealment was 
ensured using internet-based randomisation hosted by Sheffield Clinical Trials Unit. 
The outcomes assessors were blind. It was not possible to blind participants or 
therapists to group allocation. The Statistical Analysis plan was agreed prior to data-
lock. In addition to the feasibility RCT, we had nested qualitative research, fidelity 
assessment and health economics evaluation. As outlined in previously, delays in site 
set up meant that the start of recruitment was delayed. However we kept the original 
recruitment end date and so were able to deliver the trial, intervention and follow up 
assessments in the time period originally agreed albeit with reduced numbers. Issues 
with recruitment and recommendations for improvements are detailed in section 3.6.2 
Participants were willing to be randomised although in the interviews some control 
group participants seemed to misunderstand why they were randomised to usual care 
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(e.g. thinking they did not qualify for the intervention). This suggests that the purpose 
of randomisation and result of the allocation needs to be explained more clearly. We 
were able to recruit a diverse sample in terms of demographic and clinical 
characteristics. 
 
The control arm in this trial was treatment as usual therefore there was no active 
control arm or any attempt to control for attention. We decided against including an 
attention control group, as there is already evidence that the benefit from behavioural 
activation to treat depression in other settings is a specific effect of treatment rather 
than a non-specific effect of extra attention. In a trial of CBT for post-stroke 
depression
25
 it was difficult to deliver an attention placebo intervention that was 
credible to participants, easy to facilitate, and included none of the active intervention 
strategies. Further consideration should be given to including an attention control 
third arm but the benefits of this would have to be weighed up against the difficulties 
associated with the associated increase in sample size that this would require. 
 
As noted recently by Popp and Schneider
125
 there is no ‘gold standard’ for attention 
placebo controls in trials of psychosocial interventions. Our main argument against 
including an attention control group is that there is already evidence for the 
effectiveness of BA for treating depression in other settings. In particular, in a 
recently updated meta-analysis of RCTs of BA for depression
126
 six of the 26 studies 
used treatment as usual for the control, 15 used a waiting list control and three used a 
psychological placebo intervention, and one study had a waiting list and a placebo as 
controls. The meta-analysis found that BA was superior to controls. A smaller effect 
size was found in studies using a placebo intervention compared with a waiting list or 
usual care, but these effect sizes were still statistically significant. There is therefore 
up to date evidence that BA is an effective treatment for depression in the general 
population. 
 
In the qualitative process evaluation from the COBRA trial (non-inferiority trial 
comparing CBT and BA for depression)
49
 while common factors such as being 
listened to and feeling understood were valued by participants, in addition to these the 
researchers found that specific aspects associated with the CBT and BA were 
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important. In a definitive trial evaluating BA for treating post-stroke depression it 
would therefore be important to use a process evaluation to focus on the mechanisms 
of change that may be taking place within BA. For example, in an ongoing cluster-
RCT of BA by mental health nurses for treating late life depression in primary care, 
BA is being compared with treatment as usual rather than an attention control 
condition and one of the research questions is  to explore the mechanisms of change 
that account for the effectiveness of BA compared with treatment as usual. 
127
  
 
We do not have detailed information on what usual care was at each of the sites. It 
was intended that treatment as usual data would be gathered from the resource use 
inventory but, as this questionnaire covered all services received, whether treatment 
was as usual, was sought out for by participants or paid for etc., it does not provide 
the specific usual care information that would be valuable to collect in a definitive 
trial.  
Regarding the disappointment expressed by some participants who were randomised 
to the control group, it is worth noting that the attrition rate was lower in the usual 
care group compared with the BA group. This suggests that allocation to the usual 
care group did not deter people from remaining as participants in the study and 
completing the outcome questionnaires. To alleviate the disappointment for 
participants allocated to the usual care group, we would recommend that the training 
provided to staff who are explaining the study and taking consent should include 
additional time spent explaining the concept of randomisation in lay terms. In addition 
we would recommend that the training includes additional time spent on how to 
explain the randomisation outcome to participants, in particular to those who have 
been allocated to the usual care group (and who will therefore not be receiving the BA 
therapy). The materials for this training (such as example scripts and role play tasks) 
would be developed in collaboration with the PPI group. 
 
7.4.2 Fidelity assessment 
We assessed the fidelity of the delivery of the intervention through therapy record 
forms for every session and then video recording a sample of sessions. The video 
analysis was limited as recordings were incomplete and did not include all sites. We 
had intended to select participants and sessions iteratively using purposive sampling 
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but this was not possible due to practicalities and resources. We only had one video 
camera for the study; this meant that each therapist only had the camera for a short 
period and they could only record available sessions for those who consented to this. 
Technical issues such as the camera battery running low meant that some sessions 
were only partially recorded. Therefore, we cannot be sure that all sessions at all sites 
were delivered in accordance with the manual; in a future study it would be logical to 
review videos during the trial and ensure sufficient funding for all sites to have a 
video camera throughout the study. However, in addition to the training and the 
therapy manual, weekly clinical supervision by a local Clinical Psychologist and 
monthly teleconferences with the Chief Investigator and an NHS Consultant Clinical 
Psychologist were provided. These meetings did not raise any concerns suggesting 
that the therapists were not following the manual. 
 
We did not assess the competencies of the therapists in the study (although 
appropriate clinical supervision was provided) and in a definitive trial. To our 
knowledge, a validated competency assessment for behavioural activation is not 
currently available. We note that Ekers, Richards, McMillan, Bland and Gilbody
61
 
developed a fidelity checklist for use in their trial evaluating BA (delivered by generic 
mental health workers) for treating depression and there may be scope for this to 
inform training and monitoring of therapy in a definitive trial. 
 
7.4.3 Health economics 
BEADS has shown that it is feasible to collect the data to conduct a rigorous 
economic evaluation – including data to help inform an analysis taking a societal 
perspective, including indirect costs, and potentially including spill-over health-
related quality of life effects. The collection of data required for the economic 
evaluation was successful and it would be feasible to collect similar data in a full trial. 
However, it is important to note that participants reported some difficulty answering 
the resource use questionnaire due to issues with recall – this should be carefully 
considered when designing the data collection approach in a definitive trial. In 
addition, given the importance of carer costs, consideration should be given to 
collecting information on carer time over a longer time-period, to provide more 
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reliable information for a societal analysis. Resource use diaries represent an 
alternative approach, but also have limitations. 
 
Our analyses suggest that there would be a very high value to obtaining further 
information on key parameters within the economic model – this value is likely to far 
exceed the cost of running a full trial. It would be most valuable to obtain more 
information on the NHS, PSS and societal costs associated with the health states 
included in the economic model. Often it is difficult to collect such information with 
precision even in definitive trials, but there remains substantial value to obtaining 
further information on other parameters such as the relapse rate, utilities and response 
rates, which would be best achieved through a randomised controlled trial. 
 
It was not our aim to provide definitive estimates of the cost-effectiveness of the BA 
treatment. However, our preliminary analysis of the cost-effectiveness of the 
intervention suggests that it may represent a dominant treatment strategy (i.e. cost 
saving and QALY gaining) from a societal perspective, but is of borderline cost-
effectiveness from an NHS and PSS perspective. Yet, these results should be 
interpreted with some caution, particularly because our within-trial analysis resulted 
in QALY losses for the BA treatment. Due to the higher response rate observed in the 
intervention group and the assumed higher utility score associated with good 
response, our modelled analysis provided an opposite result, but there is clearly 
considerable uncertainty around this. 
 
7.4.4 The qualitative research 
The nested qualitative research has helped our interpretation of the feasibility results. 
As well as interviewing participants who had received the intervention, we 
interviewed carers and also participants who were randomised to the control group in 
order to gain their perspectives. Participants were selected purposively to represent 
the centres, range of severity of depression, and stroke survivors with and without 
aphasia.  
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7.5 Results in the context of other studies of psychological interventions for 
post-stroke depression 
As outlined in section 1.2, there is currently limited evidence for the clinical and cost-
effectiveness of psychological therapies for post-stroke depression.
38
 Previous studies 
of psychological interventions have recruited people early after stroke and excluded 
people with severe communication or cognitive problems. The CALM study
17
 found 
that BA improved mood at 6 months follow up in stroke participants with aphasia and 
low mood. In BEADS we have shown that BA can be delivered to a broader sample 
that included people with and without aphasia or cognitive impairment. A reduction in 
depression was found in the BA arm improved although the purpose of BEADS was 
to evaluate feasibility and so we did not aim for itto be powered for efficacy. 
 
7.6 Patient and public involvement (PPI) 
The PPI group (two stroke survivors and a carer) were particularly helpful in 
improving the patient information materials and this led to us developing a study 
summary card and a spiral bound version of the aphasia-friendly information sheet. 
The therapists were invited to a PPI meeting as the group wanted to ask the therapists 
about their experience of delivering the therapy and working with people with 
depression. Both the therapists and PPI members gave positive feedback about this 
meeting and we would recommend this approach in a future study. The PPI group 
gave feedback on the draft of the Plain English Summary and will be asked to 
feedback on drafts of the final study newsletter for participants.  
 
As we had a separate PPI group and included people with significant aphasia in this 
group we did not have a PPI representative on the Trial Steering Committee. With 
hindsight, tt would be beneficial in a definitive trial for a member of the PPI group to 
also sit on the Trial Steering Committee to ensure that the PPI representation is 
integrated into the overall monitoring of the study.  
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8 Conclusions 
Overall BEADS has shown that it was feasible for BA to be delivered by an Assistant 
Psychologist or IAPT therapist and that the therapy was acceptable to participants, 
carers and therapists. We were able to recruit participants but due, to delays in site set 
up, the overall recruitment rate was lower than anticipated. We have used the 
recruitment rate from BEADS to estimate the number of sites and duration of 
recruitment that would be needed for a definitive trial. Although we have identified 
approaches for improving recruitment, the issue remains as to whether 16 study sites 
could be identified which could deliver the service over 24 months to achieve the 
sample size estimate required for a definitive trial. 
 
A scoping study is first needed to identify whether there are a sufficient number of 
sites who are willing and able to recruit participants and deliver the BA intervention 
for a definitive trial. In selecting appropriate sites for the study it would be necessary 
for the site to have a PI in the stroke service who is able to commit time to facilitating 
participant recruitment across the different recruitment routes; this would be essential 
given the number of sites in the study. The site would also have to have an 
appropriately qualified clinician who could provide the local clinical supervision to 
the study therapist. Where a site did not already have a therapist in post to deliver the 
BA intervention it would be necessary to secure excess treatment costs to fund this 
and also to allow sufficient time in the study set up to appoint therapists.  
 
Implications for healthcare 
 Half of the people who returned the PHQ-9 at initial screening scored as 
depressed which highlights the prevalence of post-stroke depression and the 
importance of mood screening after stroke. It is particularly important to 
ensure that people with aphasia and/or cognitive impairments are included 
within mood screening. 
 
 As the trial was not powered for efficacy it is not appropriate to draw 
conclusions on the efficacy of BA for treating PSD. However, we have shown 
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it is feasible to deliver BA to people with no or mild to moderate aphasia or 
cognitive impairment.  
 
 We found that, following training, Assistant Psychologists and a 
Psychological Wellbeing Practitioner were able to deliver the BA intervention 
in this trial. This provides different potential models for the delivery of BA, 
namely through stroke services or IAPT services. As we found recruitment to 
be more difficult when using the IAPT service as a main site for recruitment 
compared with the stroke service sites, this suggests that a referral pathway 
would need to established to link stroke and IAPT services at sites where such 
a pathway does not exist. We would need to further explore the competencies 
required for delivering BA to stroke patients with depression to identify 
whether the therapy could also be delivered by other clinicians following 
appropriate training, such as mental health nurses.  
 
Recommendations for a phase three trial 
The first step is to identify whether there are sufficient sites willing and able to deliver 
the services needed which could sustain recruitment over the study timeframe. Then if 
a definitive trial were to be undertaken, based on our findings, we would recommend 
the following: 
 
Essential/high priority 
 
● Recruit through stroke services rather than using IAPT as a main site for 
recruitment. 
● Provide at site support or central monitoring of recruitment 
● PI and site staff engagement. Although there were monthly teleconferences 
between the CI and the therapists and regular newsletters to update the sites of 
key changes and phases of the study, for a definitive trial, regular 
teleconferences could be arranged for the site staff and PIs so that they felt 
more engaged and this may improve recruitment at sites. 
● Sending out regular newsletters to all participants informing them of the 
study’s progress to help them feel more engaged in the study. This may 
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increase retention as some participants in the control arms commented that 
they did not think they needed to complete the follow up assessment that were 
sent as they did not realise they were still involved in the study.  
● Amend the therapy record form so that the content of the between session task 
is recorded as some components of therapy (e.g. graded tasks) may be covered 
as a between session task. 
● Ensure that study staff and CRN staff resourcing is allocated accordingly for 
the most effective recruitment routes (e.g. hospital databases required a large 
number of letters to be sent out but this is efficient in terms of sending out a 
mailing to potential participants).  
 
Moderate priority 
 
● The therapists were only in post until the end of recruitment and so the study 
manager had to co-ordinate the reporting of AEs and SAEs including finding 
information on the causality during the follow up period. It would be worth 
considering funding an administrator at the sites during the follow up period. 
This would allow the sites to be more involved in follow up and in the 
reporting of AEs and SAEs as well as having related activities such as dealing 
with database discrepancies, study completion forms etc. dealt with. Having at 
site support for the full duration of the study would also help with collating 
information about treatment as usual at the sites and any other issues that arise 
after the end of the intervention. 
● Explore GP databases and social media as other sources to recruit participants, 
particularly those no longer receiving rehabilitation.  
● Ensure data on NHS, PSS and societal costs are captured. 
● Ensure sufficient data are collected to allow estimation of a relapse rate 
● Improve the collection of usual care data. For example, study leads as sites 
could contact participants regularly (such as every two to three months) to find 
out whether they have had any other intervention and follow up further details 
with staff who delivered other interventions.  
● Ensure that therapists have the capacity to start treatment sessions before 
randomising participants. 
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● Consider including a booster session(s) to support maintenance of therapy 
gains. 
● Consider providing a Quick Reference Guide for the therapists to use 
alongside the full treatment manual  
● Ensure that the training for researchers includes additional time spent on how 
to explain the randomisation outcome to participants, in particular to those 
who have been allocated to the usual care group (and who will therefore not be 
receiving the BA therapy). The materials for this training (such as example 
scripts and role play tasks) should be developed in collaboration with the PPI 
group. 
● Develop a fidelity checklist to be used to inform the training of therapists and 
the monitoring of  the videos of  therapy sessions during the trial 
 
Recommendations for future research  
Several of our recommendations for a phase three trial include approaches that are 
also relevant to the recruitment of participants and monitoring of treatment fidelity in 
multicentre trials in stroke rehabilitation more broadly. In addition to these 
recommendations, from our experience of BEADS we have identified further areas 
for future research: 
 
 Identify whether equipoise from clinicians and researchers influences 
recruitment to RCTs in stroke rehabilitation 
 Explore methods for broadening psychological interventions for people who 
have had a stroke to be accessible for non-English speakers 
 Explore the accessibility of psychological interventions for people with severe 
aphasia and/or cognitive impairments 
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9 Appendices 
Appendix 1 Changes to Protocol 
Changes to Protocol Progress 
Report 
Date Approved by  
Detail added on notification of GPs 
following ethical review by NRES East 
Midlands – Leicester. 
 Protocol 
v2.0, 
22/01/2015 
REC 
29/01/2015 
Additional options added to the 
recruitment process following early 
feedback from participating sites. That is, 
to include the option of a streamlined 
recruitment process whereby the therapist 
can contact the patient directly by phone 
following consent to contact, and to 
broaden the recruitment routes to include 
potential participants on acute outpatient 
caseloads. 
 Protocol 
v2.1, 
19/06/2015 
REC 
08/07/2015 
Additional exclusion criteria to the effect 
that patients are not eligible to be 
recruited to BEADS if they are currently 
receiving psychological intervention; that 
they will be withdrawn from the 
intervention arm if it is subsequently 
agreed that the patient needs immediate 
clinical psychology input and to clarify 
that usual care can include psychological 
input post-randomisation. 
 Protocol 
v2.2, 
29/07/2015 
REC 
07/09/2015 
Change in study personnel and contact 
details 
Additional secondary endpoint of 
estimating sample size for a definitive 
trial. 
 Protocol 
v2.3, 
26/02/2016 
Minor 
amendment 
therefore REC 
approval not 
required. 
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Changes to Protocol Progress 
Report 
Date Approved by  
Clarification that 2 or fewer missing 
items within the PHQ-9 questionnaire 
may be imputed. 
Approval to 
implement 
received from 
CRN 
15/04/2016 
Change in study personnel (CI and Study 
Manager) and contact details  
 
 Protocol v3, 
06/05/16) 
REC 23/05/16 
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Appendix 2 Video recording categories 
Manual Content Code Other Content Code 
All sessions:    
Summarise Previous session P Social chat SC 
Review between session 
tasks 
R Information on organisation of 
sessions e.g. date, venue, time 
etc. 
IO 
Set agenda and goals for each 
session 
AG Travel arrangements T 
Agree between session tasks 
for the next session 
AN Preparing materials, tasks etc. PP 
Session Summary SU Check whether participant 
needs reminder of the next 
appointment (phone call/ text 
message) 
AR 
Review Between-Session 
Task 
RT Breaks B 
Review events since previous 
session 
RE   
    
Session 1  Therapist Activities  
Therapist to introduce 
themselves 
TI Providing explanation PE 
Explain aims of BEADS 
study 
AB Providing feedback PF 
Explain structure of sessions 
i.e. frequency, time scales, 
between visit tasks etc. 
SS Providing encouragement/ 
reassurance 
PR 
Assessment of current 
difficulties and symptoms of 
depression 
DS Summarising S 
Discuss communication 
abilities/difficulties 
CA Paraphrasing PH 
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Outline behavioural 
activation treatment rationale 
BA Presenting/ discussing BA 
strategies 
PS 
What else want to know?  K Address problems with task 
non-completion 
AP 
  Checking understanding  U 
Session 2  Give opportunities for 
participant to ask questions 
OQ 
Identification of participants 
problems (problem list) 
IP References to between-session 
activities  
RA 
Agreeing therapy goals 
(specific, measurable time-
bound) 
TG Reference to problems list PL 
  Reference to participant goals PG 
Session 3  Addressing appropriateness of 
activities 
A 
Discuss relationship between 
activity level and mood 
DR Ask participant to rate 
enjoyment of chosen activities 
AE 
Refer to behavioural model 
of depression  
BM Asking Participant Questions QQ 
Introduce idea of identifying 
enjoyable activities 
IA Reference to previous sessions Z 
    
Session 4  Participant Activity  
Review idea of identifying 
enjoyable activities 
ER Discussing BA strategies BS 
Discuss how enjoyable 
activities improve mood 
EM Discussing activities D 
Identify enjoyable activities  E Asking for information AI 
Create list of enjoyable 
activities 
L Describing problems DP 
Identify barriers to engaging 
in identified activities 
EB Asking questions Q 
Check activities are in line CG Information about sessions, I 
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with goals venue, group etc. 
Activity Scheduling plan SP Describing mood DM 
  Feedback on home activities F 
Session 5  Feedback on sessions FS 
Review whether activities 
were carried out (rate success 
or problem solve for non-
completion) 
AO Hospital visit discussion HD 
Identify suitable activities to 
be completed as between-
session task (new activities/ 
increased frequency of 
activities) 
SA Speech and language therapy 
discussion 
ST 
Recap idea of activity 
scheduling 
RS   
Agree which activities to be 
carried out for following 
week 
AW Appendices/ Worksheets  
  Graded task principle 
discussion/explanation 
GT 
Session 6  Use of graded task principle  UG 
Review whether activities 
were carried out as scheduled  
CS Use of/reference to activity 
diaries/schedules 
UD 
Identify one activity per day 
to be scheduled 
OA Use of /reference to mood 
rating scales 
UM 
Identify any potential 
obstacles to completing 
activities and address them 
PO Use of/ reference to activity 
lists 
AL 
  Use of/ reference to activity 
schedule/ activity monitor 
AS 
Session 7  Use of/ reference to participant 
specific communication 
resources 
C 
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Review relationship between 
activity schedule and mood 
SM   
Identify common problems in 
planning or carrying out 
activities 
CP   
Problem solving strategy PK   
    
Session 8    
Review and rate 
achievements in regards to 
goals set at start of therapy 
GA   
Addressing a new or 
unachieved goal 
N   
Discuss behavioural 
strategies to achieve goal 
DB   
Introduce idea of therapy 
ending 
TE   
Highlight successful 
behavioural strategies and 
progress 
H   
    
Session 9    
Address reasons for non-
completion of between-
session tasks 
NC   
Discuss therapy ending DE   
Highlight successes and 
achieved goals and consider 
continuation of these post 
therapy 
TC   
Identify with participant how 
behavioural strategies can be 
used to address goals 
BG   
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Develop plan to cope with 
future mood problems  
PM   
    
Session 10    
Review problems addressed 
during therapy 
TP   
Summarise successful 
strategies and skills used 
US   
Discuss generalisation of 
skills to future situations 
(relapse prevention) 
GS   
Questions and answers QA   
Remind them about 6 month 
follow up protocol (indicate 
date) 
RM   
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Appendix 3 Resource use costs 
Resource use Unit cost(£) Reference 
Inpatient stay per night 
(general) 
389.10 Reference costs 2015-2016 
(Weighted average of regular day 
of night admission) 
Inpatient stay per night 
(Myocardial Infarction) 
442.85 Reference costs 2015-2016 
(Weighted average of EL, EL 
XS, NEL, NEL XS, NES for 
EB10A-EB10E) 
Inpatient stay per night 
(Orthopaedics) 
433.54 Reference costs 2015-2016 
(Weighted average of EL, EL 
XS, NEL, NEL XS, NES for 
HE11A-HE83C) 
Outpatient attendance 116.92 Reference costs 2015-2016 
(Weighted average of total 
outpatient attendances data) 
Outpatient: Psychiatry 171.41 Reference costs 2015-2016 
(Total; 715 old age psychiatry) 
Outpatient: Clinical 
psychology 
144.70 Reference costs 2015-2016 
(Total; 656 clinical psychology) 
Outpatient: 
Psychotherapy 
199.06 Reference costs 2015-2016 
(Total; 713 psychotherapy) 
Outpatient: Liaison 
mental health  
105.08 Reference costs 2015-2016 
(Total; 722 liaison psychiatry) 
Outpatient: Accident 
and emergency  
146.86 Reference costs 2015-2016 
(Total; 180 accident and 
emergency) 
Outpatient (other) 
170.60  
Reference costs 2015-2016 
(Total; 328 stroke medicine) 
127.67  
Reference costs 2015-2016 
(Total; 320 cardiology) 
167.05  
Reference costs 2015-2016 
(Total; 300 general medicine) 
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48.33  
Reference costs 2015-2016 
(Total; 650 physiotherapy) 
116.05  
Reference costs 2015-2016 
(Total; 652 speech and language 
therapy) 
79.19  
Reference costs 2015-2016 
(Total; 662 optometry) 
117.01  
Reference costs 2015-2016 
(Total; 110 trauma and 
orthopaedics) 
175.60  
Reference costs 2015-2016 
(Total; 400 neurology) 
154.77  
Reference costs 2015-2016 
(Total; 340 respiratory medicine) 
58.33  
Reference costs 2015-2016 
(Total; 840 audiology) 
114.60  
Reference costs 2015-2016 
(Total; 658 orthotics) 
107.52 Reference costs 2015-2016 
Diagnostic imaging (outpatient); 
weighted average RD20A to 
RD27Z) 
GP consultation (at 
surgery) 
3.90 (per minute of 
patient contact) 
PSSRU 2016: pp145 
GP consultation (home 
visit) 
4.90 (per minute, 
including travel) 
PSSRU 2013: pp191 
Practice nurse (at 
surgery) 
43 (per hour) PSSRU 2016: pp143 
Community nurse 67 (per hour) PSSRU 2015: pp169 
Community 
occupational therapist 
44 (per hour) PSSRU 2016: pp159 
Hospital-based 
physiotherapist 
38 (per hour) PSSRU 2015: pp217 
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Hospital-based speech 
and language therapist 
38 (per hour) PSSRU 2015: pp219 
Home care worker 24 (per hour face-to-
face, weekday) 
PSSRU 2016: pp160 
NHS counsellor  50 (per hour) PSSRU 2014: pp51 
NHS psychologist 52 (per hour, based 
on AfC band 7) 
PSSRU 2016: pp137 
NHS psychotherapist 52 (per hour, based 
on AfC band 7) 
PSSRU 2016: pp137 
Community based 
mental health nurse 
75 PSSRU 2015: pp170 
Social worker / case 
manager 
79 (per hour of client 
contact) 
PSSRU 2016: pp156 
CBT therapist 97 (per session) PSSRU 2016: pp77 
Home care worker 24 (per hour) PSSRU 2016: pp160 
Podiatrist 32 (per hour, based 
on AfC band 5) 
PSSRU 2016: pp137 
Stroke support 25 (per hour, based 
on higher level 
clinical support 
worker; AfC band 3) 
PSSRU 2016: pp137 
Other primary care 
contact (NHS 
community mental 
health services for older 
people) 
43 (per hour) PSSRU 2016: pp167 
Day care for people 
requiring mental health 
support 
8.20 (per hour) PSSRU 2016: pp38 
 
Re-ablement service 43 (per hour of client 
contact) 
PSSRU 2016: 179 
Private and voluntary 
day care for people 
8 (per hour) PSSRU 2016: pp39 
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requiring mental health 
support 
Lost employment hours 
/ carer time 
12.10 (per hour, 
based on median 
hourly earnings) 
Annual survey of hours and 
earnings, ONS 2016b 
Behaviour activation 57 (per hour of face 
to face contact) 
PSSRU 2016: pp40 (based on 
Richards et al (2016))  
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Appendix 4 A worked example of the Audit Trail of the analysis and framework 
development 
 
Please note that this is a worked example of the audit trial and some sections/field 
notes have been removed. The detailed trail can be obtained from the authors. 
 
Step 1 (Framework development): The following categories (thematic constructs) 
were developed based on a priori issues covered in the interview schedule and extant 
literature. 
 
Step 2 (Familiarisation and revised framework): GT was immersed in the data by 
reading and re-reading the verbatim transcripts and listening to audio-recordings to 
note salient points, and recurrent ideas noted under each category. Memos were used 
to provide a visible audit trail of an emerging theme or subtheme. 
Patient- and carer-participant interviews: 
 
Notes. 
a
After reading the transcripts, GT and RdN decided to consider outcomes as a separate category 
as they constituted a prominent part of the interview data. This also fit well with the aims of the project 
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(determining the acceptability of the outcome measures). Therefore, Category 1 in Step 1 was divided 
into two categories and the titles were changed. 
b
Category name was changed to better reflect the 
interview data.  
c
Another category was created by GT after reading the interview transcripts as the 
changes occurred in patients’ lives after stroke were frequently discussed by the patients. These 
changes were stroke-related and not study- or therapy-related. GT and RdN agreed to keep this 
category as it provided context for the interviews. 
d
This theme was created to incorporate experiences 
(e.g. family problems) that did not fit with other themes within this category but were considered 
important by some participants in relation to their stroke experiences. 
 
Therapist participant interviews: 
 
Notes. 
1
Experiences of participants from the therapists’ perspective was a recurrent theme. GT initially 
considered this as a separate category, but after discussion with RdN, they decided to have this theme 
under the Category “Therapist views of delivering the intervention” as it fit well within this category in 
terms of providing a context and further explanation/understanding for their experiences of delivering 
the therapy. 
Step 3 (Indexing and mapping): Mapping the data onto the constructed thematic 
framework by coding and indexing various sections of the data to specific thematic 
constructs. The indexing process was iteratively completed by GT, with input from 
RdN, and used the constant comparison method to check and compare each item with 
rest of the data, requiring GT to go back to previously analysed transcripts as the new 
themes or sub-themes emerges to check if they were also evident in these transcripts. 
This ensured that any additional themes/sub-themes were added to reflect the nuances 
within the data. Midway through the coding of the transcripts, RdN also examined 
five transcripts which had been coded by GT, to check the coding of the data 
independently. Memos were used to provide a visible audit trail. 
Patient and carer participant interviews: 
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Notes #1. 
a
The name of this category was changed from “Participant views on trial and the procedures” 
to “Study experiences” to cover all the relevant experiences related to the study (e.g. motivation to 
participate, understanding the rationale and understanding the research process). 
b‘Motivation and 
understanding’ theme that was developed in Step 2 was divided into two separate themes “motivation 
and reason to participate” and “understanding the study rationale” as these represented distinct but 
inter-related constructs. Theme 1.1 was further developed into two sub-themes (i.e. general and specific 
to BEADS) to reflect participant views better as the motivation and reason to participate were different 
for each participant. 
 
 
Notes #2. 
a
While some participants made general comments about the focus of the measures, some 
participants commented on specific measures. Therefore, we coded these comments under two sub-
themes. Another sub-theme was created for participants’ ratings. bSimilarly, when talking about the 
ease of understanding, participants either made comments generally or on specific measures. Therefore, 
data were coded into two sub-themes. 
c
The sub-theme ‘repetition’ emerged from our reading and 
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interpretation of the data. Therefore, data were coded into two sub-themes. GT went back to previously 
analysed transcripts to check if it was also evident in already analysed transcripts. 
 
 
 
Notes #3. 
a
As this thematic construct was only evident in intervention group participants, we decided to 
change the name of the theme to reflect this. 
b
After discussing this sub-theme, RdN and GT agreed to 
rename it as ‘perceived mediators of change’ to emphasise that certain aspects of therapy were 
perceived by participants as helpful, mediating a change. 
c
During coding of carer interviews, a new 
sub-theme, called ‘role of carer in sessions’, emerged regarding the format of therapy. GT went back to 
previously analysed transcripts to check whether it was also evident in those transcripts already 
analysed. 
 
 
Notes #4. 
a
The name of the thematic construct was changed to ‘Gains and changes’ to cover all the 
themes and sub-themes within this category. 
b
Some participants attributed changes they experienced to 
the study, whereas others discussed changes they experienced in general and did not attribute these 
changes to the study. Therefore, we decided to divide this theme into two sub-themes. 
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Notes #5. 
a
The name of the thematic construct was changed to make it clearer and also to be more 
comprehensive of the experiences of the participants. 
b
The theme ‘Stroke-related changes’ was divided 
into 2 sub-themes to incorporate carer-specific experiences. 
c
This theme was also divided into 2 sub-
themes to be able to differentiate and compare helpful and unhelpful support/strategies (not therapy-
related) used by participants. 
 
 
 
 
Therapist-participant interviews: 
 
Notes a. 
1
GT revised the names of the thematic construct and the theme a.1, in consultation with RdN, 
for the purpose of clarity. 
2
This theme was further divided into two sub-themes to better differentiate 
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therapists’ observations regarding the changes in participants and the helpful/unhelpful aspects of 
therapy to participants. 
 
 
 
Notes b. 
1
This theme was further divided into 4 sub-themes as the interviews focused on 4 different 
types of support provided (i.e., manual, training, supervision, monitoring). 
2
This theme was further 
divided into two sub-themes as both barriers and facilitators to integrating the trial into wider services 
emerged from our reading and interpretation of the data. 
 
 
 
Notes c. 
1
The name of the thematic construct was revised, in consultation with RdN, to make it more 
comprehensive and clear. 
 
Step 4 (Charting): After mapping all the data, a matrix was generated by GT in 
which the data were charted to summarise each main theme. One matrix per thematic 
category across participants was developed, containing summaries of the views and 
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experiences of the participants, and references to verbatim quotes in the transcripts. 
This facilitated the process of comparing and contrasting data from individual 
participants across themes. Each matrix was reviewed by RdN to ensure its rigour and 
credibility. Disagreements were resolved by discussion. Memos were used to provide 
a visible audit trail. 
[Please note. The matrices and the corresponding field notes have been removed from this worked 
example of the audit trail. The full audit trail can be obtained from the corresponding author] 
 
Step 5 (Interpretation): The matrices and the field notes were then used in the 
interpretation of the data. The interpretation process was iterative and relied on 
consultation between GT and RdN regarding the viability and relevance of a theme, to 
interrogate theoretical constructs, and to unpack nuances within the data. 
[Please note. The field notes regarding the interpretation process have been removed from this worked 
example of the audit trail. The full audit trail can be obtained from the corresponding author] 
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Appendix 5 Semi-structured interview guide: Participants (version 1) 
[Please note: This is a semi-structured topic guide that is designed to be used flexibly 
with each participant. As such, the questions and prompts (presented as sub-
questions) asked in each interview are likely to vary slightly.] 
 
Opening question 
1. Please can you tell me about your experience of being involved in the study? 
 
Recruitment and group allocation 
2. How did you come to be involved in the study? 
a. What did that feel like 
3. How did it feel to be allocated to your study group? 
a. How did it feel (not) to be allocated to receive the behavioural activation 
therapy? 
 
Study procedures 
4. What did you think about the information we collected from you at the beginning 
and end of the study? 
a. How easy (or not) were the questionnaires to complete? 
b. What did you think about how many questionnaires you needed to 
complete? 
c. Did the questionnaires ask about things that were relevant for you, in 
relation to what the study was about? 
d. How would you rate the assessments on a scale of 1-10 (1 did not capture 
important aspects of my experience to 10 fully captured the important 
aspects of my experience)  
 
For intervention participants only 
5. How did you find the therapy? 
a. What did you find helpful about the therapy? Any particular aspects? 
b. What did you find unhelpful about the therapy? Any particular aspects? 
c. Were there any particular aspects which were good or bad? 
6. How do you think we could improve the therapy in the future? 
7. Would you recommend this therapy to other people with low mood after a stroke? 
 
Impact/Perceived benefits 
8. Have you experienced any changes since taking part in this study? 
a. What are these changes? 
b. How do you make sense of these changes? 
 
Other issues 
9. Is there anything else you would like to tell me about?
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Appendix 6 Semi-structured interview guide: Carers (version 1) 
[Please note: This is a semi-structured topic guide that is designed to be used flexibly with each 
participant. As such, the questions and prompts (presented as sub-questions) asked in each interview 
are likely to vary slightly.] 
 
Opening questions 
1. Please can you tell me about your experience of being involved in the study? 
2. Please can you tell me about your (insert appropriate descriptor: 
spouse/partner/family member/friend)’s experience of being involved in the study? 
 
Recruitment and group allocation 
3. How did you come to be involved in the study? 
a. What did that feel like? 
4. How did it feel for your (insert appropriate descriptor) to be allocated to their 
study group? 
b. How did it feel for them (not) to be allocated to receive the behavioural 
activation therapy? 
 
Study procedures 
6. What did you think about the information we collected from you at the beginning 
and end of the study? 
a. How easy (or not) were the questionnaires to complete? 
b. What did you think about how many questionnaires you needed to 
complete? 
c. Did the questionnaires ask about things that were relevant for you, in 
relation to what the study was about? 
d. How would you rate the assessments on a scale of 1-10? (1: did not 
capture important aspects of my experience to 10: fully captured the 
important aspects of my experience)  
 
For carers of intervention participants only 
7. How much involvement did you have in the therapy? 
a. What did you have to do? 
b. Were you happy with this level of involvement? 
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c. What did you find helpful or unhelpful about the therapy? Any particular 
aspects? 
8. How do you think we could improve the therapy for people like your (insert 
appropriate descriptor) in the future? 
9. Would you recommend this therapy to other people with low mood after a stroke? 
 
Impact/Perceived benefits 
10. Have you or your (insert appropriate descriptor) experienced any changes since 
taking part in this study? 
a. What are these changes? 
b. How do you make sense of these changes? 
Other issues 
11. Is there anything else you would like to tell me about? 
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Appendix 7 Semi-structured interview guide: Staff (version 1) 
[Please note: This is a semi-structured topic guide that is designed to be used flexibly 
with each participant. As such, the questions and prompts (presented as sub-
questions) asked in each interview are likely to vary slightly.] 
 
Opening question 
1. Please can you tell me about your experience of being involved in the study? 
 
Intervention delivery 
2. Please can you tell me about your experiences of delivering the therapy? 
a. How easy/difficult was it to implement the therapy with people who have 
had a stroke and those with communication difficulties? 
b. What went well?  
c. What were the difficulties and how did you overcome them? 
d. How did you find the training that you received? 
e. How did you find using the manual? 
f. How did you find the clinical supervision at site/by the trial therapists? 
g. How did you find the monitoring of your practice by the research study?? 
3. How did participants find the therapy? 
h. Were there any particular aspects which were good or bad? 
i. Did participants experience any changes/benefits from the therapy? 
4. How do you think the therapy could be improved in the future? 
5. Would you recommend this therapeutic approach to other psychologists working 
with people with post-stroke depression? 
 
Study procedures 
6. Please can you tell me about the recruitment process? 
j. How could this be improved for a future trial? 
7. How did you find the study procedures, i.e. working to the protocol? 
k. How could this be improved for a future trial? 
8. What did you think about the measures we used at baseline? 
l. How would you rate the assessments on a scale of 1-10 (1 did not capture 
important aspects of the experience to 10 fully captured the important 
aspects of the experience)  
 
Service barriers and facilitators 
9. Please can you tell me about your experience of working on the trial within your 
department? 
10. What are the main barriers to integrating the trial practice into the wider service of 
your department?  
12. What are the main facilitators of integrating the trial practice into the wider 
service of your department? 
 
Other issues 
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13. Is there anything else you would like to tell me about
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Appendix 8 Completed COREQ checklist 
Consolidated criteria for reporting qualitative studies (COREQ): 32-item 
checklist 
Developed from:  
Tong A., Sainsbury, P. & Craig, J. Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual 
Health Care 2007;19:349-57 
Topic No. 
Item 
Guide questions/description Reported on 
Section # (Page #) 
Domain 1: Research team and reflexivity 
Personal Characteristics 
Interviewer/facilitator 1 Which author/s conducted the 
interview or focus group? 
Section 2.4.1 (p. 
39); 
Acknowledgements 
(p. 186-187); 
Contributions of 
Authors (p. 187-
189) 
Credentials 2 What were the researcher’s 
credentials? E.g. PhD, MD 
Section 2.4.1 (p. 
39); 
Acknowledgements 
(p. 186-187); 
Contributions of 
Authors (p. 187-
189) 
Occupation 3 What was their occupation at 
the time of the study? 
Section 2.4.1 (p. 
39); 
Acknowledgements 
(p. 186-187); 
Contributions of 
Authors (p. 187-
189) 
Gender 4 Was the researcher male or Section 2.4.1 (p. 
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female? 39); 
Acknowledgements 
(p. 186-187); 
Contributions of 
Authors (p. 187-
189) 
Experience and 
training 
5 What experience or training 
did the researcher have? 
Section 2.4.1 (p. 
39) 
Relationship with participants 
Relationship 
established 
6 Was a relationship established 
prior to study 
commencement?  
Section 2.4.2 (p. 
39) 
Participant 
knowledge of the 
interviewer 
7 What did the participants 
know about the researcher? 
e.g. personal goals, reasons 
for doing the research? 
Section 2.4 (p. 39-
40); Section 2.4.2 
(p. 39) 
Interviewer 
characteristics 
8 What characteristics were 
reported about the inter 
viewer/facilitator? e.g. Bias, 
assumptions, reasons and 
interests in the research topic 
Section 2.4.1 (p. 
39) 
Domain 2: Study design 
Theoretical framework 
Methodological 
orientation and 
Theory 
9 What methodological 
orientation was stated to 
underpin the study? e.g. 
grounded theory, discourse 
analysis, ethnography, 
phenomenology, content 
analysis 
Section 2.4.3 (p. 
40) 
Participant selection 
Sampling 10 How were participants 
selected? e.g. purposive, 
Section 2.4.4 (p. 
41) 
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convenience, consecutive, 
snowball 
Method of approach 11 How were participants 
approached? e.g. face-to-face, 
telephone, mail, email 
Section 2.4.4 (p. 
41); Section 2.1.4 
(p. 9-15) 
Sample size 12 How many participants were 
in the study? 
Section 2.4 (p. 39); 
Chapter 6 (p. 126)  
Non-participation 13 How many people refused to 
participate or dropped out? 
Reasons? 
Appendix 9 (p. 
230-231) 
Setting 
Setting of data 
collection 
14 Where was the data 
collected? e.g. home, clinic, 
workplace 
Section 2.4 (p. 39) 
Presence of non-
participants 
15 Was anyone else present 
besides the participants and 
researchers? 
Section 2.4 (p. 39) 
Description of 
sample 
16 What are the important 
characteristics of the sample? 
e.g. demographic data, date 
Chapter 6 (p.126); 
Appendix 19 (p. 
247) 
Data collection 
Interview guide 17 Were questions, prompts, 
guides provided by the 
authors? Was it pilot tested? 
Section 2.4.5 (p. 
41-42); Appendices 
5, 6 & 7 (p. 220-
224) 
Repeat interviews 18 Were repeat inter views 
carried out? If yes, how 
many? 
No 
Audio/visual 
recording 
19 Did the research use audio or 
visual recording to collect the 
data? 
Section 2.4 (p. 39) 
Field notes 20 Were field notes made during 
and/or after the interview or 
Section 2.4.3 (p.40) 
Section 2.4.6 (p. 
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focus group? 42-43) and 
Appendix 4 (p. 
213-219) 
Duration 21 What was the duration of the 
inter views or focus group? 
Section 2.4 (p. 39) 
Data saturation 22 Was data saturation 
discussed? 
Section 2.4.4 (p. 
41) 
Transcripts returned 23 Were transcripts returned to 
participants for comment 
and/or correction? 
No 
Domain 3: analysis and findings 
Data analysis 
Number of data 
coders 
24 How many data coders coded 
the data? 
Section 2.4.6 (p. 
42-43); Appendix 4 
(p. 213-219) 
Description of the 
coding tree 
25 Did authors provide a 
description of the coding 
tree? 
Chapter 6 (p.126) 
& Appendix 4 (p. 
213-219) 
Derivation of themes 26 Were themes identified in 
advance or derived from the 
data? 
Section 2.4.6 (p. 
42-43); Appendix 4 
(p. 213-219) 
Software 27 What software, if applicable, 
was used to manage the data? 
N/A 
Participant checking 28 Did participants provide 
feedback on the findings? 
No 
Reporting 
Quotations presented 29 Were participant quotations 
presented to illustrate the 
themes/findings? Was each 
quotation identified? e.g. 
participant number 
Chapter 6 (p.126-
161) 
Data and findings 
consistent 
30 Was there consistency 
between the data presented 
Chapter 7 (p.162-
179) 
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and the findings? 
Clarity of major 
themes 
31 Were major themes clearly 
presented in the findings? 
Chapter 6 (p.126-
161);  Appendix 4 
(p. 213-219) 
Clarity of minor 
themes 
32 Is there a description of 
diverse cases or discussion of 
minor themes? 
Chapter 6 (p.126-
161) 
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Appendix 9 Reasons given for drop out in 9 participants 
ID Type of 
attrition 
Reason given Treatment 
arm 
Sessions 
completed 
 
A1/048 Lost to follow 
up 
Completed other 
measures but not PHQ-
9 
Intervention 9  
C7/006 Withdrew from 
intervention and 
LTFU 
Physical health/Lack of 
time 
Intervention 1  
C7/009 Withdrew from 
intervention and 
LTFU 
Not enough time Intervention 2  
C1/040 Withdrew 
consent 
No time and 
personal/family reasons 
Intervention 0  
A1/027 Lost to follow 
up 
Unknown Intervention 10  
B1/155 Randomised in 
error 
 Intervention 0  
A4/009 Lost to follow 
up 
Out of country caring 
for a relative so could 
Intervention 8  
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not complete follow up 
C7/014 Withdrew from 
intervention and 
did not want to 
be followed up 
Health deteriorated 
following suicide 
attempt. Inappropriate 
to follow up 
Intervention 5  
A1/173 Lost to follow 
up 
Too ill on day and could 
not contact again 
Control  NA  
A1/123 Investigator 
decision not to 
follow up- at 
end of life 
At end of life Control NA  
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Appendix 10 Data collected outside of collection window and delays in randomisation 
223 
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Appendix 11 Frequency of content of manual applicable on all sessions 
 Session 
2 
 Session 
3 
 Session 
4 
 Session 
6 
 Session 
7 
 Session 
10 
 Total  
 n % n % n % n % n % n % n % 
Manual content                
Summarise Previous session 4 11.1 0 0 0 0 0 0 1 5.6 0 0 5 4.6 
Review between session tasks 1 2.8 3 12.5 1 12.5 0 0 0 0 0 0 2 1.9 
Set agenda and goals for each 
session 
5 13.9 1 4.2 0 0 1 7.7 3 16.7 0 0 10 9.3 
Agree between session tasks 
for the next session 
3 8.3 3 12.5 0 0 1 7.7 5 27.8 0 0 12 11.1 
Session Summary 2 5.6 0 0 1 12.5 0 0 0 0 0 0 3 2.8 
Review Between-Session 
Task 
1 2.8 3 12.5 0 0 1 7.7 1 5.6 0 0 6 5.6 
Review events since previous 
session 
3 8.3 6 25.0 6 75.0 7 53.8 6 33.3 1 11.1 29 26.9 
               
Other Content               
Social chat 10 27.8 10 41.7 0 0 1 7.7 1 5.6 8 88.9 30 27.8 
Information on organisation of 
sessions 
3 8.3 1 4.2 0 0 2 15.4 0 0 0 0 6 5.6 
Travel arrangements 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Preparing materials, tasks etc. 4 11.1 0 0 0 0 0 0 1 5.6 0 0 5 4.6 
Check whether participant 
needs reminder of the next 
appointment  
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Appendix 12 Frequency of content of manual applicable on specific sessions 
 Session 
2 
 Session 
3 
 Session 
4 
 Session 
6 
 Session 
7 
 Session 
10 
 Total  
 n % n % n % n % n % N % n % 
Session 2                
Identification of participants 
problems  
14 41.2 0 0 0 0 0 0 0 0 0 0 14 19.2 
Agreeing therapy goals  20 58.8 0 0 0 0 0 0 0 0 0 0 20 27.4 
Session 3               
Discuss relationship between 
activity level and mood 
0 0 6 60.0 0 0 0 0 0 0 0 0 6 8.2 
Refer to behavioural model 
of depression  
0 0 1 10.0 0 0 0 0 0 0 0 0 1 1.4 
Introduce idea of identifying 
enjoyable activities 
0 0 3 30.0 0 0 0 0 0 0 0 0 3 4.1 
Session 4               
Review idea of identifying 
enjoyable activities 
0 0 0 0 3 50.0 0 0 0 0 0 0 3 4.1 
Discuss how enjoyable 
activities improve mood 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Identify enjoyable activities  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Create list of enjoyable 
activities 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Identify barriers to engaging 
in identified activities 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Check activities are in line 
with goals 
0 0 0 0 2 33.3 0 0 0 0 0 0 2 2.7 
Activity Scheduling plan 0 0 0 0 1 16.7 0 0 0 0 0 0 1 1.4 
Session 6               
Review whether activities 
were carried out as scheduled  
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Identify one activity per day 
to be scheduled 
0 0 0 0 0 0 4 36.4 0 0 0 0 4 5.5 
Identify any potential 
obstacles to completing 
activities and address them 
0 0 0 0 0 0 7 63.6 0 0 0 0 7 9.6 
Session 7               
Review relationship between 
activity schedule and mood 
0 0 0 0 0 0 0 0 6 60.0 0 0 6 8.2 
Identify common problems 
in planning or carrying out 
activities 
0 0 0 0 0 0 0 0 4 40.0 0 0 4 5.5 
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Session 10               
Review problems addressed 
during therapy 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Summarise successful 
strategies and skills used 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Discuss generalisation of 
skills to future situations  
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Questions and answers 0 0 0 0 0 0 0 0 0 0 2 100.0 2 2.7 
Remind them about 6 month 
follow up protocol 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Appendix 13 Frequency of Therapist and Participant Activities 
 Session 
2 
 Session 
3 
 Session 
4 
 Session 
6 
 Session 
7 
 Session 
10 
 Total  
 n % n % n % n % n % n % n % 
Therapist activities               
Providing explanation 9 13.2 2 3.2 2 7.4 1 5.9 6 9.4 0 0 20 7.7 
Providing feedback 1 1.5 0 0 0 0 0 0 0 0 0 0 1 0.4 
Providing encouragement/ 
reassurance 
3 4.4 5 8.1 2 7.4 3 17.6 3 4.7 0 0 16 6.1 
Summarising 5 7.4 1 1.6 2 7.4 2 11.8 3 4.7 1 4.3 14 5.4 
Paraphrasing 2 2.9 0 0 0 0 0 0 1 1.6 0 0 3 1.1 
Presenting/ discussing BA 
strategies 
0 0 9 14.5 2 7.4 0 0 6 9.4 0 0 17 6.5 
Address problems with task 
non-completion 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Checking understanding  0 0 0 0 0 0 0 0 0 0 1 4.3 1 0.4 
Give opportunities for 
participant to ask questions 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
References to between-session 0 0 0 0 0 0 0 0 1 1.6 0 0 1 0.4 
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activities  
Reference to problems list 1 1.5 0 0 0 0 0 0 0 0 0 0 1 0.4 
Reference to participant goals 2 1.3 6 9.6 1 3.7 0 0 2 3.1 0 0 11 4.2 
Addressing appropriateness of 
activities 
1 1.5 2 3.2 0 0 0 0 0 0 2 8.7 5 1.9 
Ask participant to rate 
enjoyment of chosen activities 
0 0 0 0 2 7.4 2 11.8 2 3.1 2 8.7 8 3.1 
Asking participant Questions 4 5.9 3 4.8 1 3.7 0 0 5 7.8 3 13.0 16 6.1 
Reference to previous sessions 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
               
Participant activities               
Discussing BA strategies 0 0 1 1.6 0 0 0 0 1 1.6 0 0 2 0.8 
Discussing activities 14 20.6 12 19.4 6 22.2 0 0 8 12.5 8 34.8 48 18.4 
Asking for information 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Describing problems 20 12.7 18 29.0 3 11.1 5 29.4 19 29.7 1 4.3 66 25.3 
Asking questions 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Information about sessions, 
venue, group etc. 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Describing mood 2 1.3 3 4.8 3 11.1 1 5.9 4 6.3 1 4.3 14 5.4 
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Feedback on home activities 1 1.5 0 0 1 3.7 2 11.8 2 3.1 1 4.3 7 2.7 
Feedback on sessions 1 1.5 0 0 1 3.7 0 0 0 0 2 8.7 4 1.5 
Hospital visit discussion 2 2.9 0 0 1 3.7 1 5.9 1 1.6 1 4.3 6 2.3 
Speech and language therapy 
discussion 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
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Appendix 14 Distributions of costs relevant to the NHS and PSS perspective 
(complete case analysis) 
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Appendix 15 Distributions of costs relevant to the societal perspective (complete 
case analysis) 
0
2
4
6
8
1
0
F
re
q
u
e
n
c
y
0 20000 40000 60000 80000 100000
Societal costs (£)
Control group
0
2
4
6
8
1
0
F
re
q
u
e
n
c
y
0 20000 40000 60000 80000 100000
Societal costs (£)
Intervention group
233 
 
Appendix 16 Change in EQ-5D-5L split by response (based on imputed data) 
 Number of 
participants 
(of which had 
missing 
utility data) 
Change in 
EQ-5D-5L 
from 
baseline 
Standard 
Error 
95% 
Confidence 
Interval 
Control (No 
response) 
18(2) 0.04 0.05 [-0.07, 0.16] 
Intervention 
(No response) 
8(2) -0.04 0.12 [-0.29, 0.22] 
Control 
(Response) 
5(1) 0.23 0.18 [-0.16, 0.62] 
Intervention 
(Response) 
17(6) 0.03 0.08 [-0.14, 0.20] 
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Appendix 17 Model parameters and distributions 
Parameter Base case value Uncertainty distribution 95% Confidence interval 
EQ-5D-5L (Utility) 
Non-response 0.52 Beta (26.22, 24.17) [0.38, 0.66] 
Response 0.59 Beta (39.77, 28.08) [0.47, 0.70] 
Monthly costs (NHS and PSS perspective) 
Non-response £383.61 Gamma (6.12, 62.68) [142.52, 741.94] 
Response £473.55 Gamma (7.77, 60.97) [201.48, 860.37] 
Monthly costs (Societal perspective) 
Non-response £4,229.19 Gamma (18.68, 226.42) [2,534.04, 6,352.24] 
Response £2,968.70 Gamma (10.36, 286.67) [1,446.01, 5,032.93] 
Probability of a good response 
Non-response 0.22 Beta (5, 18) [0.08, 0.40] 
Response 0.68 Beta (17, 8) [0.49, 0.84] 
Other parameters 
Number of BA sessions 8.08 Gamma (143.05, 0.06) [7.34, 10.05] 
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Appendix 18 Results from EVPPI, excluding all costs except intervention costs 
 Per person 
EVPPI (£) 
Standard 
Error 
EVPPI for UK 
over 10 years (£) 
Health costs (response) 0 0 0 
Health costs (no response) 0 0 0 
Societal costs (response) 0 0 0 
Societal costs (no response) 0 0 0 
Utility (response) 0 0.05 384 
Utility (no response) 0 0 0 
Probability of good response 
(intervention) 0.02 0.03 6,279 
Probability of good response 
(control) 0.07 0.19 29,720 
Relapse rate 34.23 4.4 14,040,000 
Number of BA sessions 0 0 0 
Probability of death 0 0 0 
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Appendix 19 Participant characteristics for qualitative feedback interviews 
Participant 
no. 
Age 
(years) 
Sex Lateralisation 
stroke 
Weakness 
side 
FAST 
score 
VAMS 
SAD 
Score 
PHQ 
score 
Randomisation Days 
since 
stroke 
Carer 
age 
Carer sex Carer’s 
relationship to 
patient 
A1/034 50-54 Male Right Left 26 97 21 Intervention 573    
A1/053 60-64 Male Right Left 30 47 10 Control 241    
A1/084 66-70 Female Left Right 21 24 11 Intervention 181 80 Male Partner 
A1/124 80-84 Male Left Right 22 25 13 Control 239 73 Female Partner 
A4/002 80-84 Female Left Left 27 22 11 Control 297 85 Male Partner 
A6/001 85-99 Female Right Left 25 23 21 Control 1192 88 Male Partner 
A6/002 50-54 Male Right Left 30 50 14 Intervention 998    
A7/004 70-74 Female Left Right 24 59 12 Control 489 72 Male Partner 
B1/087 75-89 Male Unknown Unknown 27 73 14 Intervention 388 58 Female Partner 
B6/001 40-44 Female Left Right 30 65 13 Control 950    
C1/009 65-69 Male Right Left 30 51 15 Control 1075   Female Partner 
C1/047 70-74 Female Right Left 26 49 17 Control 370 69 Male Partner 
C4/005 60-64 Male Unknown Unknown 30 21 20 Control 199    
C7/001 50-54 Male Left Right 22 3 10 Intervention 199    
C7/013 65-69 Male Right Left 27 82 18 Control 207 68 Female Partner 
C7/017 50-54 Male Left Left 26 47 21 Intervention 135 48 Female Partner 
 
